CA2534866A1 - Piperazine derivatives for the treatment of hiv infections - Google Patents
Piperazine derivatives for the treatment of hiv infections Download PDFInfo
- Publication number
- CA2534866A1 CA2534866A1 CA002534866A CA2534866A CA2534866A1 CA 2534866 A1 CA2534866 A1 CA 2534866A1 CA 002534866 A CA002534866 A CA 002534866A CA 2534866 A CA2534866 A CA 2534866A CA 2534866 A1 CA2534866 A1 CA 2534866A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- methyl
- preparation
- piperazin
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 4
- 150000004885 piperazines Chemical class 0.000 title description 3
- 208000031886 HIV Infections Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 371
- 150000003839 salts Chemical class 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000012453 solvate Substances 0.000 claims abstract description 43
- 208000030507 AIDS Diseases 0.000 claims abstract description 13
- 206010038997 Retroviral infections Diseases 0.000 claims abstract description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 90
- -1 benzopiperidinyl Chemical group 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 125000002947 alkylene group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- KXLKYTFVIKKVMW-MOPGFXCFSA-N (2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-[2-(1h-pyrazol-5-ylamino)quinolin-5-yl]oxypropan-1-one Chemical compound O([C@@H](C)C(=O)N1[C@@H](CN(CC1)C(=O)C=1C=CC=CC=1)C)C(C1=CC=2)=CC=CC1=NC=2NC1=CC=NN1 KXLKYTFVIKKVMW-MOPGFXCFSA-N 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- OQRSXFNMNAQFEB-SJORKVTESA-N 4-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1O[C@@H](C)C(=O)N1[C@H](C)CN(C(=O)C=2C=CC=CC=2)CC1 OQRSXFNMNAQFEB-SJORKVTESA-N 0.000 claims description 2
- KVDRFBPETGPOMO-CVEARBPZSA-N 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-4-methoxy-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC)=C1O[C@@H](C)C(=O)N1[C@H](C)CN(C(=O)C=2C=CC=CC=2)CC1 KVDRFBPETGPOMO-CVEARBPZSA-N 0.000 claims description 2
- AHSGKFLIDGDUAT-CABCVRRESA-N 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-4-methoxypyridine-2-carboxamide Chemical compound COC1=CC(C(N)=O)=NC=C1O[C@@H](C)C(=O)N1[C@H](C)CN(C(=O)C=2C=CC=CC=2)CC1 AHSGKFLIDGDUAT-CABCVRRESA-N 0.000 claims description 2
- VMJUDEOSVIYEMQ-SJORKVTESA-N 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-n-cyclopropyl-4-methoxypyridine-2-carboxamide Chemical compound O=C([C@H](C)OC1=CN=C(C=C1OC)C(=O)NC1CC1)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 VMJUDEOSVIYEMQ-SJORKVTESA-N 0.000 claims description 2
- ZZEULHDTBKKLTM-MSOLQXFVSA-N 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-n-methylisoquinoline-1-carboxamide Chemical compound O=C([C@H](C)OC1=C2C=CN=C(C2=CC=C1)C(=O)NC)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 ZZEULHDTBKKLTM-MSOLQXFVSA-N 0.000 claims description 2
- 150000001539 azetidines Chemical class 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical class C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- LHWZXDKKFSHAAG-MOPGFXCFSA-N (2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-[1-(1h-pyrazol-5-ylamino)isoquinolin-5-yl]oxypropan-1-one Chemical compound O([C@@H](C)C(=O)N1[C@@H](CN(CC1)C(=O)C=1C=CC=CC=1)C)C(C1=CC=N2)=CC=CC1=C2NC1=CC=NN1 LHWZXDKKFSHAAG-MOPGFXCFSA-N 0.000 claims 1
- QXBJKOAVZCBULE-SJORKVTESA-N (2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-[8-chloro-2-(methylamino)quinolin-5-yl]oxypropan-1-one Chemical compound O=C([C@H](C)OC=1C2=CC=C(N=C2C(Cl)=CC=1)NC)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 QXBJKOAVZCBULE-SJORKVTESA-N 0.000 claims 1
- MASAQSXMNRMCGV-SJORKVTESA-N 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-n-ethyl-4-methoxypyridine-2-carboxamide Chemical compound C1=NC(C(=O)NCC)=CC(OC)=C1O[C@@H](C)C(=O)N1[C@H](C)CN(C(=O)C=2C=CC=CC=2)CC1 MASAQSXMNRMCGV-SJORKVTESA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 176
- 239000000203 mixture Substances 0.000 abstract description 126
- 230000008569 process Effects 0.000 abstract description 10
- 239000000543 intermediate Substances 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 375
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 183
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- 239000000243 solution Substances 0.000 description 107
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 102
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 87
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 84
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- 239000011541 reaction mixture Substances 0.000 description 73
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- 239000007787 solid Substances 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 51
- 235000019341 magnesium sulphate Nutrition 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 49
- 239000000741 silica gel Substances 0.000 description 49
- 229910002027 silica gel Inorganic materials 0.000 description 49
- 238000004440 column chromatography Methods 0.000 description 48
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000002904 solvent Substances 0.000 description 38
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 34
- 239000003921 oil Substances 0.000 description 32
- 235000019198 oils Nutrition 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 31
- 239000006260 foam Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 239000000284 extract Substances 0.000 description 21
- 241000725303 Human immunodeficiency virus Species 0.000 description 20
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- BCXBBYDLRSJZTE-SNVBAGLBSA-N [(3r)-3-methylpiperazin-1-yl]-phenylmethanone Chemical compound C1CN[C@H](C)CN1C(=O)C1=CC=CC=C1 BCXBBYDLRSJZTE-SNVBAGLBSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 8
- LPEKGGXMPWTOCB-GSVOUGTGSA-N methyl (R)-lactate Chemical compound COC(=O)[C@@H](C)O LPEKGGXMPWTOCB-GSVOUGTGSA-N 0.000 description 8
- DDBKATBZHGPNRV-CVEARBPZSA-N methyl 5-[(2s)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-4-methoxypyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(OC)=C1O[C@@H](C)C(=O)N1[C@H](C)CN(C(=O)C=2C=CC=CC=2)CC1 DDBKATBZHGPNRV-CVEARBPZSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 5
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical group O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- MONMFXREYOKQTI-UHFFFAOYSA-N 2-bromopropanoic acid Chemical compound CC(Br)C(O)=O MONMFXREYOKQTI-UHFFFAOYSA-N 0.000 description 2
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GWNOTCOIYUNTQP-FQLXRVMXSA-N 4-[4-[[(3r)-1-butyl-3-[(r)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid Chemical compound N([C@@H](C(=O)N1CCCC)[C@H](O)C2CCCCC2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 GWNOTCOIYUNTQP-FQLXRVMXSA-N 0.000 description 2
- WHSIIJQOEGXWSN-UHFFFAOYSA-N 4-bromo-2-methoxyphenol Chemical compound COC1=CC(Br)=CC=C1O WHSIIJQOEGXWSN-UHFFFAOYSA-N 0.000 description 2
- MQKFSXLBPPCAGR-UHFFFAOYSA-N 6,7-dimethoxy-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=C1C=C(OC)C(OC)=C2 MQKFSXLBPPCAGR-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 108010017088 CCR5 Receptors Proteins 0.000 description 2
- 102000004274 CCR5 Receptors Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- BHNWNRLWIWPOLQ-UHFFFAOYSA-N acmc-1c4b5 Chemical compound ClI(=O)=O.ClI(=O)=O.ClI(=O)=O.ClI(=O)=O.C[N+](C)(C)CC1=CC=CC=C1 BHNWNRLWIWPOLQ-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960000366 emtricitabine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- SBHVDHKJXXFHQL-UHFFFAOYSA-N imidazo[4,5-c]pyridine-5-carboxylic acid Chemical compound OC(=O)N1C=CC2=NC=NC2=C1 SBHVDHKJXXFHQL-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BVWTXUYLKBHMOX-UHFFFAOYSA-N methyl vanillate Chemical compound COC(=O)C1=CC=C(O)C(OC)=C1 BVWTXUYLKBHMOX-UHFFFAOYSA-N 0.000 description 2
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229940081066 picolinic acid Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KFICIXOVLUKPDJ-VXGBXAGGSA-N (2r)-1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1[C@@H](C)N(C(=O)[C@H](O)C)CCN1C(=O)C1=CC=CC=C1 KFICIXOVLUKPDJ-VXGBXAGGSA-N 0.000 description 1
- ZTENZJJCFACIAK-ADWVOTLJSA-N (2r)-2-[[(1r,3s,4s)-3-[[4-(5-benzyl-2-ethylpyrazol-3-yl)piperidin-1-yl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methylamino]-3-methylbutanoic acid Chemical compound C1=C(C2CCN(C[C@@H]3[C@H](C[C@H](C3)N(C)[C@H](C(C)C)C(O)=O)C=3C=C(F)C=CC=3)CC2)N(CC)N=C1CC1=CC=CC=C1 ZTENZJJCFACIAK-ADWVOTLJSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- JAPPBTBDQQKEHG-ZETCQYMHSA-N (2s)-2-[2-methoxy-4-(methylcarbamoyl)phenoxy]propanoic acid Chemical compound CNC(=O)C1=CC=C(O[C@@H](C)C(O)=O)C(OC)=C1 JAPPBTBDQQKEHG-ZETCQYMHSA-N 0.000 description 1
- XMBSMMCPKFDGEO-ZETCQYMHSA-N (2s)-2-amino-5-[[amino-(2-methoxyethylamino)methylidene]amino]pentanoic acid Chemical compound COCCNC(=N)NCCC[C@H](N)C(O)=O XMBSMMCPKFDGEO-ZETCQYMHSA-N 0.000 description 1
- SSEJSSNDPMMWBQ-YFKPBYRVSA-N (3s)-3-methylpiperazine-1-carboxylic acid Chemical compound C[C@H]1CN(C(O)=O)CCN1 SSEJSSNDPMMWBQ-YFKPBYRVSA-N 0.000 description 1
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- SLHQAWYLGDYXFE-UHFFFAOYSA-N 1-(3-methoxy-2-methylphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1C SLHQAWYLGDYXFE-UHFFFAOYSA-N 0.000 description 1
- WBQOUAWRPNBNNW-UHFFFAOYSA-N 1-(3-methoxy-4-phenylmethoxyphenyl)pyrazole Chemical compound COC1=CC(N2N=CC=C2)=CC=C1OCC1=CC=CC=C1 WBQOUAWRPNBNNW-UHFFFAOYSA-N 0.000 description 1
- DBPMWRYLTBNCCE-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CN=C(OC)C=2NC=C1C(=O)C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 DBPMWRYLTBNCCE-UHFFFAOYSA-N 0.000 description 1
- OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 description 1
- DJCBFFSLTRCHLT-JHJMLUEUSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-bromopropan-1-one Chemical compound C1[C@@H](C)N(C(=O)C(Br)C)CCN1C(=O)C1=CC=CC=C1 DJCBFFSLTRCHLT-JHJMLUEUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- GQWMNVOVQZIPJC-UHFFFAOYSA-N 2-(trifluoromethoxy)phenol Chemical compound OC1=CC=CC=C1OC(F)(F)F GQWMNVOVQZIPJC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KXKCTSZYNCDFFG-UHFFFAOYSA-N 2-Methoxy-5-nitrophenol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1O KXKCTSZYNCDFFG-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 description 1
- BTOMIMSUTLPSHA-UHFFFAOYSA-N 2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-n-(2-methyl-4-sulfamoylphenyl)acetamide Chemical compound CC1=CC(S(N)(=O)=O)=CC=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC(Cl)=CC(C#N)=C1 BTOMIMSUTLPSHA-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical group [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- QPYWTEPJJSGXST-UHFFFAOYSA-N 2-chloro-4-methylbenzenesulfonyl bromide Chemical compound ClC1=C(S(=O)(=O)Br)C=CC(=C1)C QPYWTEPJJSGXST-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- PKJBKCJDRDHTGZ-UHFFFAOYSA-N 2-methoxy-4-methylsulfanylphenol Chemical compound COC1=CC(SC)=CC=C1O PKJBKCJDRDHTGZ-UHFFFAOYSA-N 0.000 description 1
- NXVAEVHJWOBXKG-UHFFFAOYSA-N 2-methoxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1OC NXVAEVHJWOBXKG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 1
- KVLRRULUXONAGA-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-methylquinazolin-4-one Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC(F)=C1 KVLRRULUXONAGA-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- UVCIMIRWHXWFAI-UHFFFAOYSA-N 3-methoxy-2-methylbenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1C UVCIMIRWHXWFAI-UHFFFAOYSA-N 0.000 description 1
- RUEQNYRXPSUQBC-UHFFFAOYSA-N 3-methoxy-4-phenylmethoxybenzonitrile Chemical compound COC1=CC(C#N)=CC=C1OCC1=CC=CC=C1 RUEQNYRXPSUQBC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GYXNTPVMXGBRQW-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(Br)C=C1OC(F)(F)F GYXNTPVMXGBRQW-UHFFFAOYSA-N 0.000 description 1
- AEGJXXCGTFMRGY-UHFFFAOYSA-N 4-bromo-2-methoxy-1-phenylmethoxybenzene Chemical compound COC1=CC(Br)=CC=C1OCC1=CC=CC=C1 AEGJXXCGTFMRGY-UHFFFAOYSA-N 0.000 description 1
- RKXKSZGILNYOAQ-UHFFFAOYSA-N 4-hydroxy-3-methoxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(O)C(OC)=C1 RKXKSZGILNYOAQ-UHFFFAOYSA-N 0.000 description 1
- DIDKWCOCQJWMDJ-UHFFFAOYSA-N 5-(1,1-dioxothiazinan-2-yl)-n-[(4-fluorophenyl)methyl]-8-hydroxy-1,6-naphthyridine-7-carboxamide Chemical compound C12=CC=CN=C2C(O)=C(C(=O)NCC=2C=CC(F)=CC=2)N=C1N1CCCCS1(=O)=O DIDKWCOCQJWMDJ-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- NFVBVKHGDDDCEA-UHFFFAOYSA-N 5-hydroxynaphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1O NFVBVKHGDDDCEA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- WWPKRXOOVICNJY-UHFFFAOYSA-N 6-methoxynaphthalen-2-ol Chemical compound C1=C(O)C=CC2=CC(OC)=CC=C21 WWPKRXOOVICNJY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- JNXUGJMCFLONJN-UHFFFAOYSA-N 8-chloroquinolin-2(1H)-one Chemical compound C1=CC(=O)NC2=C1C=CC=C2Cl JNXUGJMCFLONJN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 101100027017 Caenorhabditis elegans ntc-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229940098777 Corticosteroid agonist Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- XLJSKZRVJHXGHF-UHFFFAOYSA-N N-ethyl-3-methoxypyridine-2-carboxamide Chemical compound C(C)NC(=O)C1=NC=CC=C1OC XLJSKZRVJHXGHF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710150451 Protein Bel-1 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- XQYASZNUFDVMFH-CQSZACIVSA-N [5-chloro-2-[2-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)NC(N)=O)C)N1CC1=CC=C(F)C=C1 XQYASZNUFDVMFH-CQSZACIVSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 239000002556 chemokine receptor agonist Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960001447 fomivirsen Drugs 0.000 description 1
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- CSNXUYRHPXGSJD-UHFFFAOYSA-N isoquinolin-5-ol Chemical compound N1=CC=C2C(O)=CC=CC2=C1 CSNXUYRHPXGSJD-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000005573 methoxybenzenes Chemical class 0.000 description 1
- LILZDDAFQNFXLU-VIFPVBQESA-N methyl (2s)-2-quinolin-5-yloxypropanoate Chemical compound C1=CC=C2C(O[C@@H](C)C(=O)OC)=CC=CC2=N1 LILZDDAFQNFXLU-VIFPVBQESA-N 0.000 description 1
- PJSKJGYGIBLIAS-UHFFFAOYSA-N methyl 3-hydroxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1C PJSKJGYGIBLIAS-UHFFFAOYSA-N 0.000 description 1
- NIILYUCSOILJQE-UHFFFAOYSA-N methyl 5-hydroxy-4-methoxypyridine-2-carboxylate Chemical compound COC(=O)C1=CC(OC)=C(O)C=N1 NIILYUCSOILJQE-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WJHGJDGITRCZLH-UHFFFAOYSA-N methyl isoquinoline-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=NC=CC2=C1 WJHGJDGITRCZLH-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001749 primary amide group Chemical group 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 102220115880 rs199505812 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003156 secondary amide group Chemical group 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- SRLDYDBELQHEKL-QRPNPIFTSA-M sodium;(2s)-2-quinolin-5-yloxypropanoate Chemical compound [Na+].C1=CC=C2C(O[C@@H](C)C([O-])=O)=CC=CC2=N1 SRLDYDBELQHEKL-QRPNPIFTSA-M 0.000 description 1
- LZKJPWJJSTWQEB-UHFFFAOYSA-M sodium;[4-[[2-[2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl-propanoylazanide Chemical compound [Na+].CC1=CC(S(=O)(=O)[N-]C(=O)CC)=CC=C1NC(=O)COC1=CC=CC=C1C(=O)C1=CC(Cl)=CC(C#N)=C1 LZKJPWJJSTWQEB-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940010343 valcyte Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1 to R5 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives. The compounds of the present invention inhibit the interaction of gp 120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, or AIDS.
Description
PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS
This invention relates to piperazine derivatives, to processes for their preparation, to compositions containing them and to their use.
More particularly, the present invention relates to the use of piperazine derivatives in the treatment of HIV, such as HIV-1, and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS).
Entry of HIV-1 into a target cell requires cell-surface CD4 and 1o additional host cell cofactors. It is recognised that for efficient entry into target cells, human immunodeficiency viruses require a chemokine receptor, such as CCR5 or CXCR-4, as well as the primary receptor CD4. The principal cofactor for the entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCRS, a receptor for the ~3 t5 chemokines RANTES, MiP-1a and MIP-1~i (Deng et al., 1996, Nature, 38, 661-666). HIV attaches to the CD4 molecules on target cells through a region of its envelope protein, gp120. It is believed that the CD4 binding site on the gp120 of HIV interacts with the CD4 molecule on the target cell surface and undergoes conformational changes, which allow it to bind to further cell-2o surface receptors such as CCR5 or CXCR-4. This brings the viral envelope in closer proximity to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the host cell surface, subsequent fusion with the cell membrane and, ultimately, entry of the viral core into the cell. Accordingly, compounds that inhibit the binding of gp120 with CD4, and 25 hence prevent the entry of HIV-1 into a target cell, should be useful in the treatment of HIV, such as HIV-1, and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS).
According to a first aspect of the present invention, there is provided a compound of formula (I) O
R4 N- _R' R~~ N
Rz o (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:
This invention relates to piperazine derivatives, to processes for their preparation, to compositions containing them and to their use.
More particularly, the present invention relates to the use of piperazine derivatives in the treatment of HIV, such as HIV-1, and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS).
Entry of HIV-1 into a target cell requires cell-surface CD4 and 1o additional host cell cofactors. It is recognised that for efficient entry into target cells, human immunodeficiency viruses require a chemokine receptor, such as CCR5 or CXCR-4, as well as the primary receptor CD4. The principal cofactor for the entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCRS, a receptor for the ~3 t5 chemokines RANTES, MiP-1a and MIP-1~i (Deng et al., 1996, Nature, 38, 661-666). HIV attaches to the CD4 molecules on target cells through a region of its envelope protein, gp120. It is believed that the CD4 binding site on the gp120 of HIV interacts with the CD4 molecule on the target cell surface and undergoes conformational changes, which allow it to bind to further cell-2o surface receptors such as CCR5 or CXCR-4. This brings the viral envelope in closer proximity to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the host cell surface, subsequent fusion with the cell membrane and, ultimately, entry of the viral core into the cell. Accordingly, compounds that inhibit the binding of gp120 with CD4, and 25 hence prevent the entry of HIV-1 into a target cell, should be useful in the treatment of HIV, such as HIV-1, and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS).
According to a first aspect of the present invention, there is provided a compound of formula (I) O
R4 N- _R' R~~ N
Rz o (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:
R' is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo, C1-C6 alkoxy, CF3, OCF3, or CN;
R2 and R3 are independently H, or C1-C6alkyl;
R4 is C1-C6 alkyl;
1o R5 is phenyl; naphthyl; or a C-linked, 6 to 10 membered, mono- or bicyclic, aromatic or partially saturated, heterocycle wherein said heterocycle contains 1 to 4 nitrogen heteroatom(s), 1 or 2 nitrogen and 1 oxygen heteroatoms, or 1 or 2 nitrogen and 1 sulphur heteroatoms; wherein said phenyl, napthyl or heterocycle is optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C~ cycloalkyl, phenyl, OH, C1-Cg alkoxy, C1-C6 alkoxy C1-C6 alkyl, OC1-C6fluoroalkyl, Co-C2 alkylene NR6R', halo, Co-C2 alkylene CN, Co-C2 alkylene C02R8, Co-C2 alkylene CONR6R', Co-C2 alkylene SR9, Co-C2 alkylene SOR9, Co-C2 alkylene S02R9, Co-C2 alkylene SO2NR6R', Co-C2 alkylene NR$CORg, 2o Co-C2 alkylene NR$CONR6R', Co-C2 alkylene NR8SO2R9, or Co-C2 alkylene R'°, or, where R5 is a heterocycle, oxo;
R6 and R' are independently H, C1-C6 alkyl, C3-C~ cycloalkyl, phenyl or Rlo;
or when taken together with the nitrogen to which they are attached form an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, or thiomorpholine ring; wherein the said substituents are 1 or 2 groups selected from C1-C6 alkyl, or Co-C° alkylene NH2;
R$ is H, Ci-C6 alkyl or phenyl;
R9 is C1-C6 alkyl or phenyl; and R'° is imidazolyl, pyrazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzimidazolyl, indazolyl, quinazolinyl, phthalazinyl, benzoxazolyl or quinoxalinyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, cyano or halo.
R2 and R3 are independently H, or C1-C6alkyl;
R4 is C1-C6 alkyl;
1o R5 is phenyl; naphthyl; or a C-linked, 6 to 10 membered, mono- or bicyclic, aromatic or partially saturated, heterocycle wherein said heterocycle contains 1 to 4 nitrogen heteroatom(s), 1 or 2 nitrogen and 1 oxygen heteroatoms, or 1 or 2 nitrogen and 1 sulphur heteroatoms; wherein said phenyl, napthyl or heterocycle is optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C~ cycloalkyl, phenyl, OH, C1-Cg alkoxy, C1-C6 alkoxy C1-C6 alkyl, OC1-C6fluoroalkyl, Co-C2 alkylene NR6R', halo, Co-C2 alkylene CN, Co-C2 alkylene C02R8, Co-C2 alkylene CONR6R', Co-C2 alkylene SR9, Co-C2 alkylene SOR9, Co-C2 alkylene S02R9, Co-C2 alkylene SO2NR6R', Co-C2 alkylene NR$CORg, 2o Co-C2 alkylene NR$CONR6R', Co-C2 alkylene NR8SO2R9, or Co-C2 alkylene R'°, or, where R5 is a heterocycle, oxo;
R6 and R' are independently H, C1-C6 alkyl, C3-C~ cycloalkyl, phenyl or Rlo;
or when taken together with the nitrogen to which they are attached form an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, or thiomorpholine ring; wherein the said substituents are 1 or 2 groups selected from C1-C6 alkyl, or Co-C° alkylene NH2;
R$ is H, Ci-C6 alkyl or phenyl;
R9 is C1-C6 alkyl or phenyl; and R'° is imidazolyl, pyrazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzimidazolyl, indazolyl, quinazolinyl, phthalazinyl, benzoxazolyl or quinoxalinyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, cyano or halo.
The term "alkyl" as a group or part of a group includes straight chain and branched groups. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n=butyl, i-butyl, sec-butyl and t-butyl. The term "C3_7 cycloalkyl"
means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The term "halo" means fluoro, chloro, bromo or iodo.
In a further embodiment, R' is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo.
In yet a further embodiment, R' is phenyl, fluorophenyl or pyridyl.
In yet a further embodiment, R' is phenyl.
o In yet a further embodiment, R2 is C~-C4alkyl.
In yet a further embodiment, R2 is methyl.
In yet a further embodiment, R3 is H.
In yet a further embodiment, R4 is C1-C4alkyl.
In yet a further embodiment, R4 is methyl.
In yet a further embodiment, R5 is an optionally substituted phenyl, naphthyl, pyridyl, indazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzopiperidinyl or benzoxazolyl; wherein said substituents are to 3 atoms or groups selected from C1-C6 alkyl, C~-C6 alkoxy, halo, CN, CO2R8, CONR6R7, or R'o.
2o In yet a further embodiment, R5 is an optionally substituted phenyl or pyridyl, wherein said substituents are 1 to 3 groups selected from C1-C6 alkoxy, C02R8, or CONR6R'.
In yet a further embodiment, R6 is H or Ci-C4 alkyl.
In yet a further embodiment, R' is H, C1-C4 alkyl or C3-C6 cycloalkyl.
In yet a further embodiment, R8 is C1-C4 alkyl.
In yet a further embodiment, R'° is imidazolyl, pyrazolyl, triazolyl or oxadiazolyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C4 alkyl, C1-C4 alkoxy, cyano or halo.
In yet a further embodiment, there is provided a compound of formula (la) O
N~R~
R ' Rv N
O ~ R2 O
(la) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R'; R2, R3, R4 and R5 are as defined hereinabove with respect to a compound of formula (I), including all combinations of particular described embodiments thereof.
In yet a further embodiment, there is provided a compound of formula (1b) O
R ~N R1 RIO N
(1b) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R', R2, R4 and R5 are as defined hereinabove with respect to a compound of formula (I), including all combinations of particular described embodiments thereof.
It is to be understood that the invention covers all combinations of particular embodiments of the invention as described hereinabove, consistent with the definition of compounds of formula (I).
The compounds of the invention include compounds of formula (I) and pharmaceutically acceptable salts, solvates or derivatives thereof (wherein 2o derivatives include complexes, polymorphs, prodrugs and isotopically-labeled compounds, as well as salts, solvates and salt solvates thereof), and isomers thereof. In a further embodiment, the compounds of the invention are the compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, in particular the compounds of formula (I). It is to be understood that the aforementioned compounds of the invention include polymorphs and isomers thereof.
Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof.
Suitable acid addition salts are formed from acids which form non-toxic 3o salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate, bisulphate, borate, bromide, camsylate, carbonate, chloride, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrobromide, hydrochloride]
hydroiodide, iodide, iseth'ionate, lactate, malate, maleate, malonate, mesylate, ~ methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen 5 phosphate/dihydrogen phosphate, saccharate, stearate, succinate, sulphate, tartrate, tosylate and trifluoroacetate salts.
Suitable base salts are formed from bases which form non-toxic salts.
Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, o potassium, sodium, tromethamine and zinc salts.
For a review on suitable salts, see "Handbook of Pharmaceutical Salts:
Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Pharmaceutically acceptable salts of compounds of formula (I) may be prepared by one or more of three methods:
(i) by reacting the compound of formula (I) with the desired acid or base;
(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired 2o acid or base; or (iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
All three reactions are typically carried out in solution. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised.
The compounds of the invention may exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular 3o complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Complexes include clathrates, i.e. drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the pharmaceutical drug which contain two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
The compounds of the present invention may have the ability to crystallize in more than one form, a characteristic known as polymorphism, and all such polymorphic forms ("polymorphs") are encompassed within the scope of the invention. Polymorphism generally can occur as a response to changes in temperature or pressure or both, and can also result from variations in the crystallization process. Polymorphs can be distinguished by 1 o various physical characteristics, and typically the x-ray diffraction patterns, solubility behavior, and melting point of the compound are used to distinguish polymorphs.
Certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T
Higuchi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon 2o Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro moieties' as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985).
Some examples of prodrugs in accordance with the invention include:
(i) where the compound of formula (I) contains a carboxylic acid functionality (-CO~H), an ester thereof, for example, replacement of the hydrogen with (Cy-C6)alkyl;
(ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with (C1-C6)alkanoyloxymethyl; and (iii) where the compound of formula (I) contains a primary or secondary amino functionality (-NH2 or -NHR where R ~ H), an amide thereof, for ss example, replacement of one or both hydrogens with (Ci-Cio)alkanoyl.
means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The term "halo" means fluoro, chloro, bromo or iodo.
In a further embodiment, R' is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo.
In yet a further embodiment, R' is phenyl, fluorophenyl or pyridyl.
In yet a further embodiment, R' is phenyl.
o In yet a further embodiment, R2 is C~-C4alkyl.
In yet a further embodiment, R2 is methyl.
In yet a further embodiment, R3 is H.
In yet a further embodiment, R4 is C1-C4alkyl.
In yet a further embodiment, R4 is methyl.
In yet a further embodiment, R5 is an optionally substituted phenyl, naphthyl, pyridyl, indazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzopiperidinyl or benzoxazolyl; wherein said substituents are to 3 atoms or groups selected from C1-C6 alkyl, C~-C6 alkoxy, halo, CN, CO2R8, CONR6R7, or R'o.
2o In yet a further embodiment, R5 is an optionally substituted phenyl or pyridyl, wherein said substituents are 1 to 3 groups selected from C1-C6 alkoxy, C02R8, or CONR6R'.
In yet a further embodiment, R6 is H or Ci-C4 alkyl.
In yet a further embodiment, R' is H, C1-C4 alkyl or C3-C6 cycloalkyl.
In yet a further embodiment, R8 is C1-C4 alkyl.
In yet a further embodiment, R'° is imidazolyl, pyrazolyl, triazolyl or oxadiazolyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C4 alkyl, C1-C4 alkoxy, cyano or halo.
In yet a further embodiment, there is provided a compound of formula (la) O
N~R~
R ' Rv N
O ~ R2 O
(la) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R'; R2, R3, R4 and R5 are as defined hereinabove with respect to a compound of formula (I), including all combinations of particular described embodiments thereof.
In yet a further embodiment, there is provided a compound of formula (1b) O
R ~N R1 RIO N
(1b) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R', R2, R4 and R5 are as defined hereinabove with respect to a compound of formula (I), including all combinations of particular described embodiments thereof.
It is to be understood that the invention covers all combinations of particular embodiments of the invention as described hereinabove, consistent with the definition of compounds of formula (I).
The compounds of the invention include compounds of formula (I) and pharmaceutically acceptable salts, solvates or derivatives thereof (wherein 2o derivatives include complexes, polymorphs, prodrugs and isotopically-labeled compounds, as well as salts, solvates and salt solvates thereof), and isomers thereof. In a further embodiment, the compounds of the invention are the compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, in particular the compounds of formula (I). It is to be understood that the aforementioned compounds of the invention include polymorphs and isomers thereof.
Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof.
Suitable acid addition salts are formed from acids which form non-toxic 3o salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate, bisulphate, borate, bromide, camsylate, carbonate, chloride, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrobromide, hydrochloride]
hydroiodide, iodide, iseth'ionate, lactate, malate, maleate, malonate, mesylate, ~ methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen 5 phosphate/dihydrogen phosphate, saccharate, stearate, succinate, sulphate, tartrate, tosylate and trifluoroacetate salts.
Suitable base salts are formed from bases which form non-toxic salts.
Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, o potassium, sodium, tromethamine and zinc salts.
For a review on suitable salts, see "Handbook of Pharmaceutical Salts:
Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Pharmaceutically acceptable salts of compounds of formula (I) may be prepared by one or more of three methods:
(i) by reacting the compound of formula (I) with the desired acid or base;
(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired 2o acid or base; or (iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
All three reactions are typically carried out in solution. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised.
The compounds of the invention may exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular 3o complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Complexes include clathrates, i.e. drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the pharmaceutical drug which contain two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
The compounds of the present invention may have the ability to crystallize in more than one form, a characteristic known as polymorphism, and all such polymorphic forms ("polymorphs") are encompassed within the scope of the invention. Polymorphism generally can occur as a response to changes in temperature or pressure or both, and can also result from variations in the crystallization process. Polymorphs can be distinguished by 1 o various physical characteristics, and typically the x-ray diffraction patterns, solubility behavior, and melting point of the compound are used to distinguish polymorphs.
Certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T
Higuchi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon 2o Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro moieties' as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985).
Some examples of prodrugs in accordance with the invention include:
(i) where the compound of formula (I) contains a carboxylic acid functionality (-CO~H), an ester thereof, for example, replacement of the hydrogen with (Cy-C6)alkyl;
(ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with (C1-C6)alkanoyloxymethyl; and (iii) where the compound of formula (I) contains a primary or secondary amino functionality (-NH2 or -NHR where R ~ H), an amide thereof, for ss example, replacement of one or both hydrogens with (Ci-Cio)alkanoyl.
Further examples of replacement groups in accordance with the -foregoing examples and examples of other prodrug types in accordance with the invention may be found in the aforementioned references.
Moreover, certain compounds of formula (I) may themselves act as s prodrugs of other compounds of formula (I).
Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites in accordance with the invention include:
(i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH3 -> -CH20H):
(ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH);
(iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR'R2 -> -NHR' or -NHR2);
(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (-NHR' -> -NH2);
(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH); and (vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH2 -> COOH).
In view of the definition of R4, compounds of formula (I) contain one or more asymmetric carbon atoms and therefore exist as two or more optical isomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, geometric cisltrans (or Z/E) isomers are possible, and where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') may occur. It follows that a single compound may exhibit more than one type of isomerism.
Included within the scope of the present invention are all optical 3o isomers, geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, D-lactate or L
lysine, or racemic, for example, DL-tartrate or DL-arginine.
Cisltrans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
Moreover, certain compounds of formula (I) may themselves act as s prodrugs of other compounds of formula (I).
Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites in accordance with the invention include:
(i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH3 -> -CH20H):
(ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH);
(iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR'R2 -> -NHR' or -NHR2);
(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (-NHR' -> -NH2);
(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH); and (vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH2 -> COOH).
In view of the definition of R4, compounds of formula (I) contain one or more asymmetric carbon atoms and therefore exist as two or more optical isomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, geometric cisltrans (or Z/E) isomers are possible, and where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') may occur. It follows that a single compound may exhibit more than one type of isomerism.
Included within the scope of the present invention are all optical 3o isomers, geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, D-lactate or L
lysine, or racemic, for example, DL-tartrate or DL-arginine.
Cisltrans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or o fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically ~5 HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50%
isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
2o Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994).
The present invention also includes all pharmaceutically acceptable 25 isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes suitable for inclusion in the compounds of the so invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C' 1sC and '4C, chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 1231 and '251, nitrogen, such as'3N and 15N, oxygen, such as'S0, 170 and'$O, phosphorus, such as 32P, and sulphur, such as 35S.
Certain isotopically-labelled compounds of formula (I), for example, 35 those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e.'4C, are particularly useful for this purpose in view of their ease-of incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting trom greater metaoonc stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Substitution with positron emitting isotopes, such as "C, '$F,'50 and '3N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
o Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
~5 Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, d6-acetone, d6-DMSO.
Preferred compounds of formula (I) include the compounds of Examples 1-94; and pharmaceutically acceptable salts, solvates or 2o derivatives thereof. Particularly preferred compounds of formula (I) include:
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)]-2-(3-methyl-1 H-indazol-4-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[2-(2H-pyrazol-3-ylamino)-quinolin-5-yloxy]-propan-1-one;
25 5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-isoquinoline-1-carboxylic acid methylamide;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(5-chloro-2-methylamino-quinolin-5-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[1-(2H-pyrazol-3-ylamino)-3o isoquinolin-5-yloxy]-propan-1-one;
4-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-3-methoxy-N-methyl-benzamide;
5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methylamide;
35 5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid amide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-' methoxy-pyridine-2-carboxylic acid ethylamide;
5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cyclopropylamide;
5 and pharmaceutically acceptable salts, solvates or derivatives thereof.
In the general processes, and schemes, that follow: R' to R9 are as previously defined unless otherwise stated; X is halo or hydroxy; Y is a leaving group, such as chloro, bromo, tosylate, mesylate or hydroxy; DMF is 1o N,N-dimethylformamide; DMSO is dimethylsulphoxide; THF is tetrahydrofuran; WSCDI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DCC is N,N'-dicyclohexylcarbodiimide; HOAT is 1-hydroxy-7-azabenzotriazole; HOBt is 1-hydroxybenzotriazole hydrate; HBTU is O-(1 H-benzotriazol-1-yl)-N,N,N,I~P-tetramethyluronium hexafluorophosphate;
PyBOP~ is benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate; PyBrOP is bromo-tris-pyrrolidino-phosphonium hexafluorophosphate; Hunigs base is N-ethyldiisopropylamine; and Mukaiyama's reagent is 2-chloro-1-methylpyridinium iodide.
Compounds of formula (I) may be prepared by any methods known for 2o the preparation of compounds of analogous structure.
Compounds of formula (I), and intermediates thereto, may be prepared according to the schemes that follow.
It will be appreciated by those skilled in the art that certain of the procedures described in the schemes for the preparation of compounds of formula (I) or intermediates thereto may not be applicable to some of the possible substituents.
It will be further appreciated by those skilled in the art that it may be necessary or desirable to carry out the transformations described in the schemes in a different order from that described, or to modify one or more of 3o the.transformations, to provide the desired compound of formula (I).
It will be still further appreciated by those skilled in the art that, as illustrated in the schemes that follow, it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions.
In particular, it may be necessary or desirable to protect amino groups. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G
M Wuts, third edition, (Johri Wiley and Sons, 1999), in particular chapter 7, pages 494=653 ("Protection for the Amino Group"), incorporated herein by reference, which also describes methods for the removal of such groups.
s The amino protecting groups boc, benzyloxycarbonyl, benzyl and acetyl are of particular use in the preparation of compounds of formula (I) and intermediates thereto.
Scheme 1 ~NH
HN~2 (IX) O
a ~R' (V) O
R3 R4 Rs R4 ~NH s N"R' Rw X
RIO N~2 O HN~ 2 (VII) I O R
O (IV) X
Y
a ~ ( ) ~ (VIII) X"R' (V) (c) O
N"R' N ~2 R
(II) R~ OH
(III) (f) R3~
R4 ~N R' RIO N
O (I) With specific reference to scheme 1, the transformations depicted therein may be effected as follows:
(a)-(e) Acid-amine coupling reactions Typically the acid chloride or acid bromide of formulae (V), (VI) or (VIII), and the appropriate piperazine of formulae (IV), (VII) or (IX), optionally with an excess of an acid acceptor such as triethylamine or N ethyl-N,N
diisopropylamine, are reacted in a solvent, such as an haloalkane (e.g.
dichloromethane) or an ether (e.g. THF) at room temperature for 1-24 hours.
The reactions may conveniently be carried out by reacting the relevant piperazine with 1.1 equivalents of the relevant acid chloride in dichloromethane at room temperature for 1 hour.
1o In a further embodiment the acid of formulae (V), (VI) or (VIII), activated by suitable reagents such as WSCDI/DCC and HOBdHOAt, the appropriate piperazine of formulae (IV), (VII) or (IX), and an excess of an acid acceptor such as triethylamine or N ethyl-N,N diisopropylamine, are reacted in a solvent such as an haloalkane (e.g. dichloromethane), an ether (e.g.
THF) or DMF at room temperature for 4-48 hours. The reactions may conveniently be carried out by reacting the relevant piperazine, 1.4 equivalents of WSCDI, 1.4 equivalents of HOBt, 2.2 equivalents of triethylamine and 1.1 equivalents of the relevant carboxylic acid in dichloromethane at room temperature for 18 hours.
2o In yet a further embodiment, the acid of formulae (V), (VI) or (VIII), the appropriate piperazine of formulae (IV), (VII) or (IX), and either HBTU, PyBOP, PyBrOP or Mukaiyama's reagent, and an excess of an acid acceptor such as triethylamine or N ethyl-N,N diisopropylamine, may be reacted in a solvent such as an haloalkane (e.g. dichloromethane) or an ether (e.g. THF) at room temperature for 4-24 hours. The reactions may conveniently be carried out by reacting the relevant piperazine, 1.0 equivalents of the relevant carboxylic acid and 1.5 equivalents of HBTU in either dichloromethane or DMF at room temperature for 14 hours.
(f) Nucleophilic substitution 3o i) When Y= CI, Br, mesylate, tosylate:
Typically compounds of formulae (II) and (III), with an acid acceptor, such as triethylamine , N ethyl-N,N diisopropylamine or an alkali metal carbonate, are reacted in a solvent such as an haloalkane (e.g.
dichloromethane), an ether (e.g. THF) or acetone at a temperature between room temperature and reflux for 1-24 hours. The reactions may conveniently be carried out by reacting compounds of formulae (II) and (III) with 1.0 equivalents of caesium carbonate in acetone at reflux for 14 hours.
ii) When Y= OH:
Typically compounds of formulae (II) and (III), triphenylphosphine or tri-o-tolylphosphine, and either diethyl azodicarboxylate or di-isopropyl azodicarboxylate, are reacted in a solvent such as an haloalkane (e.g.
dichloromethane) or an ether (e.g. THF) at a temperature between room temperature and reflux for 1-24 hours. The reactions may conveniently be carried out by reacting compounds of formulae (II) and (III) with 1.2 equivalents of triphenylphosphine and 1.1 equivalents of di-isopropyl azodicarboxylate in THF at room temperature for 14 hours.
1o Compounds of formula (VI) in reaction steps (a) and (d) may be prepared according to scheme 1 a that follows.
Scheme 1 a R4 R5 OH (III) Ra Ra OR ~ RIO OR ~ RIO OH
Y
O (J) (h) O
O
(X) (XI) (VI) wherein R is a lower alkyl such as C1-C6 alkyl.
(g) Nucleophilic substitution Nucleophilic substitution may be effected according to the conditions described for step (f) hereinabove.
(h) Ester hydrolysis Typically, compounds of formula (XI), aqueous alkali metal hydroxide solution or aqueous hydrochloric acid solution, and an optional co-solvent such as ethanol or dioxane, are heated at a temperature between 60 and 100°C for 1-18 hours. The reactions may conveniently be carried out by heating compounds of formula (XI) in aqueous 1 N sodium hydroxide solution and dioxane heated at 60 °C for 2 hours.
so Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Compounds of formulae (II), (IV) and (VII) are key intermediates and represent a particular aspect of the present invention.
Compounds of formulae (III), (V), (VIII), (IX) and (X) are either known compounds or may be prepared by conventional chemistry.
According to another aspect, the invention provides the following processes for preparing compounds of formula (I).
5 According to a first process (A), compounds of formula (I) may be prepared by coupling an acid of formula (V) O
X" R' (V) 1o with a piperazine of formula (IV), under conventional acid-amine coupling conditions.
R4 ~NH
R ~O N
(IV) Conveniently, acid-amine coupling is effected under the conditions described 15 hereinabove in connection with scheme 1, steps (a)-(e).
Acoording to a second process (B), compounds of formula (I) may be prepared by coupling an acid of formula (VI) RIO X
~ (VI) with a piperazine of formula (VII), under conventional acid-amine coupling conditions.
O
N- _R1 HN
R2 (VII) Conveniently, acid amine coupling is effected under the conditions described hereinabove in connection with scheme 1, steps (a)-(e).
According to a third process (C), compounds of formula (I) may be-prepared by nucleophilic substitution of a compound of formula (II) O
R3 ~~
a N~R~
R ' N
Y ~ R2 O (II) with an alcohol R50H of formula (III) under conventional conditions.
Conveniently, nucleophilic substitution is effected under the conditions described hereinabove in connection with scheme 1, step (f).
According to a fourth process (D), compounds of formula (I) may be 1o prepared from other compounds of formula (I) by functional group interconversion under conventional conditions. For example, compounds of formula (I) which contain an ester group may be converted to corresponding compounds of formula (I) which contain a primary or secondary amide group by reacting the former with ammonia or a primary amine respectively.
The compounds of the invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, and AIDS.
Accordingly, in another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof 2o for use as a medicament.
In another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof for use in the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
In another aspect the invention provides the use of a compound of formula (I) or of a pharmaceutically acceptable salt, solvate or derivative thereof for the manufacture of a medicament for the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
In another aspect the invention provides a method of treatment of a mammal suffering from HIV, a retroviral infection genetically related to HIV, or 3o AIDS which comprises treating said mammal with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof.
The compounds of the invention may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or in any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable 1o excipients. The term "excipient" is used herein to describe any ingredient other than the compounds) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Pharmaceutical compositions suitable for the delivery of compounds of the invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).
2o The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs.
3o Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents andlor suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
s5 The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001 ).
'18 For tablet dosage forms, depending on dose, the drug may make up -from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the-dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, s sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the 1o dosageform.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
Tablets may also optionally comprise surface active agents, such as 2o sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnesium stearate, 2s calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt°/~ to 10 wt°/~, preferably from 0.5 wt% to 3 wt% of the tablet.
Other possible ingredients include anti-oxidants, colourants, flavours, so preservatives and taste-masking agents.
Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt%
lubricant.
35 Tablet blends may be compressed directly or by roller to form tablets.
Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or~
uncoated; it may even be encapsulated.
The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1 ", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).
Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Suitable modified release formulations for the purposes of the 1o invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral 2o administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard 3o pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the compound. Examples of such formulations include drug-coated sterits and PGLA microspheres.
The compounds of the invention may also be administered topically to 5 the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, 1o white petrolatum, glycerin, polyethylene glycol and propylene glycol.
Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999).
Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle 1s or needle-free (e.g. PowderjectT"", BiojectTM, etc.) injection.
Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally 20 or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser so contains a solution or suspension of the compound comprising, for example, ethanol (optionally, aqueous ethanol) or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, the propellants) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid -processing to form nanoparticles, high pressure homogenisation, or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as I leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, 1o glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 p1 to 1 OOpI. A typical formulation may comprise a compound of the invention, propylene glycol, sterile water, ethanol and sodium chloride.
Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. lJnits in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1 Ng to 1 Omg of the compound of the invention.
3o The overall daily dose will typically be in the range 1 pg to 200mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema.
Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Formulations for rectal/vaginal administration may be formulated to be-immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g.
absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as o niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.
The compounds of the invention may be combined with soluble 2o macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of so which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98!55148.
Inasmuch as it may desirable to administer a compound of the invention in combination with another therapeutic agent, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound of the invention, may conveniently be combined in the form of a kit suitable for coadministration of the-compositions.
Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
The kit of the invention is particularly suitable for administering different o dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.
For administration to human patients, having a weight of about 65 to 70kg, the total daily dose of a compound of the invention is typically in the range 1 to 10000mg, such as 10 to 1000mg, for example 25 to 500mg, depending, of course, on the mode of administration, the age, condition and weight of the patient, and will in any case be at the ultimate discretion of the 2o physician. The total daily dose may be administered in single or divided doses.
Accordingly in another aspect the invention provides a pharmaceutical composition including a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers.
The compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives have the advantage that they are more selective, have a more rapid onset of action, are more potent, are better absorbed, are more stable, are more resistant to metabolism, have a reduced 'food effect', have an improved safety profile or have other more desirable properties (e.g. with respect to solubility or hygroscopicity) than the compounds of the prior art.
The compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives may be administered alone or as part of a combination therapy. Thus included within the scope of the present invention are embodiments comprising coadministration of, and compositions which contain, in addition to a compound of the invention, one or more additional therapeutic agents. Such multiple drug regimens, often referred to as-combination therapy, may ~ be used in the treatment and prevention of infection by human immunodeficiency virus, HIV. The use of such combination therapy is especially pertinent with respect to the treatment and prevention of infection and multiplication of the human immunodeficiency virus, HIV, and related pathogenic retroviruses within a patient in need of treatment or one at risk of becoming such a patient. The ability of such retroviral pathogens to evolve within a relatively short period of time into strains resistant to any monotherapy which has been administered to said 1o patient is well known in the literature. A recommended treatment for HIV is a combination drug treatment called Highly Active Anti-Retroviral Therapy, or HAART. HAART combines three or more HIV drugs. Thus, the methods of treatment and pharmaceutical compositions of the present invention may employ a compound of the invention in the form of monotherapy, but said ~5 methods and compositions may also be used in the form of combination therapy in which one or more compounds of the invention are coadministered in combination with one or more additional therapeutic agents such as those described in detail further herein.
In a further embodiment of the invention, combinations of the present 2o invention include treatment with a compound of formula (l), or a pharmaceutically acceptable salt, solvate or derivative thereof, and one or more additional therapeutic agents selected from the following: HIV protease inhibitors, including but not limited to indinavir, ritonavir, saquinavir, nelfinavir, lopinavir, amprenavir, atazanavir, tipranavir, AG1859 and TMC 114; non 25 nucleoside reverse transcriptase inhibitors (NNRTIs), including but not limited to nevirapine, delavirdine, capravirine, efavirenz, GW-8248, GW-5634 and TMC125; nucleoside/nucleotide reverse transcriptase inhibitors, including but not limited to zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, adefovir dipivoxil, tenofovir, emtricitabine and alovudine; CCR5 3o antagonists, including but not limited to:
N-f (1 S)-3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1 ]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide or a pharmaceutically acceptable salt, solvate or derivative thereof, s5 methyl 1-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl}-2-methyl-4,5,6,7-tetrahydro-1 H imidazo[4,5-c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or~
derivative thereof, methyl - 3-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl)-2-methyl-4,5,6,7-tetrahydro-3H imidazo[4,5-5 c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or derivative thereof, ethyl 1-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl}-2-methyl-4,5,6,7-tetrahydro-1 H imidazo[4,5-c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or ~o derivative thereof, Sch-D, ONO-4128, GW-873140, AMD-887 and CMPD-167; other agents which inhibit the interaction of gp120 with CD4, including but not limited to BMS806 and BMS-488043; other agents which inhibit the entry of HIV into a target cell, including but not limited to enfuviritide, T1249, PRO 542 and 15 PRO 140; integrase inhibitors, including but not limited to L-870,810; and RNaseH inhibitors.
There is also included within the scope the present invention, combinations of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof, together with one or more additional 2o therapeutic agents independently selected from the group consisting of proliferation inhibitors, e.g. hydroxyurea; immunomodulators, such as granulocyte macrophage colony stimulating growth factors (e.g.
sargramostim), and various forms of interferon or interferon derivatives;
other chemokine receptor agonists/antagonists, such as CXCR4 antagonists (e.g.
25 AMD-070); tachykinin receptor modulators (e.g. NtC1 antagonists) and various forms of interferon or interferon derivatives; agents which substantially inhibit, disrupt or decrease viral transcription or RNA replication such as inhibitors of tat (transcriptional trans activator) or nef (negative regulatory factor);
agents which substantially inhibit, disrupt or decrease translation of one or more so proteins expressed by the virus (including, but not limited to, down regulation of protein expression or antagonism of one or more proteins) other than reverse transcriptase, such as Tat or Nef; agents which influence, in particular down regulate, CCR5 receptor expression; chemokines that induce CCR5 receptor internalisation such MIP-1 a, MIP-1 [3, RANTES and derivatives thereof; and other agents that inhibit viral infection or improve the condition or outcome of HIV-infected individuals through different mechanisms.
Agents which influence (in particular down regulate) CCR5 receptor-expression include immunosupressants, such as calcineurin inhibitors (e.g. tacroliinus and cyclosporin A); steroids; agents which interfere with cytokine production or signalling, such as Janus Kinase (JAK) inhibitors (e.g. JAK-3 inhibitors, including 3-{(3R,4R)-4-methyl-3-[methyl-(7H
pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile) and pharmaceutically acceptable salts, solvates or derivatives thereof; cytokine antibodies (e.g. antibodies that inhibit the interleukin-2 (IL-2) receptor, including basiliximab and daclizumab); and agents which interfere with cell 1o activation or cell cycling, such as rapamycin.
There is also included within the scope the present invention, combinations of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof, together with one or more additional therapeutic agents which slow down the rate of metabolism of the compound 5 of the invention, thereby leading to increased exposure in patients.
Increasing the exposure in such a manner is known as boosting. This has the benefit of increasing the efficacy of the compound of the invention or reducing the dose required to achieve the same efficacy as an unboosted dose. The metabolism of the compounds of the invention includes oxidative processes 2o carried out by P450 (CYP450) enzymes, particularly CYP 3A4 and conjugation by UDP glucuronosyl transferase and sulphating enzymes. Thus, among the agents that may be used to increase the exposure of a patient to a compound of the present invention are those that can act as inhibitors of at least one isoform of the cytochrome P450 (CYP450) enzymes. The isoforms 25 of CYP450 that may be beneficially inhibited include, but are not limited to, CYP1 A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4. Suitable agents that may be used to inhibit CYP 3A4 include, but are not limited to, ritonavir, saquinavir or ketoconazole.
It will be appreciated by a person skilled in the art, that a combination so drug treatment, as described herein above, may comprise two or more compounds having the same, or different, mechanism of action. Thus, by way of illustration only, a combination may comprise a compound of the invention and: one or more NNRTIs; one or more NRTIs and a PI; one or more NRTIs and a CCR5 antagonist; a PI; a PI and an NNRTI; and so on.
35 In addition to the requirement of therapeutic efficacy, which may necessitate the use of therapeutic agents in addition to the compounds of the invention, there may be additional rationales which compel or highly recommend the use of a combination of a compound of the invention and -another therapeutic agent, such as in the treatment of diseases or conditions which directly result from or indirectly accompany the basic or underlying disease or condition. For example, it may be necessary or at least desirable to treat Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Human Papillomavirus (HPV), opportunistic infections (including bacterial and fungal infections), neoplasms, and other conditions which occur as the result of the immune-compromised state of the patient being treated. Other therapeutic agents may be used with the compounds of the invention, e.g., in order to 1o provide immune stimulation or to treat pain and inflammation which accompany the initial and fundamental HlV infection.
Accordingly, therapeutic agents for use in combination with the compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives also include: interferons, pegylated interferons (e.g.
peginterferon alfa-2a and peginterferon alfa-2b), lamivudine, ribavirin, and emtricitabine for the treatment of hepatitis; antifungals such as fluconazole, itraconazole, and voriconazole; antibacterials such as azithromycin and clarithromycin; interferons, daunorubicin, doxorubicin, and paclitaxel for the treatment of AIDS related fCaposi's sarcoma; and cidofovir, fomivirsen, 2o foscarnet, ganciclovir and valcyte for the treatment of cytomegalovirus (CMV) retinitis.
Further combinations for use according to the invention include combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof with a CCR1 antagonist, such as BX-471; a beta adrenoceptor agonist, such as salmeterol; a corticosteroid agonist, such fluticasone propionate; a LTD4 antagonist, such as montelukast; a muscarinic antagonist, such as tiotropium bromide; a PDE4 inhibitor, such as cilomilast or roflumilast; a CO?C-2 inhibitor, such as celecoxib, valdecoxib or rofecoxib;
an alpha-2-delta ligand, such as gabapentin or pregabalin; a beta-interferon, so such as REBIF; a TNF receptor modulator, such as a TNF-alpha inhibitor (e.g. adalimumab), a HMG CoA reductase inhibitor, such as a statin (e.g.
atorvastatin); or an immunosuppressant, such as cyclosporin or a macrolide such as tacrolimus.
In the above-described combinations, the compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof and other therapeutic agents) may be administered, in terms of dosage forms, either separately or in conjunction with each other; and in terms of their time of administration, either simultaneously or sequentially. Thus, the administration -of one component agent may be prior to, concurrent with, or subsequent to the administration of the other component agent(s).
Accordingly, in a further aspect the invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof and one or more additional therapeutic agents.
It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.
1o The invention is illustrated by the following Examples and Preparations in which the following further abbreviations may be used:
0.88 ammonia = concentrated ammonium hydroxide solution, 0.88 SG
h = hour min = minute LRMS = low resolution mass spectrum APCI+ = atmospheric pressure chemical ionisation ESI+ = electrospray ionisation NMR = nuclear magnetic resonance tlc - thin layer chromatography 2o Me = methyl Example 1 (2S~[(2R~ 4-Benzoyl-2-methyl-~perazin-1-yl)-2-(quinolin-5-yloxy)-propan-1-one Me ~N I \
Ni I O N /
\ O Me A solution of (2S)-2-(quinolin-5-yloxy)-propionic acid sodium salt (Preparation 2) (1.0 g, 4.6 mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J.
Med. Chem. (2000), 43(23), 4499) (0.94 g, 4.6 mmol), O-(1 H-benzotriazol-1-so yl)-N,N,I~P,I~P-tetramethyluronium hexafluorophosphate (2.62 g, 6.9 mmol) and triethylamine (1.93 ml, 13.8 mmol) in N,N dimethylformamide (30 ml) was stirred under a nitrogen atmosphere at room temperature for 14 hours. The reaction mixture was diluted with dichloromethane (100 ml), washed with water (3 X 50 ml), dried (MgS04) and solvent evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel eluting with dichloromethane: methanol (98:2) to afford the title compound as a white solid (0.91 g).
1 H NMR (400MHz, CDC13): b: 8.90 (1 H, m), 8.60 (1 H, m), 7.70 (1 H, m), 7.55 (1 H, m), 7.20-7.40 (6H, m), 6.85 (1 H, m), 5.15 (1 H, m), 4.80-2.80 (7H, m), 1.70 (3H, d), 0.90 (3H, br s) ppm.
LRMS (APCI+) : m/z [M+H]+ 404.
1o Example 2 3-f2-l(2Rl-4-Benzovl-2-methyl-piperazin-1-vl)-1-methyl-2-oxo-ethoxv]-2-methyl-benzoic acid methyl ester Me ~N ~ \
Me0 \ O N
O Me O Me Cesium carbonate (0.39 g, 1.2 mmol) was added portionwise to a solution of 1-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one (Preparation 3) (0.41 g, 1.2 mmol) and 3-hydroxy-2-methyl-benzoic acid methyl ester (Tet. Lett. (2000), 41 (11 ), 1741 ) (0.2 g, 1.2 mmol) in acetone (10 ml) and the mixture heated under reflux for 14 hours. The cooled reaction 2o mixture was evaporated to dryness under reduced pressure and the residue partitioned between dichloromethane (50 ml) and water (10 ml). The organic phase was separated and the aqueous phase extracted with dichloromethane (3 X 30 ml), the combined organic extracts were dried (MgS04) and solvent evaporated under reduced pressure to afford the title compound as a white solid (0.5 g).
1 H NMR (400MHz, CDC13): S: 7.50-7.30 (6H, m), 7.15 (1 H, m), 6.95 (1 H, m), 4.95 (1 H, m), 4.80-2.80 (7H, m), 3.90 (3H, s), 2.40 (3H, s), 1.65 (3H, d), 1.20 (3H, br s) ppm.
LRMS (APCI+) : mlz [M+H]+ 425.
3o Examples 3-12 were prepared by the method described above for Example 1, using the corresponding acid of formula (VI) and piperazine of formula (VI I). LRMS was by APCI+ and data quoted are for [M+H]+.
Mass Example Structure Spec.
Number Data /
3 \ I Me ~N I \ 386 CI O /
O Me O
Me ~N \
4 \ ~ N ~ , 380 Me O
Me O Me O
Me ~N \
5 \ I N ~ / 408 ~o HN~ ~ Me O F
Me ~N \
6 ~ / ~ _ N ~ / 422 \ ~ ~ ~ Me O
Me ~N \ F
N ~ / 422 N, Y ~O
\ O Me O
Me ~N \
8 ~ / I _ N ~ / 422 N, Y O F
\ ~ Me O
Me ~N Nw 9 ~ / ~ N ~ / 405 N, Y ~O
\ O Me Mass Example .
Structure Spec.
Number Data Me ~N ~ ~ N
N ~ o N ~ 405 \ ~ O Me O O
Me~H \ ~ Me ~''N ~ \' 440 OMe O Me O
Me ~N ~ \
12 \ o N ~ 407 HN
N- O Me Me Examples 13-45 were prepared by the method described above for Example 2, using the corresponding compound of formula (II) and R5~H.
LRMS was by APCI+ and data quoted are for [M+H]+, unless otherwise s stated.
Mass Example Structure Spec.
Number Data o 13 \ I Me ~N I j 386 Ci O
O Me Mass Example Structure Spec.
Number Data /
14 \ I Me ~N I j 380 Me O
Me O Me O
15 \ I Me ~N I j 366 Me O
Me O
O
16 \ ~ Me ~N I ~ 391 Me O
CN O Me O
17 \ I Me ~N I ~ 383 O
OMe O Me O
18 ~ ~ Me ~N ~ , 393 o O
=--N O Me O
Me ~N
19 w I N ~ , 419 N
O Me O
20 \ I Me ~N I j 367 -O
Me O Me O
/ N Me ~N
21 ~ ~ N ~ , 368 O
Me O Me Mass Example Structure Spec.
Number Data Me ~N \ 403 22 N~ ~ o N ~ ~ (ESI+, \ I O Me M+) O
F
Me ~N \
23 / I N ~ , 421 \ N O Me Me p 24 \ ( Me ~N I \ (ESI+, ~ M+) Me O Me O
25 N~ ) / Me ~N ~ / 393 H
N O
O Me O
26 \ ~ / Me ~N I j 402 O
O Me O
Me ~N
27 / ~ N ~ , 403 i I~ ,o \ N O Me O
Me ~N
28 ~ ~ o N ~ ~ 403 NJ O Me Mass Example .
Structure Spec.
Number Data Me ~N \
29 / I N ~ / 402 ~o \ I O Me O O
Me~H / ~ Me ~N ~ \ 424 30 Me ~ O~N~ /
O M'e O O
Me~H / ~ Me ~N ~ \ 440 31 ~ o~N
OMe ~O( M~e O O
Et~H / ~ Me ~N ~ ~ 454 32 ~ o~N
OMe O M~e O
Me ~N ~ \
33 \ o N / 407 HN
N- O Me Me O
Me ~N ~ \
34 HN o / 407 =-N O Me Me O
35 \ ~ Me ~N I \ 368 Me O /
O Me Mass Example Structure Spec.
Number Data Me p O
36 ~ ~ , Me ~N ~ \ 434 O
O Me O
Me N
37 ~ ~ j Me ~N I j 417 O
IOI Me O
Me ~N
38 ~ , N ~ , 403 O
O Me O
39 N \ ~ ~ Me ~N I ~ 403 O
O Me O
Me ~N
Me,N ~ O~N / 421 N- O Me Me O O
41 H2N \ I Me ~N ~ j 426 O
OMe O Me O O
42 HEN \ I Me ~N ( % 410 Me O
IOI Me O O
43 H2N \ ~ Me ~N I j 426 Me0 O
IOI Me Mass Example Structure Spec.
Number Data Me ~N
44 ~ o N ~ ~ 396 H2N O O Me O
N
Me N
45 ~ ~ , ~ ~ , 405 O
O Me Example 46 (2Sl-1-f(2R)-4-Benzovl-2-methvl-piperazin-1-VI1-2-f2-methox -4- 2H-j1 2 4]triazol-3-ylLphenoxy~-propan-1-one O
NwN CHs ~N I \
H N /
O
O CHs CHs The compound of Preparation 10 (125mg, 0.26mmol) was added portionwise to a stirred solution of hydrazine monohydrate (25pL, 0.52mmol) in glacial acetic acid (4mL). The resulting solution was heated at 90°C for 3 hours. The 1o reaction mixture was then evaporated under reduced pressure and the residual colourless oil was partitioned between dichloromethane (50mL) and saturated sodium hydrogen carbonate solution (8mL). The organic phase was separated and the aqueous phase was re-extracted with dichloromethane (30mL). The combined organic phases were dried over magnesium sulfate ~5 and concentrated in vacuo to yield a colourless foam. The foam was dried under reduced pressure to afford the title compound in 94% yield, 110mg.
LRMS (ES+): mlz [M+H]+ 450 Example 47 1-f(2R -4-Benzoyl-2-methyl-piperazin-1-yl]-2-f2-methyl-3 ~1-methyl-1 H-pyrazol-3 yl)-phenoxyLpropan-1-one O
CH3 ~N
~N~ ~ O N
The compounds of Preparations 17 (100mg, 0.53mmol) and 25 (180mg, 0.53mmol) and cesium carbonate (172.7mg, 0.53mmol) in acetone (8mL) were heated under reflux for 3.5 hours. The reaction mixture was then cooled and evaporated under reduced pressure. The residue was partitioned 1o between dichloromethane (30mL) and water (8mL). The organic phase was separated and the aqueous phase was re-extracted with further dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give a light brown oil. The oil was chromatographed using an Isolute~ Flash silica column, eluting with dichloromethane:methanol, 99:1 to 97:3, to give a colourless oil. This oil was azeotroped with dichloromethane to afford the title compound as colourless foam in 89% yield, 210mg.
LRMS (ES+): m/z [M+H]+ 447 2o Example 48 1-[~(2R)-4-Benzoyl-2-methyl-piperazin-1-y~2-methyl-3-[1,2,4~oxadiazol-5-yl-phenoxy~propan-1-one CH3 ~N
O ~ O N
N
~IN CH3 O CH3 The compound of Preparation 29 (280mg, 0.62mmol) was heated in a mixture of glacial acetic acid (3mL) and dioxane (3mL) at 90°C, for 3.5 hours.
The mixture was then allowed to cool and was evaporated under reduced pressure to give a yellow oil. The oil was dissolved in ethyl acetate (50mL) and washed with 10% sodium carbonate solution (lOmL) and water (lOmL).
The organic phase was dried over magnesium sulfate and concentrated in-vacuo to give a colourless foam. The foam was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 97:3, to give a colourless oil. The oil was azeotroped with dichloromethane to afford the title s compound as a colourless foam in 44% yield, 118mg.
LRMS (ES-): m/z [M-H]-433 Example 49 (2S)-1~[(2R)-4-Benzoyl-2-meth iLl-piperazin-1-yll-2-[~2H-pyrazol-3-yl)-io phenoxy]'-propan-1-one O
CH3 ~N
N
O
H ~
N
(3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(114mg, 0.56mmol), J.
Med. Chem. 43(23), 4499; 2000], 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (167.5mg, 0.56mmol) and triethylamine (78pL, 15 0.56mmol) were added to a solution of the compound of Preparation 23 (130mg, 0.56mmol) in tetrahydrofuran (8mL) and the resulting solution was stirred at room temperature for 48 hours. The mixture was then diluted with ethyl acetate (30mL) and washed with water (lOmL), 10% citric acid (lOmL), water (lOmL) and sodium hydrogen carbonate solution. The organic phase 2o was dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 98:2 to 96:4, to give a colourless foam. The foam was azeotroped with dichloromethane and dried under reduced pressure to afford the title compound in 85% yield, 198mg.
25 LRMS (ES-): m/z [M-H]-417 Example 50 (2S)-1-[~2R~4-Benzoyl-2-metal-~perazin-1-yl]-2-[2-methyl-3-(2H-pyrazol-3-yl~ phenoxy]-propan-1-one CH3 ~N
N /
\ O
~CH3 H ~
N
The title compound was prepared by the method described above for Example 49, using the compound of Preparation 24 and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone ( J. Med. Chem. 43(23), 4499; 2000).
LRMS (ES-): m/z [M-H]-431 Example 51 1-~(2R~4-Benzoyl-2-methyl-piperazin-1-yl]-2-[~1 H-imidazol-2-yl)-2-methoxy-~ahenoxy]-propan-1-one CH3 ~N ~ \
N /
\ 0 N /
~~N CH3 The compounds of Preparation 33 (30mg, 0.16mmol) and Preparation 25 (53.5mg, 0.16mmol) and cesium carbonate (51.3mg, 0.16mmol) in N,N-dimethylformamide (4mL) were heated at 80°C for 18 hours. The reaction mixture was allowed to cool and was then evaporated under reduced 2o pressure and the residue was partitioned between dichloromethane (30mL) and water (8mL). The aqueous phase was separated and was re-extracted with dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 95:5, to afford the title compound as a beige foam in 74% yield, 52mg.
LRMS (ES+): m/z [M+H]+ 449 Examples 52 to 53 The following compounds, of the general formula shown below, were prepared by the method described above for Example 51, using the o compound of Preparation 25 and the appropriate phenol.
CH3 ~N
N
O
R O
No. R~ Data 52 ~ N LRMS (ES-): m/z [M-H]~
N\
53 j LRMS (ES-): mlz [M+Na]+
~N 471 ~
~5 Examples 54 to 57 The following compounds, of the general formula shown below, were prepared by the method described above for Example 51, using the compound of Preparation 25 and the appropriate phenol.
CH3 ~N
R\O N /
No. R5 LRMS (APCI+~: m/z [M+H]+
54 j H3 429 s \
H3C~
o' H3C~
57 ~ / ~ 482 H2N~ //
/% /
0 ~ _ Example 54: phenol prepared as described in Preparation 67 Example 55: phenol prepared as described in Preparation 68 Example 56: 6-methoxy-2-naphthol is commercially available Example 57: 5-hydroxy-1-naphthalene sulfonamide is commercially available Example 58 1-f(2Rl-4-Benzovl-2-methyl-aioerazin-1-vll-2-(4-methanesulfonvl-2-methox i~henoxy~-propan-1-one O O
_1I
H3C II / CH3 ~N \
o \ ~ N
-o H C~~ O CH3 A solution of oxone (215mg, 0.35mmol) in water (2mL) was added to a solution of the compound of Example 54 (100mg, 0.23mmol) in methanol (4mL) and the mixture was stirred for 18 hours at room temperature. The solvent was then evaporated under reduced pressure and the residue was partitioned between water (20mL) and dichloromethane (20mL). The aqueous layer was separated and re-extracted with dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 95:5 to afford the title com~aound as a white solid in 78% yield, 80mg.
LRMS (APCI+): m/z [M+H]+ 481 Example 59 N-~4-[2~2R)-(4-Benzoyl-2-methyl-piperazin-1-yl)-1-methyl-2-oxo-ethoxy]-3-methox~phenyl}-methanesulfonamide O H I Hs O
H3C ~ N / O CH3 ~N \
\ N /
O
Triethylamine (0.08mL, 0.57mmol) was added to a solution of the compound of Preparation 30 (150mg, 0.38mmol) in dichloromethane (3mL) and the mixture was cooled in an ice bath. Methanesufonyl chloride (0.03mL, 0.42mmol) was added dropwise and the reaction mixture was allowed to stir at room temperature for 18 hours. The mixture was then diluted with further dichloromethane (20mL) and washed with water. The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was then purified by column chromatography on silica gel, eluting with ethyl acetate:methanol, 98:2, to afford the title compound as a white solid in 49%
yield, 88mg.
LRMS (APCI+): m/z [M+H]+ 476 Example 60 ,(2S -1~-f(2R -4-Benzoyl-2-methpiperazin-1-y~-2-(2-chloro-quinolin-5-yloxy~-propan-1-one CH3 ~N
N/ I O N /
CI \ O CH3 o A solution of the compound of Preparation 46 (1.8g, 4.3mmol) in phosphorous oxychloride (5mL) was heated at 100°C for two hours. The reaction mixture was then cooled to room temperature and evaporated under reduced pressure. The residue was dissolved in dichloromethane (20mL) and washed with saturated aqueous sodium hydrogen carbonate solution (1 OmL) and water (2x1 OmL). The aqueous phase was basified with 1 M
sodium hydroxide solution and was re-extracted with ethyl acetate. The combined organic extracts were then dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate 20:80, 0:100 to afford the title 2o compound as a pale yellow solid in 31 % yield, 580mg.
'H NMR (400MHz, CDCI3) b: 1.00-1.40(m, 3H), 1.70-1.80(m, 3H), 2.80-4.80 (m, 7H), 5.20(m, 1 H), 6.90(m, 1 H), 7.20-7.45(m, 6H), 7.55-7.70 (m, 2H), 8.55(d, 1 H) LRMS (APCI+): m/z [M+H]+ 438 Examples 61 to 62 A mixture of the compound of Example 60 (30mg, 0.069mmol), tetrabutyl ammonium fluoride (18mg, 0.14mmol), triethylamine (96pL, 0.69mmol) and 3o the appropriate amine (0.69mmol) in dimethylsulfoxide (1 mL) was heated at 100°C for 24 hours. The reaction mixtures were then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1):acetonitrile, 95:5 to 5:95, to' afford the desired compounds of general formula shown below:
r \ o ( \
N /
t R6,NH
No. R6 LRMS (APCI+): m/z [M-H]+
H3C' 62 ~H3 461 Example 63 1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl)-2-(1-chloro-isoguinolin-5-ylox~
propan-1-one O
\ ~ :5 N / /
CI
1o The title compound was prepared by the method described above for Example 60, using the compound of Preparation 63 and phosphorus oxychloride.
LRMS (APCI+): m/z [M+H]+ 438 Examples 64 to 65 A mixture of the compound of Example 63 (45mg, 0.1 mmol), tetrabutyl 5 ammonium fluoride (27mg, 0.2mmol), triethylamine (140pL, 1mmol) and the appropriate amine (1 mmol) in dimethylsulfoxide (1 mL) was heated at 130°C
for 24 hours. The reaction mixtures were then purified directly by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95 to afford the desired compounds of 1o general formula shown below:
CH3 ~N
N
O
R~
N N
R' No. R6 R' LRMS (APCI+): m/z [M-HJ+
64 N~N H 485 Example 66 (2Sl-2-(2-Amino-auinolin-5-vloxv)-1-f (2R)-4-benzovl-2-methyl-piperazin-1-propan-1-one p CH3 ~N ~ \
N /
\ O
N /
s 10% Pd/C (cat) and ammonium formate (l0mg, 0.15mmol) were added to a solution of the compound of Preparation 49 (l5mg, 0.03mmol) in ethanol (1 mL) and the mixture was heated at 70°C for 2 hours. Additional ammonium formate (l0mg, 0.15mmol) and Pd(OH)2 (cat) were added and the reaction mixture was heated under reflux for a further 18 hours. The mixture was then 1o cooled and filtered through Arbocel~, washing through with ethanol (lOmL).
The filtrate was concentrated in vacuo and the residue was purified by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound in 77% yield, 9.7mg.
15 LRMS (ES+): m/z [M+H]+ 419 Example 67 l2Sl-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-2-(8-chloro-auinolin-5-vlox propan-1-one / ( CH3 ~N
N/ o N /
A mixture of the compound of Preparation 42 (30mg, 0.07mmol) and N-chlorosuccinimide (11 mg, 0.08mmol) in acetonitrile (3mL) was heated at 40°C
for 48 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in ethyl acetate (5mL) and washed with water (2x5mL). The organic phase~was dried over magnesium sulfate and concentrated in vacuo to give a yellow residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a solid in 32% yield, 9.7mg.
LRMS (APCI+): m/z [M+HJ+ 438 Examples 68 to 69 The following compounds, of the general formula shown below, were prepared by the method described above for Example 67, using the appropriate starting material and N-chlorosuccinimide.
o C~ /
Cf-13 ~N
N/ O N /
\ O CH3 No. X LRMS (APCI+): m/z [M-HJ+
Examples 68 and 69 were purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 96:4 Examples 70 and 71 The compounds were prepared from the compound of Preparation 60 and 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), using a similar preparation to Example 67. The compounds were purified by HPLC using a Phenomenex Luna C18(2) column 150x15mm (10 micron particle size, 100A porosity), using a 2 solvent eluent of acetonitrile:waterarifiuoroacetic acid (5:95:0.1 ) [solvent A] and acetonitile -[solvent B]. A solvent gradient is run at a flow-rate of 20 ml/min as in the table below. -Time min) %B
0.6 5 9.5 95 10.5 95 10.6 5 No Structure HPLC LRMS (APCI+):
retention time m/z [M+H]+
min.
70 4.99 422 F
I CH3 ~N I \
N/ I O N /
\ O CHI
71 5.77 422 / F
I CH3 ~N I \
N/ I O N /
\ O CH3 Example 72 ~2S)-1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(8-methyl-quinolin-5-yloxy~-propan-1-one I CH3 ~N \
N~ O N I
\ O CH3 A mixture of the compound of Preparation 44 (200mg, 0.4mmol), methyl boronic acid (74mg, l.2mmol), bis(triphenylphosphine)palladium(II) chloride (29mg, 0.04mmol) and potassium carbonate (229mg, l.6mmol) in N,N-dimethylformamide (4mL) was heated at 100°C for 18 hours. Tlc analysis 1o showed that the reaction was incomplete and so additional amounts of methyl boronic acid (74mg) and bis(triphenylphosphine)palladium(II) chloride (29mg) were added, and the mixture was allowed to stir for a further 24 hours at 100°C. The reaction mixture was then filtered through Arbocel~, washing through with ethyl acetate (25mL) and water (3x20mL). The layers were separated and the aqueous layer was re-extracted with ethyl acetate. The combined organic solutions were dried over magnesium sulfate and concentrated in vacuo to afford a yellow residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1):acetonitrile, 95:5 to 5:95.
The 2o appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a yellow solid in 19% yield, 33mg.
LRMS (APCI+): m/z [M+H]+ 418 Example 73 (2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-,Lrll-2-[8-~(2H-pyrazol-3-yl)-quinolin-5-yloxy~-propan-1-one 5 4M Hydrochloric acid (2mL) was added to a suspension of the compound of Preparation 45 (43mg, 0.07mmol) in methanol (2mL), and the resulting solution was stirred at room temperature for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed twice with dichloromethane. The combined organic 10 layers were dried over magnesium sulfate and concentrated in vacuo to give a yellow residue. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, to afford the title compound as a yellow solid in 68% yield, 23mg LRMS (APCI+): m/z [M+H]+ 470 Example 74 (~S)-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-2-f2-(2H-avrazol-3-vlaminol-quinolin-5-yloxy]-propan-1-one CH3 ~N
~~N N~ ~ O N
\ O CH3 N
H
A mixture of the compound of Example 60 (50mg, 0.11 mmol), 3-aminopyrazole (29mg, 0.33mmol) and triethylamine (48pL, 0.33mmol) in 2-propanol (0.5mL) was heated at 90°C in a ReactivialT"". After 18 hours, cesium fluoride (33mg, 0.22mmol) was added and the mixture was heated at 100°C for a further 48 hours. The reaction mixture was then filtered and concentrated in vacuo to afford an oily residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a yellow solid 3mg.
LRMS (APCI+): m/z [M+H]+ 485 Example 75 5-~(1S~2-[(2R -4.-Benzo~rl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy~
1 H~uinolin-2-one O
/ ~ CH3 ~N ~ \
HN \ O N /
1o The compound of Example 60 (200mg, 0.46mmol) and acetic acid (3mL) were dissolved in water and the solution was heated under reflux for 24 hours. The reaction mixture was then diluted with water and washed with dichloromethane (3x10mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The oil was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5 to afford the title compound as pale yellow solid in 40% yield, 76mg.
LRMS (APCI+): m/z [M+H]+ 418 2o Example 76 ~(1 S)-2-~(2R)-4.-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethox~r~8-chloro-1 H-quinolin-2-one O
C~
CH3 ~N ~ \
HN \ O N
The title compound was prepared by the method described above for Example 67, using the compound of Example 75 and N-chlorosuccinimide.
LRMS (APCI+): m/z [M+H]+ 454 Example 77 (2S)-1 ~[(2F~-4-Benzoyl-2-methyl-piperazin-1-yll-2-(~-methoxy-quinolin-5-ylox~r -propan-1-one CH3 ~N I \
Ni I 0 N /
H3C~0 \ O CH3 A mixture of the compound of Example 60 (20mg, 0.04mmol) and sodium methoxide (0.5M in methanol, 0.7mL) in N,N-dimethylformamide (0.5mL) was heated in a ReactivialT"" at 70°C for 6 hours. The reaction mixture was 1o cooled, and evaporated under reduced pressure. The residue was dissolved in dichloromethane (5mL) and washed with brine (5mL) and water (2x5mL).
The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in dimethylsulfoxide (0.5mL) and was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95. The appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a yellow solid in 40% yield, 7mg.
LRMS (APCI+): m/z [M+H]+ 434 2o Example 78 5-((1 S)-2-f(2R)-4-Benzovl-2-methvl-aioerazin-1-vll-1-methyl-2-oxo-ethox isoquinoline-1-carboxylic acid methyl ester O
O / ~ CH3 ~N
H3C~0 / O N /
The compound of Preparation 65 (80mg, 0.18mmol), dichloro-bis(triphenylphosphine)palladium (l5mg, 0.018mmol) and triethylamine (51 pL, 0.37mmol) were dissolved in methanol (5mL) and transferred to a sealed vessel. The vessel was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in vacuo.~ The residue was purified on an Isolute~ flash silica colur~in, eluting with dichloromethane:methanol, 99:1 to afford the title compound as a white foam in 43% yield, 36mg.
LRMS (APCI+): m/z [M+H]+ 462 Example 79 5~2-~2R -4-Benzoyl-2-methyl-pi~~erazin-1-yl]-1-methyl-2-oxo-ethoxy}-quinoline-2-carboxylic acid meth la~_ mide CH3 ~N ~ \
N
~NH
A mixture of the compound of Preparation 48 (20mg, 0.05mmol), methylamine (33% in ethanol, 30mg, 0.5mmol), O-(1 H-benzotriazol-1-yl)-N,N,N',IV-tetramethyluronium hexafluorophosphate (2mg, 0.08mmol) and triethylamine (62pL, 0.5mmol) in dichloromethane (1 mL) was stirred at room temperature for 18 hours. Additional methylamine (30mg, 0.5mmol) and triethylamine (62 pL, 0.5mmol) were added to the reaction mixture and stirring continued for a further 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x5mL) and brine (5mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo 2o to give a yellow residue. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 96:4, to afford the title compound as a white solid in 13% yield, 3mg.
LRMS (APCI+): m/z [M+H]+ 461 Example 80 5-f(1 Sl-2-f(2R)-4-Benzovl-2-r~nethvl-aiperazin-1-vll-1-methyl-2-oxo-ethox isoquinoline-1-carbox~rlic acid methylamide O
O / ~ CHs ~N
HsCwN / ~ N /
H
The title compound was prepared by the method described above for Example 79, using the compound of Example 78 and methylamine.
LRMS (APCI+): m/z [M+H]+ 461 Example 81 1o 4-~~~1 S)-2-[(2R -4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy)-N-methyl-3-trifluoromethoxy-benzamide H
H3C\N CH3 N
O
FI
F
The compound of Preparation 59 (100mg, 0.2mmol) and methylamine (33%
in ethanol, 4mL) were heated at 90°C in a ReactivialT"" for 18 hours.
The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 97:3, to afford the title compound as a pale orange foam in quantitative yield, 100mg.
LRMS (APCI+): m/z [M+H]+ 494 Example 82 ~2S)-1-f(2R -4-Benzoyl-2-methyl-piperazin-1-~r11-2-(8-chloro-2-methylamino-quinolin-5~iloxy~propan-1-one / ~ CHs N ~ I ~o H3CwN \ 0 H
5 A mixture of the compound of Preparation 52 (60mg, 0.12mmol), methylamine hydrochloride (86mg, l.2mmol), cesium fluoride (39mg, 0.24mmol) and triethylamine (0.18mL, 1.2mmol) in dimethylsulfoxide (1 mL) was heated in a microwave for 8 minutes at 170°C. The reaction mixture was then filtered and the filtrate was purified by HPLC using a Phenomenex Luna 1o C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95. The appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a brown solid in 19% yield, 10.8mg.
LRMS (APCI+): m/z [M+H]+ 467 Example 83 1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-methylamino-isoquinolin-5~i loxy~propan-1-one CH3 ~N ( \
NI /
O
\ \ 0 CH3 //~
,NH
2o The title compound was prepared by the method described above for Example 82, using the compound of Example 63 and methylamine.
LRMS (APCI+): m/z [M+H]+ 433 Example 84 (2S~1-f 2R)-4-Benzoyl-2-methyl-~perazin-1-yl]-2-(8-chloro-2-dimethylamino-auinolin-5~ilo~)-pr~an-1-one _ / ~ CH3 .
N / ( w0 H3C~ \ O CH3 N
A mixture of the compound of Preparation 52 (50mg, 0.1 mmol), dimethylamine (86mg, 1 mmol), cesium fluoride (32mg, 0.2mmol) and triethylamine (0.15mL, 1 mmol) in dimethylsulfoxide (4mL) was heated at 170°C in a ReactivialT"" for 18 hours. The reaction mixture was then filtered 1o and the filtrate was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a white solid, 5mg.
LRMS (APCI+): m/z [M+H]+ 481 Example 85 (2S)-1-f(2R)-4-Benzoyl-2-methyl-~perazin-1-yll-2-f1- 2H-pyrazol-3-ylamino)-isoquinolin-5-Lrloxy]-propan-1-one O
/ ( CH3 ~N
H
N / O N /
W
N
2o A mixture of the compound of Example 63 (45mg, 0.1 mmol), tetrabutyl ammonium fluoride (27mg, 0.2mmol), triethylamine (0.14mL, 1 mmol) and 3-aminopyrazole (83mg, 1 mmol) in dimethylsulfoxide (1 mL) was heated at 100°C for 24 hours. The reaction mixture was then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/formic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound in 39%
yield, l9mg.
LRMS (APCI+): m/z [M+H]+ 485 Example 86 ~2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1- rLl)]-2-(3,6-dimethyl-1 H-indazol-yloxy)-pro~an-1-one / ~ CH3 ~N I \
\ N /
HN ~O
N- O CHs 4M hydrochloric acid in dioxane (1 mL) was added to the compound of Preparation 77 (45mg, 86pmol) in methanol and the solution was stirred for 2 hours. The reaction mixture was evaporated under reduced pressure and the residue was dissolved in dichloromethane and basified with 1 M sodium 1o hydroxide solution to pHl2. The mixture was then passed through a phase separation column and the filtrate was concentrated in vacuo. Purification by column chromatography on silica gel, eluting with dichloromethane:methano1:0.88 ammonia, 96:4:1, afforded the title compound as a pale pin4c foam in 59~/~ yield, 20mg.
~ 5 LRMS (APCI+): m/z [M+H]+ 421 Example 87 l2Sl-1-f(2Rl-2-Methvl-4-lavridine-2-carbonyl)-aiaerazin-1-vll-2-(auinolin-5-~iloxy~propan-1-one O
/ I CH3 ~N \
N/ O N I /
\ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), picolinic acid (49mg, 0.6mmol) O-(1H-benzotriazol-1-yl)-N,N,N',hP-tetramethyluronium hexafluorophosphate (190mg, 0.75mmol) and triethylamine (0.93mL, l0mmol) in dichloromethane (3mL) was stirred for 18 hours at room temperature. The reaction mixture was then diluted with further dichloromethane and washed with sodium hydroxide (lOmL) and water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography-on silica gel, eluting with dichloromethane:methanol, 99:1 to 95:5, afforded the title compound as a white solid in 49% yield, 99mg.
LRMS (APCI+): m/z [M+H]+ 405 Example 88 (2S)-1-f4- 2-Fluoro-benzoyl)~2R)-2-methyl-loiperazin-1-girl]-2~(guinolin-5-ylo~)-propan-1-one / ~ CHs N / ~ w0 \ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), 2-fluorobenzoyl chloride and triethylamine in dichloromethane (3mL) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, afforded the title compound as a white solid in 73% yield, 153mg.
LRMS (APCI+): m/z [M+H]+ 422 2o Example 89 4-f (1 S)-2-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy?-3-methoxy-N-methyl-benzamide O O
Me~H / Me ~N \
\~ N ~/
~O
OMe O Me To a solution of (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med.
Chem. (2000), 43(23), 4499) (22 g, 0.11 mol) and (2S)-2-(2-methoxy-4-methylcarbamoyl-phenoxy)-propionic acid (25 g, 0.1 mol) (Preparation 5) in dry THF (250 ml) were added 1-N hydroxybenzatriazole monohydrate (20 g, 0.13 mol), 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) and diisopropylethylamine (17 ml, 0.1 mol). After stirring for 1 hour a further portion of 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) was added followed by additional diisopropylethylamine (17 ml, 0.1 mol).
After another hour a further portion of 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) was added followed by another portion of diisopropylethylamine (17 ml, 0.1 mol). The mixture was then stirred for a further 16 hours. After this time LCMS analysis 1o indicated that all of the propionic acid had been consumed. The reaction mixture was evaporated to give a viscous oil which was treated with water (200 ml) followed by the slow addition of concentrated aqueous hydrochloric acid until the mixture was pH 3. The resulting off-white precipitate was filtered off and washed with water (3 x 100 ml). The solid was twice re-crystallised from ethanol:water (1:1 by volume, 120 ml) to afford the title compound as a white solid (32 g).
'H NMR (400MHz, CDC13): 8 : 7.50-7.30 (6H, m), 7.27 (1 H, m), 6.9 (1 H, m) 6.08 (1 H, br s), 5.1 (11 H, br m), 4.90-2.80 (7H, m), 3.90 (3H, br s), 3.00 (3H, br s), 2.40 (3H, s), 1.70 (3H, br d), 1.40-0.9 (3H, m) ppm.
2o LRMS (ESI+) : m/z [M+H]+ 440 [a]p -26.9° (1 mg/ml in MeOH, 25°C, wavelength 589nM) Example 90 5-((1 S~[(2R)-4-Benzoyl-2-meth~piperazin-1-~]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester ~ O
Me~O N
Me ~N ~ \
\ O N
OMe O Me Di-tert-butyl azodicarboxylate (0.14 g, 0.6 mmol) and polymer supported 3o triphenylphosphine (0.25 g, 0.75 mmol) were added to a stirred solution of (2R)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)-2-hydroxy-propan-1-one (Preparation 76) (0.083 g, 0.3 mmol) and 5-hydroxy-4-methoxy-pyridine-2-carboxylic acid methyl ester (0.083 g, 0.45 mmol) (Tetrahedron Letters, 38, 1297 (1997)) in dichloromethane (3 ml) at 0°C. After one hour the reaction mixture was allowed to warm to room temperature and additional di-tert-butyl azodicarboXylate (0.14 g, 0.6 mmol) and polymer supported triphenylphosphine (0.25 g, 0.75 mmol) were added. After 18 hours at room 5 temperature the reaction mixture was filtered through Arbocel~, washing through with dichloromethane (10 mL). The filtrate was washed with saturated aqueous sodium hydrogencarbonate solution (20 ml), then the organic phase separated, dried (MgS04) and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel, 1o eluting with ethyl acetate:pentane, 80:20, then ethyl acetate and finally ethyl acetate:methanol, 95:5, to afford the title compound as a white solid, 0.1 g.
LRMS (APCI+): m/z [M+H]+ 442 Example 91 15 5-{~1S -2-('(2R -4-BenzoVl-2-methyl-piperazin-1-yll-1-methyl-2-oxo-ethoxY}-methoxy-pyridine-2-carboxylic acid methylamide O
Me Me ~N ~ \
O N
O Me 2o A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.2 g, 0.45 mmol) in a 33% w/w solution of methylamine in ethanol (3 ml) was heated in a Reacti-vialT"" at 50°C for 18 hours. After cooling to room temperature solvent was evaporated under reduced pressure. The residue 25 was purified by column chromatography on silica gel, eluting with dichloromethane:methanoI:NH3, 98:2:0.5 to 95:5:0.5, to afford the title compound as a white solid, 0.18 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.75 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 3.95 (3H, br s), 2.90 (3H, s), 1.60-1.00 (6H, so m) ppm.
Found C, 61.65; H, 6.47; N, 12.41. C23H2gN~O5. 0.1 mol CH2CI2 requires C, 61.80; H, 6.33; N, 12.48%
LRMS (APCI+): m/z [M+H]+ 441 [a]o -15.5° (1 mg/ml in MeOH, 25°C, wavelength 589nM) Example 92 , 5-f ( 1 S)-2-j(2R)-4-Benzo~rl-2-methyl-~iperazi n-1-yl]-1-methyl-2-oxo-ethoxy)-methoxy-pyridine-2-carbox relic acid amide H2N N ~ Me ~N ~ \
\ O N
OMe O Me A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy)-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.2 g, 0.45 mmol) in concentrated aqueous ammonia solution (2 ml) and methanol (1 ml) was heated in a Reacti-vialT"' at 50°C for 18 hours.
After pooling to room temperature solvent was evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanoI:NH3, 98:2:0.5 to 95:5:0.5, to afford the title compound as a white solid, 0.16 g.
'H NMR (400MHz, CD3OD): 8 : 8.05 (1 H, s), 7.75 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (9H, m), 3.95 (3H, br s), 1.60-1.00 (6H, m) ppm.
Found C, 59.67; H, 6.11; N, 12.49. C22H26N4O5. 0.25 mol CH2C12 requires C, 59.78; H, 5.97; N, 12.54%
LRMS (APCI+): m/z [M+H]+ 427 Example 93 5-(~1S)-2-[(2R -4-Benzo~l-2-methyl-loiperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid ethylamide O O
Me~H N ( Me ~N \
\ O N U
I
OMe O Me A solution of 5-f (1 S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2--oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.15 g, 0.34 mmol) in ethylamine (1 ml) was heated in a Reacti-vialT"" at 50°C for 18 hours. After cooling to room temperature solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol 96:4, to afford the title compound as a white solid, 0.14 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.80 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 4.00 (3H, br s), 3.45 (2H, q), 1.60-1.00 (6H, 1o m), 1.20 (3H, t) ppm.
Found C, 60.89; H, 6.72; N, 11.93. C24H3aN4O5. 0.25 mol CH2C12 requires C, 61.22; H, 6.46; N, 11.78%
LRMS (APCI+): m/z [M+H]+ 455 Example 94 5-~(1 S)-2-f (2R)-4-Benzoyl-2-methyl-piperazin-1-~1-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cycloprop 1y amide O
Me ~N \
N ~/
OMe O Me A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.12 g, 0.27 mmol) in cyclopropylamine (1 ml) was heated in a Reacti-vialT"' at 50°C for 18 hours. After cooling to room temperature solvent was 2s evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol 95:5, to afford the title compound as a white solid, 0.09 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.70 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 3.95 (3H, br s), 2.85 (1 H, m), 1.60-1.00 (6H, 3o m), 0.8 (2H, m), 0.6 (2H, m) ppm.
Found C, 63.02; H, 6.63; N, 11.83. C25H3pN4O5. 0.13 mol CH2C12 requires C, 63.20; H, 6.39; N, 11.73%
LRMS (APCI+): m/z [M+H]+ 467 Preparation 1 ~2S)-2- Quinolin-5-ylo~)-propionic acid methyl ester Me O OMe Triphenylphosphine (2.17 g, 8.27 mmol) was added to a stirred suspension of di-isopropyl azodicarboxylate (1.47 ml, 7.56 mmol) in THF (25 ml) at -5°C.
5-Hydroxyquinoline (1.0 g, 6.90 mmol) and methyl (R)-lactate (0.66 ml, 6.90 1o mmol) were then added and the solution allowed to stir at room temperature for 14 hours. The reaction mixture was diluted with ethyl acetate (50 ml), washed with water (30 ml), saturated potassium carbonate solution (30 ml) and brine (30 ml). The solution was dried (MgS04) and solvent evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel eluting with a gradient system of pentane : ethyl acetate (4:1 ) changing to pentane : ethyl acetate (3:2). The title compound was obtained as a white solid (1.30 g).
LRMS (APCI+) : mlz [M+H]+ 232.
2o Preparation 2 (2S)-~Quinolin-5-yloxy)-propionic acid sodium salt Me ~ O Na+
\ O
A solution of (S)-2-(quinolin-5-yloxy)-propionic acid methyl ester (Preparation 1 ) (1.30 g, 5.60 mmol) and 1 N sodium hydroxide solution (5.62 ml) in dioxane (40 ml) was heated at 60 °C for two hours. After this time tlc analysis indicated that starting material remained so additional 1 N sodium hydroxide solution (1.4 ml) was added and heating at 60 °C continued for one hour.
so The reaction mixture was then concentrated under reduced pressure to afford the title compound as a yellow solid which was used without further purification.
LRMS (ESI+) : m/z [M+H]+ 218.
PrJoaratiori 3 1-[(2R -4-Benzoyl-2-methyl-~i~erazin-1-yl]-2-bromo-propan-1-one O
Me ~N ~ \
N
Br O Me To a solution of (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med.
1o Chem. (2000), 43(23), 4499) (4.06 g, 19.6 mmol) in dichloromethane (60 ml) and N,N dimethylformamide (2 ml) were added 2-bromopropionic acid (3.0 g, 19.6 mmol), O-(1 H-benzotriazol-1-yl)-N,N,I~P,N'-tetramethyiuronium hexafluorophosphate (8.18 g, 21.6 mmol) and triethylamine (2.74 ml, 19.6 mmol). The reaction mixture was stirred at room temperature for 48 hours and then washed with water (50 ml), 10 % w/v aqueous citric acid solution (50 ml) and saturated aqueous sodium hydrogencarbonate solution (50 ml). The solution was dried (MgS~4) and solvent evaporated under reduced pressure.
The' crude product was purified by column chromatography on silica gel eluting with a gradient system of dichloromethane: methanol (99:1 ) changing 2o to dichloromethane : methanol (95:5). The product was then purified further by column chromatography on silica gel eluting with a gradient system of ethyl acetate: dichloromethane (30:70) changing to ethyl acetate: dichloromethane (45:55) to afford the title compound as a white solid (3.80 g).
LRMS (ESI+) : m/z [M+H]+ 340.
Preparation 4 4-Hydroxy-3-methoxy-N-methyl-benzamide OH
Me To a mechanically stirred suspension of vanillic acid (84 g, 0.5 mol) in dry-THF (300 ml) was added portion-wise carbonyldiimidazole (97 g, 0.6 mol).
Gaseous evolution was observed and the mixture became homogeneous after approx 5 minutes. After further stirring for 30 minutes an off-white 5 precipitate form and stirring was maintained for a further 3 hours under nitrogen. After this time LCMS analysis indicated that the vanillic acid had been consumed and a solution of 2 M methylamine in THF (1000 ml, 2 mol) was added in one portion and the mixture stirred for a further 16 hours to generate a tan precipitate. The precipitate was filtered, washed with THF
o (2 x 250m1) followed by ether (300 ml) and dried under vacuum to afford the N-methylammonium salt of the title compound (87g, 82%).
LRMS (ESI+): m/z [M+H]+ 182.
A portion of the ammonium salt {1.06g, 5 mmol) was refluxed in ethyl acetate under a stream of nitrogen for 2 hours. The reaction was evaporated to give ~5 an oily solid, which was triturated with ethyl acetate to afford the title compound as a tan solid (750 mg) LRMS (ESI+): m/z [M+H]+ 182.
Preparation 5 20 (2S)-~2-Methox~4-methylcarbamoyl-phenoxy)-propionic acid OH
Mew To a stirred mixture of triphenylphosphine (42 g, 0.16 mol), 4-hydroxy-3-25 methoxy-N-methyl-benzamide (Preparation 4) (20 g, 0.11 mol) and methyl (R)-lactate (12 g, 0.12 mol) in dry THF (300 ml) at -5 °C was added dropwise a solution of di-isopropyl azodicarboxylate (32 ml, 0.16 mmol) in dry THF
(100 ml) over 30 minutes. The solution was allowed to warm to room temperature and stirred for 2 hours. After this time tlc analysis indicated that 3o the starting phenol had been consumed. The crude reaction mixture was evaporated under reduced pressure to give a viscous oil. To a stirred solution of this oil in methanol (150 ml) was added lithium hydroxide monohydrate (5.4 g, 0.13 mol) and the mixture stirred for 48 hours. After this time LCMS
analysis indicated that the intermediate methyl ester had been consumed.
The crude reaction mixture was evaporated and partitioned between ether-(500 ml) and water (150 ml). The aqueous phase was separated and washed with ether (2 x 300 ml) and ethyl acetate (2 x 300m1). The aqueous phase was then acidified to pH 2 using concentrated aqueous hydrochloric acid resulting in the formation of a white precipitate. This precipitate was filtered off, washed with water (2 x 100m1) and recrystallised from ethanol water (1:1 by volume, 80 ml per 20 g) to afford the title compound as a white solid (21 g, 75%).
LRMS (ESI+): m/z [M+H]+ 254.
Preparation 6 , 3-Methoxy-4-[(1 S)-1-methoxycarbon I-e~y]-benzoic acid methyl ester H3C~0 CHs O
O ~CH3 ~O O
~iisopropyl azodicarboxylate (4mL, 20mmol) in tetrahydrofuran (l5mL) was added dropwise to an ice-cooled solution of methyl vanillate (3.64g, 20mmol), methyl (R)-lactate (2.08g, 20mmol) and triphenyl phosphine (5.24g, 20mmol) in tetrahydrofuran (30mL) and the reaction mixture was stirred at room temperature for 18 hours. The solvent was then evaporated under reduced pressure and the residue was stirred in a mixture of diethyl ether (50mL) and 2o hexane (50mL). The resulting precipitate was filtered off and the filtrate was concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with hexane:ethyl acetate, 85:15 to 75:25 afforded the title compound in 71 % yield, 3.8g LRMS (ES+): m/z [M+H]+ 269 Preparation 7 4-[s1 S)-1-Carboxy-ethoxy]-3-methoxy-benzoic acid methyl ester H3Cw0 CHs OH
O
,O O
Lithium hydroxide monohydrate (4.2g, 100mmol) was added portionwise to a solution of the compound of Preparation 6 (32g, 120mmol) in methanol (150mL) and the mixture was stirred at room temperature for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed with diethyl ether. The aqueous mixture was acidified with 2M hydrochloric acid to pH4 and was then 1o extracted with ethyl acetate (3x150mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The resulting foam was dried under reduced pressure to afford the title compound in 91 % yield, 23g.
LRMS (ES+): m/z [M+H]+ 255 Preparation 8 4-~~(1 S~-2-[(2R~4-Benzo~rl-2-methyl-piperazin-1-yll-1-methyl-2-oxo-ethoxy~-3-methoxy-benzoic acid methyl ester O
H~C~O CH3 ~N
N /
O
2o Hianig's base (1.BmL, 10.5mmol) was added to a solution of the compound of Preparation 7 (1.8g, 7mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(1.6g, 7.7mmol), J. Med. Chem. 43(23), 4499; 2000], and 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (2.75g, 9.1 mmol) in dichloromethane (l6mL). The mixture was stirred for 4 hours and was then evaporated under reduced pressure. The residue was taken up in ethyl acetate (200mL) and washed with 10% sodium carbonate solution (2x50mL) and brine (2x50mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with hexane:ethyl acetate, 25:75 to 5:95 afforded the title compound in 95% yield, 2.95g.
LRMS (ES+): mlz [M+H]+ 441 Pr~aration 9 4~(1 S)-2-f(2R)-4-Benzoyl-2-methylpiperazin-1 yl1-1-methyl-2-oxo-ethoxy)-3-methoxy-benzamide N
O
O
The compound of Preparation 8 (0.46g, 1.04mmol) and 2M ammonia in methanol (lOmL) were heated in a sealed vessel at 120°C for 18 hours.
The reaction mixture was then concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2 to 92:8, to afford the title compound as a colourless foam in 55% yield, 243mg.
LRMS (ES+): m/z [M+H]+ 426 Preparation 10 4-f (1 S)-2-f (2R)-4-Benzoyl-2-meth r~l-piperazin-1-yll-1-methyl-2-oxo-ethox~r)-N-dimethylaminomethylene-3-methoxy-benzamide H3C\N~CH3 ~N CH
N
O
The compound of Preparation 9 (240mg, 0.56mmol) and N,N-dimethylformamide dimethylacetal (lOmL) were heated under reflux for 7 hours. The reaction mixture was then evaporated under reduced pressure to-give a pale orange solid. The solid was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 97:3, to provide a colourless oil. The oil was then azeotroped with dichloromethane and the resulting foam was dried at 40°C for 3 hours to afford the title compound in 94 yield, 255mg.
LRMS (ES+): m/z [M+Na]+ 503 Preparations 11 to 13 The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 10 using the appropriate ketone and dimethylformamide dimethylacetal.
Rb O
\ ~CH3 Ra N~CH3 No. Ra Rb LRMS ES+ : m/z M+H +
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or o fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically ~5 HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50%
isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
2o Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994).
The present invention also includes all pharmaceutically acceptable 25 isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes suitable for inclusion in the compounds of the so invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C' 1sC and '4C, chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 1231 and '251, nitrogen, such as'3N and 15N, oxygen, such as'S0, 170 and'$O, phosphorus, such as 32P, and sulphur, such as 35S.
Certain isotopically-labelled compounds of formula (I), for example, 35 those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e.'4C, are particularly useful for this purpose in view of their ease-of incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting trom greater metaoonc stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Substitution with positron emitting isotopes, such as "C, '$F,'50 and '3N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
o Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
~5 Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, d6-acetone, d6-DMSO.
Preferred compounds of formula (I) include the compounds of Examples 1-94; and pharmaceutically acceptable salts, solvates or 2o derivatives thereof. Particularly preferred compounds of formula (I) include:
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)]-2-(3-methyl-1 H-indazol-4-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[2-(2H-pyrazol-3-ylamino)-quinolin-5-yloxy]-propan-1-one;
25 5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-isoquinoline-1-carboxylic acid methylamide;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(5-chloro-2-methylamino-quinolin-5-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[1-(2H-pyrazol-3-ylamino)-3o isoquinolin-5-yloxy]-propan-1-one;
4-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-3-methoxy-N-methyl-benzamide;
5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methylamide;
35 5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid amide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-' methoxy-pyridine-2-carboxylic acid ethylamide;
5-{(1 S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cyclopropylamide;
5 and pharmaceutically acceptable salts, solvates or derivatives thereof.
In the general processes, and schemes, that follow: R' to R9 are as previously defined unless otherwise stated; X is halo or hydroxy; Y is a leaving group, such as chloro, bromo, tosylate, mesylate or hydroxy; DMF is 1o N,N-dimethylformamide; DMSO is dimethylsulphoxide; THF is tetrahydrofuran; WSCDI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DCC is N,N'-dicyclohexylcarbodiimide; HOAT is 1-hydroxy-7-azabenzotriazole; HOBt is 1-hydroxybenzotriazole hydrate; HBTU is O-(1 H-benzotriazol-1-yl)-N,N,N,I~P-tetramethyluronium hexafluorophosphate;
PyBOP~ is benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate; PyBrOP is bromo-tris-pyrrolidino-phosphonium hexafluorophosphate; Hunigs base is N-ethyldiisopropylamine; and Mukaiyama's reagent is 2-chloro-1-methylpyridinium iodide.
Compounds of formula (I) may be prepared by any methods known for 2o the preparation of compounds of analogous structure.
Compounds of formula (I), and intermediates thereto, may be prepared according to the schemes that follow.
It will be appreciated by those skilled in the art that certain of the procedures described in the schemes for the preparation of compounds of formula (I) or intermediates thereto may not be applicable to some of the possible substituents.
It will be further appreciated by those skilled in the art that it may be necessary or desirable to carry out the transformations described in the schemes in a different order from that described, or to modify one or more of 3o the.transformations, to provide the desired compound of formula (I).
It will be still further appreciated by those skilled in the art that, as illustrated in the schemes that follow, it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions.
In particular, it may be necessary or desirable to protect amino groups. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G
M Wuts, third edition, (Johri Wiley and Sons, 1999), in particular chapter 7, pages 494=653 ("Protection for the Amino Group"), incorporated herein by reference, which also describes methods for the removal of such groups.
s The amino protecting groups boc, benzyloxycarbonyl, benzyl and acetyl are of particular use in the preparation of compounds of formula (I) and intermediates thereto.
Scheme 1 ~NH
HN~2 (IX) O
a ~R' (V) O
R3 R4 Rs R4 ~NH s N"R' Rw X
RIO N~2 O HN~ 2 (VII) I O R
O (IV) X
Y
a ~ ( ) ~ (VIII) X"R' (V) (c) O
N"R' N ~2 R
(II) R~ OH
(III) (f) R3~
R4 ~N R' RIO N
O (I) With specific reference to scheme 1, the transformations depicted therein may be effected as follows:
(a)-(e) Acid-amine coupling reactions Typically the acid chloride or acid bromide of formulae (V), (VI) or (VIII), and the appropriate piperazine of formulae (IV), (VII) or (IX), optionally with an excess of an acid acceptor such as triethylamine or N ethyl-N,N
diisopropylamine, are reacted in a solvent, such as an haloalkane (e.g.
dichloromethane) or an ether (e.g. THF) at room temperature for 1-24 hours.
The reactions may conveniently be carried out by reacting the relevant piperazine with 1.1 equivalents of the relevant acid chloride in dichloromethane at room temperature for 1 hour.
1o In a further embodiment the acid of formulae (V), (VI) or (VIII), activated by suitable reagents such as WSCDI/DCC and HOBdHOAt, the appropriate piperazine of formulae (IV), (VII) or (IX), and an excess of an acid acceptor such as triethylamine or N ethyl-N,N diisopropylamine, are reacted in a solvent such as an haloalkane (e.g. dichloromethane), an ether (e.g.
THF) or DMF at room temperature for 4-48 hours. The reactions may conveniently be carried out by reacting the relevant piperazine, 1.4 equivalents of WSCDI, 1.4 equivalents of HOBt, 2.2 equivalents of triethylamine and 1.1 equivalents of the relevant carboxylic acid in dichloromethane at room temperature for 18 hours.
2o In yet a further embodiment, the acid of formulae (V), (VI) or (VIII), the appropriate piperazine of formulae (IV), (VII) or (IX), and either HBTU, PyBOP, PyBrOP or Mukaiyama's reagent, and an excess of an acid acceptor such as triethylamine or N ethyl-N,N diisopropylamine, may be reacted in a solvent such as an haloalkane (e.g. dichloromethane) or an ether (e.g. THF) at room temperature for 4-24 hours. The reactions may conveniently be carried out by reacting the relevant piperazine, 1.0 equivalents of the relevant carboxylic acid and 1.5 equivalents of HBTU in either dichloromethane or DMF at room temperature for 14 hours.
(f) Nucleophilic substitution 3o i) When Y= CI, Br, mesylate, tosylate:
Typically compounds of formulae (II) and (III), with an acid acceptor, such as triethylamine , N ethyl-N,N diisopropylamine or an alkali metal carbonate, are reacted in a solvent such as an haloalkane (e.g.
dichloromethane), an ether (e.g. THF) or acetone at a temperature between room temperature and reflux for 1-24 hours. The reactions may conveniently be carried out by reacting compounds of formulae (II) and (III) with 1.0 equivalents of caesium carbonate in acetone at reflux for 14 hours.
ii) When Y= OH:
Typically compounds of formulae (II) and (III), triphenylphosphine or tri-o-tolylphosphine, and either diethyl azodicarboxylate or di-isopropyl azodicarboxylate, are reacted in a solvent such as an haloalkane (e.g.
dichloromethane) or an ether (e.g. THF) at a temperature between room temperature and reflux for 1-24 hours. The reactions may conveniently be carried out by reacting compounds of formulae (II) and (III) with 1.2 equivalents of triphenylphosphine and 1.1 equivalents of di-isopropyl azodicarboxylate in THF at room temperature for 14 hours.
1o Compounds of formula (VI) in reaction steps (a) and (d) may be prepared according to scheme 1 a that follows.
Scheme 1 a R4 R5 OH (III) Ra Ra OR ~ RIO OR ~ RIO OH
Y
O (J) (h) O
O
(X) (XI) (VI) wherein R is a lower alkyl such as C1-C6 alkyl.
(g) Nucleophilic substitution Nucleophilic substitution may be effected according to the conditions described for step (f) hereinabove.
(h) Ester hydrolysis Typically, compounds of formula (XI), aqueous alkali metal hydroxide solution or aqueous hydrochloric acid solution, and an optional co-solvent such as ethanol or dioxane, are heated at a temperature between 60 and 100°C for 1-18 hours. The reactions may conveniently be carried out by heating compounds of formula (XI) in aqueous 1 N sodium hydroxide solution and dioxane heated at 60 °C for 2 hours.
so Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Compounds of formulae (II), (IV) and (VII) are key intermediates and represent a particular aspect of the present invention.
Compounds of formulae (III), (V), (VIII), (IX) and (X) are either known compounds or may be prepared by conventional chemistry.
According to another aspect, the invention provides the following processes for preparing compounds of formula (I).
5 According to a first process (A), compounds of formula (I) may be prepared by coupling an acid of formula (V) O
X" R' (V) 1o with a piperazine of formula (IV), under conventional acid-amine coupling conditions.
R4 ~NH
R ~O N
(IV) Conveniently, acid-amine coupling is effected under the conditions described 15 hereinabove in connection with scheme 1, steps (a)-(e).
Acoording to a second process (B), compounds of formula (I) may be prepared by coupling an acid of formula (VI) RIO X
~ (VI) with a piperazine of formula (VII), under conventional acid-amine coupling conditions.
O
N- _R1 HN
R2 (VII) Conveniently, acid amine coupling is effected under the conditions described hereinabove in connection with scheme 1, steps (a)-(e).
According to a third process (C), compounds of formula (I) may be-prepared by nucleophilic substitution of a compound of formula (II) O
R3 ~~
a N~R~
R ' N
Y ~ R2 O (II) with an alcohol R50H of formula (III) under conventional conditions.
Conveniently, nucleophilic substitution is effected under the conditions described hereinabove in connection with scheme 1, step (f).
According to a fourth process (D), compounds of formula (I) may be 1o prepared from other compounds of formula (I) by functional group interconversion under conventional conditions. For example, compounds of formula (I) which contain an ester group may be converted to corresponding compounds of formula (I) which contain a primary or secondary amide group by reacting the former with ammonia or a primary amine respectively.
The compounds of the invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, and AIDS.
Accordingly, in another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof 2o for use as a medicament.
In another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof for use in the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
In another aspect the invention provides the use of a compound of formula (I) or of a pharmaceutically acceptable salt, solvate or derivative thereof for the manufacture of a medicament for the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
In another aspect the invention provides a method of treatment of a mammal suffering from HIV, a retroviral infection genetically related to HIV, or 3o AIDS which comprises treating said mammal with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof.
The compounds of the invention may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or in any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable 1o excipients. The term "excipient" is used herein to describe any ingredient other than the compounds) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Pharmaceutical compositions suitable for the delivery of compounds of the invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).
2o The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs.
3o Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents andlor suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
s5 The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001 ).
'18 For tablet dosage forms, depending on dose, the drug may make up -from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the-dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, s sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the 1o dosageform.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
Tablets may also optionally comprise surface active agents, such as 2o sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnesium stearate, 2s calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt°/~ to 10 wt°/~, preferably from 0.5 wt% to 3 wt% of the tablet.
Other possible ingredients include anti-oxidants, colourants, flavours, so preservatives and taste-masking agents.
Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt%
lubricant.
35 Tablet blends may be compressed directly or by roller to form tablets.
Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or~
uncoated; it may even be encapsulated.
The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1 ", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).
Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Suitable modified release formulations for the purposes of the 1o invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral 2o administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard 3o pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the compound. Examples of such formulations include drug-coated sterits and PGLA microspheres.
The compounds of the invention may also be administered topically to 5 the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, 1o white petrolatum, glycerin, polyethylene glycol and propylene glycol.
Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999).
Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle 1s or needle-free (e.g. PowderjectT"", BiojectTM, etc.) injection.
Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally 20 or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser so contains a solution or suspension of the compound comprising, for example, ethanol (optionally, aqueous ethanol) or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, the propellants) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid -processing to form nanoparticles, high pressure homogenisation, or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as I leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, 1o glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 p1 to 1 OOpI. A typical formulation may comprise a compound of the invention, propylene glycol, sterile water, ethanol and sodium chloride.
Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. lJnits in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1 Ng to 1 Omg of the compound of the invention.
3o The overall daily dose will typically be in the range 1 pg to 200mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema.
Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Formulations for rectal/vaginal administration may be formulated to be-immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g.
absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as o niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.
The compounds of the invention may be combined with soluble 2o macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of so which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98!55148.
Inasmuch as it may desirable to administer a compound of the invention in combination with another therapeutic agent, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound of the invention, may conveniently be combined in the form of a kit suitable for coadministration of the-compositions.
Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
The kit of the invention is particularly suitable for administering different o dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.
For administration to human patients, having a weight of about 65 to 70kg, the total daily dose of a compound of the invention is typically in the range 1 to 10000mg, such as 10 to 1000mg, for example 25 to 500mg, depending, of course, on the mode of administration, the age, condition and weight of the patient, and will in any case be at the ultimate discretion of the 2o physician. The total daily dose may be administered in single or divided doses.
Accordingly in another aspect the invention provides a pharmaceutical composition including a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers.
The compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives have the advantage that they are more selective, have a more rapid onset of action, are more potent, are better absorbed, are more stable, are more resistant to metabolism, have a reduced 'food effect', have an improved safety profile or have other more desirable properties (e.g. with respect to solubility or hygroscopicity) than the compounds of the prior art.
The compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives may be administered alone or as part of a combination therapy. Thus included within the scope of the present invention are embodiments comprising coadministration of, and compositions which contain, in addition to a compound of the invention, one or more additional therapeutic agents. Such multiple drug regimens, often referred to as-combination therapy, may ~ be used in the treatment and prevention of infection by human immunodeficiency virus, HIV. The use of such combination therapy is especially pertinent with respect to the treatment and prevention of infection and multiplication of the human immunodeficiency virus, HIV, and related pathogenic retroviruses within a patient in need of treatment or one at risk of becoming such a patient. The ability of such retroviral pathogens to evolve within a relatively short period of time into strains resistant to any monotherapy which has been administered to said 1o patient is well known in the literature. A recommended treatment for HIV is a combination drug treatment called Highly Active Anti-Retroviral Therapy, or HAART. HAART combines three or more HIV drugs. Thus, the methods of treatment and pharmaceutical compositions of the present invention may employ a compound of the invention in the form of monotherapy, but said ~5 methods and compositions may also be used in the form of combination therapy in which one or more compounds of the invention are coadministered in combination with one or more additional therapeutic agents such as those described in detail further herein.
In a further embodiment of the invention, combinations of the present 2o invention include treatment with a compound of formula (l), or a pharmaceutically acceptable salt, solvate or derivative thereof, and one or more additional therapeutic agents selected from the following: HIV protease inhibitors, including but not limited to indinavir, ritonavir, saquinavir, nelfinavir, lopinavir, amprenavir, atazanavir, tipranavir, AG1859 and TMC 114; non 25 nucleoside reverse transcriptase inhibitors (NNRTIs), including but not limited to nevirapine, delavirdine, capravirine, efavirenz, GW-8248, GW-5634 and TMC125; nucleoside/nucleotide reverse transcriptase inhibitors, including but not limited to zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, adefovir dipivoxil, tenofovir, emtricitabine and alovudine; CCR5 3o antagonists, including but not limited to:
N-f (1 S)-3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1 ]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide or a pharmaceutically acceptable salt, solvate or derivative thereof, s5 methyl 1-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl}-2-methyl-4,5,6,7-tetrahydro-1 H imidazo[4,5-c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or~
derivative thereof, methyl - 3-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl)-2-methyl-4,5,6,7-tetrahydro-3H imidazo[4,5-5 c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or derivative thereof, ethyl 1-endo-{8-[(3S)-3-(acetylamino)-3-(3-fluorophenyl)propyl]-8-azabicyclo[3.2.1 ]oct-3-yl}-2-methyl-4,5,6,7-tetrahydro-1 H imidazo[4,5-c]pyridine-5-carboxylate or a pharmaceutically acceptable salt, solvate or ~o derivative thereof, Sch-D, ONO-4128, GW-873140, AMD-887 and CMPD-167; other agents which inhibit the interaction of gp120 with CD4, including but not limited to BMS806 and BMS-488043; other agents which inhibit the entry of HIV into a target cell, including but not limited to enfuviritide, T1249, PRO 542 and 15 PRO 140; integrase inhibitors, including but not limited to L-870,810; and RNaseH inhibitors.
There is also included within the scope the present invention, combinations of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof, together with one or more additional 2o therapeutic agents independently selected from the group consisting of proliferation inhibitors, e.g. hydroxyurea; immunomodulators, such as granulocyte macrophage colony stimulating growth factors (e.g.
sargramostim), and various forms of interferon or interferon derivatives;
other chemokine receptor agonists/antagonists, such as CXCR4 antagonists (e.g.
25 AMD-070); tachykinin receptor modulators (e.g. NtC1 antagonists) and various forms of interferon or interferon derivatives; agents which substantially inhibit, disrupt or decrease viral transcription or RNA replication such as inhibitors of tat (transcriptional trans activator) or nef (negative regulatory factor);
agents which substantially inhibit, disrupt or decrease translation of one or more so proteins expressed by the virus (including, but not limited to, down regulation of protein expression or antagonism of one or more proteins) other than reverse transcriptase, such as Tat or Nef; agents which influence, in particular down regulate, CCR5 receptor expression; chemokines that induce CCR5 receptor internalisation such MIP-1 a, MIP-1 [3, RANTES and derivatives thereof; and other agents that inhibit viral infection or improve the condition or outcome of HIV-infected individuals through different mechanisms.
Agents which influence (in particular down regulate) CCR5 receptor-expression include immunosupressants, such as calcineurin inhibitors (e.g. tacroliinus and cyclosporin A); steroids; agents which interfere with cytokine production or signalling, such as Janus Kinase (JAK) inhibitors (e.g. JAK-3 inhibitors, including 3-{(3R,4R)-4-methyl-3-[methyl-(7H
pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile) and pharmaceutically acceptable salts, solvates or derivatives thereof; cytokine antibodies (e.g. antibodies that inhibit the interleukin-2 (IL-2) receptor, including basiliximab and daclizumab); and agents which interfere with cell 1o activation or cell cycling, such as rapamycin.
There is also included within the scope the present invention, combinations of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof, together with one or more additional therapeutic agents which slow down the rate of metabolism of the compound 5 of the invention, thereby leading to increased exposure in patients.
Increasing the exposure in such a manner is known as boosting. This has the benefit of increasing the efficacy of the compound of the invention or reducing the dose required to achieve the same efficacy as an unboosted dose. The metabolism of the compounds of the invention includes oxidative processes 2o carried out by P450 (CYP450) enzymes, particularly CYP 3A4 and conjugation by UDP glucuronosyl transferase and sulphating enzymes. Thus, among the agents that may be used to increase the exposure of a patient to a compound of the present invention are those that can act as inhibitors of at least one isoform of the cytochrome P450 (CYP450) enzymes. The isoforms 25 of CYP450 that may be beneficially inhibited include, but are not limited to, CYP1 A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4. Suitable agents that may be used to inhibit CYP 3A4 include, but are not limited to, ritonavir, saquinavir or ketoconazole.
It will be appreciated by a person skilled in the art, that a combination so drug treatment, as described herein above, may comprise two or more compounds having the same, or different, mechanism of action. Thus, by way of illustration only, a combination may comprise a compound of the invention and: one or more NNRTIs; one or more NRTIs and a PI; one or more NRTIs and a CCR5 antagonist; a PI; a PI and an NNRTI; and so on.
35 In addition to the requirement of therapeutic efficacy, which may necessitate the use of therapeutic agents in addition to the compounds of the invention, there may be additional rationales which compel or highly recommend the use of a combination of a compound of the invention and -another therapeutic agent, such as in the treatment of diseases or conditions which directly result from or indirectly accompany the basic or underlying disease or condition. For example, it may be necessary or at least desirable to treat Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Human Papillomavirus (HPV), opportunistic infections (including bacterial and fungal infections), neoplasms, and other conditions which occur as the result of the immune-compromised state of the patient being treated. Other therapeutic agents may be used with the compounds of the invention, e.g., in order to 1o provide immune stimulation or to treat pain and inflammation which accompany the initial and fundamental HlV infection.
Accordingly, therapeutic agents for use in combination with the compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives also include: interferons, pegylated interferons (e.g.
peginterferon alfa-2a and peginterferon alfa-2b), lamivudine, ribavirin, and emtricitabine for the treatment of hepatitis; antifungals such as fluconazole, itraconazole, and voriconazole; antibacterials such as azithromycin and clarithromycin; interferons, daunorubicin, doxorubicin, and paclitaxel for the treatment of AIDS related fCaposi's sarcoma; and cidofovir, fomivirsen, 2o foscarnet, ganciclovir and valcyte for the treatment of cytomegalovirus (CMV) retinitis.
Further combinations for use according to the invention include combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or derivative thereof with a CCR1 antagonist, such as BX-471; a beta adrenoceptor agonist, such as salmeterol; a corticosteroid agonist, such fluticasone propionate; a LTD4 antagonist, such as montelukast; a muscarinic antagonist, such as tiotropium bromide; a PDE4 inhibitor, such as cilomilast or roflumilast; a CO?C-2 inhibitor, such as celecoxib, valdecoxib or rofecoxib;
an alpha-2-delta ligand, such as gabapentin or pregabalin; a beta-interferon, so such as REBIF; a TNF receptor modulator, such as a TNF-alpha inhibitor (e.g. adalimumab), a HMG CoA reductase inhibitor, such as a statin (e.g.
atorvastatin); or an immunosuppressant, such as cyclosporin or a macrolide such as tacrolimus.
In the above-described combinations, the compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof and other therapeutic agents) may be administered, in terms of dosage forms, either separately or in conjunction with each other; and in terms of their time of administration, either simultaneously or sequentially. Thus, the administration -of one component agent may be prior to, concurrent with, or subsequent to the administration of the other component agent(s).
Accordingly, in a further aspect the invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof and one or more additional therapeutic agents.
It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.
1o The invention is illustrated by the following Examples and Preparations in which the following further abbreviations may be used:
0.88 ammonia = concentrated ammonium hydroxide solution, 0.88 SG
h = hour min = minute LRMS = low resolution mass spectrum APCI+ = atmospheric pressure chemical ionisation ESI+ = electrospray ionisation NMR = nuclear magnetic resonance tlc - thin layer chromatography 2o Me = methyl Example 1 (2S~[(2R~ 4-Benzoyl-2-methyl-~perazin-1-yl)-2-(quinolin-5-yloxy)-propan-1-one Me ~N I \
Ni I O N /
\ O Me A solution of (2S)-2-(quinolin-5-yloxy)-propionic acid sodium salt (Preparation 2) (1.0 g, 4.6 mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J.
Med. Chem. (2000), 43(23), 4499) (0.94 g, 4.6 mmol), O-(1 H-benzotriazol-1-so yl)-N,N,I~P,I~P-tetramethyluronium hexafluorophosphate (2.62 g, 6.9 mmol) and triethylamine (1.93 ml, 13.8 mmol) in N,N dimethylformamide (30 ml) was stirred under a nitrogen atmosphere at room temperature for 14 hours. The reaction mixture was diluted with dichloromethane (100 ml), washed with water (3 X 50 ml), dried (MgS04) and solvent evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel eluting with dichloromethane: methanol (98:2) to afford the title compound as a white solid (0.91 g).
1 H NMR (400MHz, CDC13): b: 8.90 (1 H, m), 8.60 (1 H, m), 7.70 (1 H, m), 7.55 (1 H, m), 7.20-7.40 (6H, m), 6.85 (1 H, m), 5.15 (1 H, m), 4.80-2.80 (7H, m), 1.70 (3H, d), 0.90 (3H, br s) ppm.
LRMS (APCI+) : m/z [M+H]+ 404.
1o Example 2 3-f2-l(2Rl-4-Benzovl-2-methyl-piperazin-1-vl)-1-methyl-2-oxo-ethoxv]-2-methyl-benzoic acid methyl ester Me ~N ~ \
Me0 \ O N
O Me O Me Cesium carbonate (0.39 g, 1.2 mmol) was added portionwise to a solution of 1-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one (Preparation 3) (0.41 g, 1.2 mmol) and 3-hydroxy-2-methyl-benzoic acid methyl ester (Tet. Lett. (2000), 41 (11 ), 1741 ) (0.2 g, 1.2 mmol) in acetone (10 ml) and the mixture heated under reflux for 14 hours. The cooled reaction 2o mixture was evaporated to dryness under reduced pressure and the residue partitioned between dichloromethane (50 ml) and water (10 ml). The organic phase was separated and the aqueous phase extracted with dichloromethane (3 X 30 ml), the combined organic extracts were dried (MgS04) and solvent evaporated under reduced pressure to afford the title compound as a white solid (0.5 g).
1 H NMR (400MHz, CDC13): S: 7.50-7.30 (6H, m), 7.15 (1 H, m), 6.95 (1 H, m), 4.95 (1 H, m), 4.80-2.80 (7H, m), 3.90 (3H, s), 2.40 (3H, s), 1.65 (3H, d), 1.20 (3H, br s) ppm.
LRMS (APCI+) : mlz [M+H]+ 425.
3o Examples 3-12 were prepared by the method described above for Example 1, using the corresponding acid of formula (VI) and piperazine of formula (VI I). LRMS was by APCI+ and data quoted are for [M+H]+.
Mass Example Structure Spec.
Number Data /
3 \ I Me ~N I \ 386 CI O /
O Me O
Me ~N \
4 \ ~ N ~ , 380 Me O
Me O Me O
Me ~N \
5 \ I N ~ / 408 ~o HN~ ~ Me O F
Me ~N \
6 ~ / ~ _ N ~ / 422 \ ~ ~ ~ Me O
Me ~N \ F
N ~ / 422 N, Y ~O
\ O Me O
Me ~N \
8 ~ / I _ N ~ / 422 N, Y O F
\ ~ Me O
Me ~N Nw 9 ~ / ~ N ~ / 405 N, Y ~O
\ O Me Mass Example .
Structure Spec.
Number Data Me ~N ~ ~ N
N ~ o N ~ 405 \ ~ O Me O O
Me~H \ ~ Me ~''N ~ \' 440 OMe O Me O
Me ~N ~ \
12 \ o N ~ 407 HN
N- O Me Me Examples 13-45 were prepared by the method described above for Example 2, using the corresponding compound of formula (II) and R5~H.
LRMS was by APCI+ and data quoted are for [M+H]+, unless otherwise s stated.
Mass Example Structure Spec.
Number Data o 13 \ I Me ~N I j 386 Ci O
O Me Mass Example Structure Spec.
Number Data /
14 \ I Me ~N I j 380 Me O
Me O Me O
15 \ I Me ~N I j 366 Me O
Me O
O
16 \ ~ Me ~N I ~ 391 Me O
CN O Me O
17 \ I Me ~N I ~ 383 O
OMe O Me O
18 ~ ~ Me ~N ~ , 393 o O
=--N O Me O
Me ~N
19 w I N ~ , 419 N
O Me O
20 \ I Me ~N I j 367 -O
Me O Me O
/ N Me ~N
21 ~ ~ N ~ , 368 O
Me O Me Mass Example Structure Spec.
Number Data Me ~N \ 403 22 N~ ~ o N ~ ~ (ESI+, \ I O Me M+) O
F
Me ~N \
23 / I N ~ , 421 \ N O Me Me p 24 \ ( Me ~N I \ (ESI+, ~ M+) Me O Me O
25 N~ ) / Me ~N ~ / 393 H
N O
O Me O
26 \ ~ / Me ~N I j 402 O
O Me O
Me ~N
27 / ~ N ~ , 403 i I~ ,o \ N O Me O
Me ~N
28 ~ ~ o N ~ ~ 403 NJ O Me Mass Example .
Structure Spec.
Number Data Me ~N \
29 / I N ~ / 402 ~o \ I O Me O O
Me~H / ~ Me ~N ~ \ 424 30 Me ~ O~N~ /
O M'e O O
Me~H / ~ Me ~N ~ \ 440 31 ~ o~N
OMe ~O( M~e O O
Et~H / ~ Me ~N ~ ~ 454 32 ~ o~N
OMe O M~e O
Me ~N ~ \
33 \ o N / 407 HN
N- O Me Me O
Me ~N ~ \
34 HN o / 407 =-N O Me Me O
35 \ ~ Me ~N I \ 368 Me O /
O Me Mass Example Structure Spec.
Number Data Me p O
36 ~ ~ , Me ~N ~ \ 434 O
O Me O
Me N
37 ~ ~ j Me ~N I j 417 O
IOI Me O
Me ~N
38 ~ , N ~ , 403 O
O Me O
39 N \ ~ ~ Me ~N I ~ 403 O
O Me O
Me ~N
Me,N ~ O~N / 421 N- O Me Me O O
41 H2N \ I Me ~N ~ j 426 O
OMe O Me O O
42 HEN \ I Me ~N ( % 410 Me O
IOI Me O O
43 H2N \ ~ Me ~N I j 426 Me0 O
IOI Me Mass Example Structure Spec.
Number Data Me ~N
44 ~ o N ~ ~ 396 H2N O O Me O
N
Me N
45 ~ ~ , ~ ~ , 405 O
O Me Example 46 (2Sl-1-f(2R)-4-Benzovl-2-methvl-piperazin-1-VI1-2-f2-methox -4- 2H-j1 2 4]triazol-3-ylLphenoxy~-propan-1-one O
NwN CHs ~N I \
H N /
O
O CHs CHs The compound of Preparation 10 (125mg, 0.26mmol) was added portionwise to a stirred solution of hydrazine monohydrate (25pL, 0.52mmol) in glacial acetic acid (4mL). The resulting solution was heated at 90°C for 3 hours. The 1o reaction mixture was then evaporated under reduced pressure and the residual colourless oil was partitioned between dichloromethane (50mL) and saturated sodium hydrogen carbonate solution (8mL). The organic phase was separated and the aqueous phase was re-extracted with dichloromethane (30mL). The combined organic phases were dried over magnesium sulfate ~5 and concentrated in vacuo to yield a colourless foam. The foam was dried under reduced pressure to afford the title compound in 94% yield, 110mg.
LRMS (ES+): mlz [M+H]+ 450 Example 47 1-f(2R -4-Benzoyl-2-methyl-piperazin-1-yl]-2-f2-methyl-3 ~1-methyl-1 H-pyrazol-3 yl)-phenoxyLpropan-1-one O
CH3 ~N
~N~ ~ O N
The compounds of Preparations 17 (100mg, 0.53mmol) and 25 (180mg, 0.53mmol) and cesium carbonate (172.7mg, 0.53mmol) in acetone (8mL) were heated under reflux for 3.5 hours. The reaction mixture was then cooled and evaporated under reduced pressure. The residue was partitioned 1o between dichloromethane (30mL) and water (8mL). The organic phase was separated and the aqueous phase was re-extracted with further dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give a light brown oil. The oil was chromatographed using an Isolute~ Flash silica column, eluting with dichloromethane:methanol, 99:1 to 97:3, to give a colourless oil. This oil was azeotroped with dichloromethane to afford the title compound as colourless foam in 89% yield, 210mg.
LRMS (ES+): m/z [M+H]+ 447 2o Example 48 1-[~(2R)-4-Benzoyl-2-methyl-piperazin-1-y~2-methyl-3-[1,2,4~oxadiazol-5-yl-phenoxy~propan-1-one CH3 ~N
O ~ O N
N
~IN CH3 O CH3 The compound of Preparation 29 (280mg, 0.62mmol) was heated in a mixture of glacial acetic acid (3mL) and dioxane (3mL) at 90°C, for 3.5 hours.
The mixture was then allowed to cool and was evaporated under reduced pressure to give a yellow oil. The oil was dissolved in ethyl acetate (50mL) and washed with 10% sodium carbonate solution (lOmL) and water (lOmL).
The organic phase was dried over magnesium sulfate and concentrated in-vacuo to give a colourless foam. The foam was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 97:3, to give a colourless oil. The oil was azeotroped with dichloromethane to afford the title s compound as a colourless foam in 44% yield, 118mg.
LRMS (ES-): m/z [M-H]-433 Example 49 (2S)-1~[(2R)-4-Benzoyl-2-meth iLl-piperazin-1-yll-2-[~2H-pyrazol-3-yl)-io phenoxy]'-propan-1-one O
CH3 ~N
N
O
H ~
N
(3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(114mg, 0.56mmol), J.
Med. Chem. 43(23), 4499; 2000], 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (167.5mg, 0.56mmol) and triethylamine (78pL, 15 0.56mmol) were added to a solution of the compound of Preparation 23 (130mg, 0.56mmol) in tetrahydrofuran (8mL) and the resulting solution was stirred at room temperature for 48 hours. The mixture was then diluted with ethyl acetate (30mL) and washed with water (lOmL), 10% citric acid (lOmL), water (lOmL) and sodium hydrogen carbonate solution. The organic phase 2o was dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 98:2 to 96:4, to give a colourless foam. The foam was azeotroped with dichloromethane and dried under reduced pressure to afford the title compound in 85% yield, 198mg.
25 LRMS (ES-): m/z [M-H]-417 Example 50 (2S)-1-[~2R~4-Benzoyl-2-metal-~perazin-1-yl]-2-[2-methyl-3-(2H-pyrazol-3-yl~ phenoxy]-propan-1-one CH3 ~N
N /
\ O
~CH3 H ~
N
The title compound was prepared by the method described above for Example 49, using the compound of Preparation 24 and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone ( J. Med. Chem. 43(23), 4499; 2000).
LRMS (ES-): m/z [M-H]-431 Example 51 1-~(2R~4-Benzoyl-2-methyl-piperazin-1-yl]-2-[~1 H-imidazol-2-yl)-2-methoxy-~ahenoxy]-propan-1-one CH3 ~N ~ \
N /
\ 0 N /
~~N CH3 The compounds of Preparation 33 (30mg, 0.16mmol) and Preparation 25 (53.5mg, 0.16mmol) and cesium carbonate (51.3mg, 0.16mmol) in N,N-dimethylformamide (4mL) were heated at 80°C for 18 hours. The reaction mixture was allowed to cool and was then evaporated under reduced 2o pressure and the residue was partitioned between dichloromethane (30mL) and water (8mL). The aqueous phase was separated and was re-extracted with dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 95:5, to afford the title compound as a beige foam in 74% yield, 52mg.
LRMS (ES+): m/z [M+H]+ 449 Examples 52 to 53 The following compounds, of the general formula shown below, were prepared by the method described above for Example 51, using the o compound of Preparation 25 and the appropriate phenol.
CH3 ~N
N
O
R O
No. R~ Data 52 ~ N LRMS (ES-): m/z [M-H]~
N\
53 j LRMS (ES-): mlz [M+Na]+
~N 471 ~
~5 Examples 54 to 57 The following compounds, of the general formula shown below, were prepared by the method described above for Example 51, using the compound of Preparation 25 and the appropriate phenol.
CH3 ~N
R\O N /
No. R5 LRMS (APCI+~: m/z [M+H]+
54 j H3 429 s \
H3C~
o' H3C~
57 ~ / ~ 482 H2N~ //
/% /
0 ~ _ Example 54: phenol prepared as described in Preparation 67 Example 55: phenol prepared as described in Preparation 68 Example 56: 6-methoxy-2-naphthol is commercially available Example 57: 5-hydroxy-1-naphthalene sulfonamide is commercially available Example 58 1-f(2Rl-4-Benzovl-2-methyl-aioerazin-1-vll-2-(4-methanesulfonvl-2-methox i~henoxy~-propan-1-one O O
_1I
H3C II / CH3 ~N \
o \ ~ N
-o H C~~ O CH3 A solution of oxone (215mg, 0.35mmol) in water (2mL) was added to a solution of the compound of Example 54 (100mg, 0.23mmol) in methanol (4mL) and the mixture was stirred for 18 hours at room temperature. The solvent was then evaporated under reduced pressure and the residue was partitioned between water (20mL) and dichloromethane (20mL). The aqueous layer was separated and re-extracted with dichloromethane (30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 95:5 to afford the title com~aound as a white solid in 78% yield, 80mg.
LRMS (APCI+): m/z [M+H]+ 481 Example 59 N-~4-[2~2R)-(4-Benzoyl-2-methyl-piperazin-1-yl)-1-methyl-2-oxo-ethoxy]-3-methox~phenyl}-methanesulfonamide O H I Hs O
H3C ~ N / O CH3 ~N \
\ N /
O
Triethylamine (0.08mL, 0.57mmol) was added to a solution of the compound of Preparation 30 (150mg, 0.38mmol) in dichloromethane (3mL) and the mixture was cooled in an ice bath. Methanesufonyl chloride (0.03mL, 0.42mmol) was added dropwise and the reaction mixture was allowed to stir at room temperature for 18 hours. The mixture was then diluted with further dichloromethane (20mL) and washed with water. The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was then purified by column chromatography on silica gel, eluting with ethyl acetate:methanol, 98:2, to afford the title compound as a white solid in 49%
yield, 88mg.
LRMS (APCI+): m/z [M+H]+ 476 Example 60 ,(2S -1~-f(2R -4-Benzoyl-2-methpiperazin-1-y~-2-(2-chloro-quinolin-5-yloxy~-propan-1-one CH3 ~N
N/ I O N /
CI \ O CH3 o A solution of the compound of Preparation 46 (1.8g, 4.3mmol) in phosphorous oxychloride (5mL) was heated at 100°C for two hours. The reaction mixture was then cooled to room temperature and evaporated under reduced pressure. The residue was dissolved in dichloromethane (20mL) and washed with saturated aqueous sodium hydrogen carbonate solution (1 OmL) and water (2x1 OmL). The aqueous phase was basified with 1 M
sodium hydroxide solution and was re-extracted with ethyl acetate. The combined organic extracts were then dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate 20:80, 0:100 to afford the title 2o compound as a pale yellow solid in 31 % yield, 580mg.
'H NMR (400MHz, CDCI3) b: 1.00-1.40(m, 3H), 1.70-1.80(m, 3H), 2.80-4.80 (m, 7H), 5.20(m, 1 H), 6.90(m, 1 H), 7.20-7.45(m, 6H), 7.55-7.70 (m, 2H), 8.55(d, 1 H) LRMS (APCI+): m/z [M+H]+ 438 Examples 61 to 62 A mixture of the compound of Example 60 (30mg, 0.069mmol), tetrabutyl ammonium fluoride (18mg, 0.14mmol), triethylamine (96pL, 0.69mmol) and 3o the appropriate amine (0.69mmol) in dimethylsulfoxide (1 mL) was heated at 100°C for 24 hours. The reaction mixtures were then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1):acetonitrile, 95:5 to 5:95, to' afford the desired compounds of general formula shown below:
r \ o ( \
N /
t R6,NH
No. R6 LRMS (APCI+): m/z [M-H]+
H3C' 62 ~H3 461 Example 63 1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl)-2-(1-chloro-isoguinolin-5-ylox~
propan-1-one O
\ ~ :5 N / /
CI
1o The title compound was prepared by the method described above for Example 60, using the compound of Preparation 63 and phosphorus oxychloride.
LRMS (APCI+): m/z [M+H]+ 438 Examples 64 to 65 A mixture of the compound of Example 63 (45mg, 0.1 mmol), tetrabutyl 5 ammonium fluoride (27mg, 0.2mmol), triethylamine (140pL, 1mmol) and the appropriate amine (1 mmol) in dimethylsulfoxide (1 mL) was heated at 130°C
for 24 hours. The reaction mixtures were then purified directly by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95 to afford the desired compounds of 1o general formula shown below:
CH3 ~N
N
O
R~
N N
R' No. R6 R' LRMS (APCI+): m/z [M-HJ+
64 N~N H 485 Example 66 (2Sl-2-(2-Amino-auinolin-5-vloxv)-1-f (2R)-4-benzovl-2-methyl-piperazin-1-propan-1-one p CH3 ~N ~ \
N /
\ O
N /
s 10% Pd/C (cat) and ammonium formate (l0mg, 0.15mmol) were added to a solution of the compound of Preparation 49 (l5mg, 0.03mmol) in ethanol (1 mL) and the mixture was heated at 70°C for 2 hours. Additional ammonium formate (l0mg, 0.15mmol) and Pd(OH)2 (cat) were added and the reaction mixture was heated under reflux for a further 18 hours. The mixture was then 1o cooled and filtered through Arbocel~, washing through with ethanol (lOmL).
The filtrate was concentrated in vacuo and the residue was purified by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound in 77% yield, 9.7mg.
15 LRMS (ES+): m/z [M+H]+ 419 Example 67 l2Sl-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-2-(8-chloro-auinolin-5-vlox propan-1-one / ( CH3 ~N
N/ o N /
A mixture of the compound of Preparation 42 (30mg, 0.07mmol) and N-chlorosuccinimide (11 mg, 0.08mmol) in acetonitrile (3mL) was heated at 40°C
for 48 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in ethyl acetate (5mL) and washed with water (2x5mL). The organic phase~was dried over magnesium sulfate and concentrated in vacuo to give a yellow residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a solid in 32% yield, 9.7mg.
LRMS (APCI+): m/z [M+HJ+ 438 Examples 68 to 69 The following compounds, of the general formula shown below, were prepared by the method described above for Example 67, using the appropriate starting material and N-chlorosuccinimide.
o C~ /
Cf-13 ~N
N/ O N /
\ O CH3 No. X LRMS (APCI+): m/z [M-HJ+
Examples 68 and 69 were purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 96:4 Examples 70 and 71 The compounds were prepared from the compound of Preparation 60 and 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), using a similar preparation to Example 67. The compounds were purified by HPLC using a Phenomenex Luna C18(2) column 150x15mm (10 micron particle size, 100A porosity), using a 2 solvent eluent of acetonitrile:waterarifiuoroacetic acid (5:95:0.1 ) [solvent A] and acetonitile -[solvent B]. A solvent gradient is run at a flow-rate of 20 ml/min as in the table below. -Time min) %B
0.6 5 9.5 95 10.5 95 10.6 5 No Structure HPLC LRMS (APCI+):
retention time m/z [M+H]+
min.
70 4.99 422 F
I CH3 ~N I \
N/ I O N /
\ O CHI
71 5.77 422 / F
I CH3 ~N I \
N/ I O N /
\ O CH3 Example 72 ~2S)-1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(8-methyl-quinolin-5-yloxy~-propan-1-one I CH3 ~N \
N~ O N I
\ O CH3 A mixture of the compound of Preparation 44 (200mg, 0.4mmol), methyl boronic acid (74mg, l.2mmol), bis(triphenylphosphine)palladium(II) chloride (29mg, 0.04mmol) and potassium carbonate (229mg, l.6mmol) in N,N-dimethylformamide (4mL) was heated at 100°C for 18 hours. Tlc analysis 1o showed that the reaction was incomplete and so additional amounts of methyl boronic acid (74mg) and bis(triphenylphosphine)palladium(II) chloride (29mg) were added, and the mixture was allowed to stir for a further 24 hours at 100°C. The reaction mixture was then filtered through Arbocel~, washing through with ethyl acetate (25mL) and water (3x20mL). The layers were separated and the aqueous layer was re-extracted with ethyl acetate. The combined organic solutions were dried over magnesium sulfate and concentrated in vacuo to afford a yellow residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1):acetonitrile, 95:5 to 5:95.
The 2o appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a yellow solid in 19% yield, 33mg.
LRMS (APCI+): m/z [M+H]+ 418 Example 73 (2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-,Lrll-2-[8-~(2H-pyrazol-3-yl)-quinolin-5-yloxy~-propan-1-one 5 4M Hydrochloric acid (2mL) was added to a suspension of the compound of Preparation 45 (43mg, 0.07mmol) in methanol (2mL), and the resulting solution was stirred at room temperature for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed twice with dichloromethane. The combined organic 10 layers were dried over magnesium sulfate and concentrated in vacuo to give a yellow residue. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, to afford the title compound as a yellow solid in 68% yield, 23mg LRMS (APCI+): m/z [M+H]+ 470 Example 74 (~S)-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-2-f2-(2H-avrazol-3-vlaminol-quinolin-5-yloxy]-propan-1-one CH3 ~N
~~N N~ ~ O N
\ O CH3 N
H
A mixture of the compound of Example 60 (50mg, 0.11 mmol), 3-aminopyrazole (29mg, 0.33mmol) and triethylamine (48pL, 0.33mmol) in 2-propanol (0.5mL) was heated at 90°C in a ReactivialT"". After 18 hours, cesium fluoride (33mg, 0.22mmol) was added and the mixture was heated at 100°C for a further 48 hours. The reaction mixture was then filtered and concentrated in vacuo to afford an oily residue. The residue was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a yellow solid 3mg.
LRMS (APCI+): m/z [M+H]+ 485 Example 75 5-~(1S~2-[(2R -4.-Benzo~rl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy~
1 H~uinolin-2-one O
/ ~ CH3 ~N ~ \
HN \ O N /
1o The compound of Example 60 (200mg, 0.46mmol) and acetic acid (3mL) were dissolved in water and the solution was heated under reflux for 24 hours. The reaction mixture was then diluted with water and washed with dichloromethane (3x10mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The oil was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5 to afford the title compound as pale yellow solid in 40% yield, 76mg.
LRMS (APCI+): m/z [M+H]+ 418 2o Example 76 ~(1 S)-2-~(2R)-4.-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethox~r~8-chloro-1 H-quinolin-2-one O
C~
CH3 ~N ~ \
HN \ O N
The title compound was prepared by the method described above for Example 67, using the compound of Example 75 and N-chlorosuccinimide.
LRMS (APCI+): m/z [M+H]+ 454 Example 77 (2S)-1 ~[(2F~-4-Benzoyl-2-methyl-piperazin-1-yll-2-(~-methoxy-quinolin-5-ylox~r -propan-1-one CH3 ~N I \
Ni I 0 N /
H3C~0 \ O CH3 A mixture of the compound of Example 60 (20mg, 0.04mmol) and sodium methoxide (0.5M in methanol, 0.7mL) in N,N-dimethylformamide (0.5mL) was heated in a ReactivialT"" at 70°C for 6 hours. The reaction mixture was 1o cooled, and evaporated under reduced pressure. The residue was dissolved in dichloromethane (5mL) and washed with brine (5mL) and water (2x5mL).
The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in dimethylsulfoxide (0.5mL) and was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95. The appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a yellow solid in 40% yield, 7mg.
LRMS (APCI+): m/z [M+H]+ 434 2o Example 78 5-((1 S)-2-f(2R)-4-Benzovl-2-methvl-aioerazin-1-vll-1-methyl-2-oxo-ethox isoquinoline-1-carboxylic acid methyl ester O
O / ~ CH3 ~N
H3C~0 / O N /
The compound of Preparation 65 (80mg, 0.18mmol), dichloro-bis(triphenylphosphine)palladium (l5mg, 0.018mmol) and triethylamine (51 pL, 0.37mmol) were dissolved in methanol (5mL) and transferred to a sealed vessel. The vessel was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in vacuo.~ The residue was purified on an Isolute~ flash silica colur~in, eluting with dichloromethane:methanol, 99:1 to afford the title compound as a white foam in 43% yield, 36mg.
LRMS (APCI+): m/z [M+H]+ 462 Example 79 5~2-~2R -4-Benzoyl-2-methyl-pi~~erazin-1-yl]-1-methyl-2-oxo-ethoxy}-quinoline-2-carboxylic acid meth la~_ mide CH3 ~N ~ \
N
~NH
A mixture of the compound of Preparation 48 (20mg, 0.05mmol), methylamine (33% in ethanol, 30mg, 0.5mmol), O-(1 H-benzotriazol-1-yl)-N,N,N',IV-tetramethyluronium hexafluorophosphate (2mg, 0.08mmol) and triethylamine (62pL, 0.5mmol) in dichloromethane (1 mL) was stirred at room temperature for 18 hours. Additional methylamine (30mg, 0.5mmol) and triethylamine (62 pL, 0.5mmol) were added to the reaction mixture and stirring continued for a further 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x5mL) and brine (5mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo 2o to give a yellow residue. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 96:4, to afford the title compound as a white solid in 13% yield, 3mg.
LRMS (APCI+): m/z [M+H]+ 461 Example 80 5-f(1 Sl-2-f(2R)-4-Benzovl-2-r~nethvl-aiperazin-1-vll-1-methyl-2-oxo-ethox isoquinoline-1-carbox~rlic acid methylamide O
O / ~ CHs ~N
HsCwN / ~ N /
H
The title compound was prepared by the method described above for Example 79, using the compound of Example 78 and methylamine.
LRMS (APCI+): m/z [M+H]+ 461 Example 81 1o 4-~~~1 S)-2-[(2R -4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy)-N-methyl-3-trifluoromethoxy-benzamide H
H3C\N CH3 N
O
FI
F
The compound of Preparation 59 (100mg, 0.2mmol) and methylamine (33%
in ethanol, 4mL) were heated at 90°C in a ReactivialT"" for 18 hours.
The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 97:3, to afford the title compound as a pale orange foam in quantitative yield, 100mg.
LRMS (APCI+): m/z [M+H]+ 494 Example 82 ~2S)-1-f(2R -4-Benzoyl-2-methyl-piperazin-1-~r11-2-(8-chloro-2-methylamino-quinolin-5~iloxy~propan-1-one / ~ CHs N ~ I ~o H3CwN \ 0 H
5 A mixture of the compound of Preparation 52 (60mg, 0.12mmol), methylamine hydrochloride (86mg, l.2mmol), cesium fluoride (39mg, 0.24mmol) and triethylamine (0.18mL, 1.2mmol) in dimethylsulfoxide (1 mL) was heated in a microwave for 8 minutes at 170°C. The reaction mixture was then filtered and the filtrate was purified by HPLC using a Phenomenex Luna 1o C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95. The appropriate fraction was then azeotroped with diethyl ether to afford the title compound as a brown solid in 19% yield, 10.8mg.
LRMS (APCI+): m/z [M+H]+ 467 Example 83 1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-methylamino-isoquinolin-5~i loxy~propan-1-one CH3 ~N ( \
NI /
O
\ \ 0 CH3 //~
,NH
2o The title compound was prepared by the method described above for Example 82, using the compound of Example 63 and methylamine.
LRMS (APCI+): m/z [M+H]+ 433 Example 84 (2S~1-f 2R)-4-Benzoyl-2-methyl-~perazin-1-yl]-2-(8-chloro-2-dimethylamino-auinolin-5~ilo~)-pr~an-1-one _ / ~ CH3 .
N / ( w0 H3C~ \ O CH3 N
A mixture of the compound of Preparation 52 (50mg, 0.1 mmol), dimethylamine (86mg, 1 mmol), cesium fluoride (32mg, 0.2mmol) and triethylamine (0.15mL, 1 mmol) in dimethylsulfoxide (4mL) was heated at 170°C in a ReactivialT"" for 18 hours. The reaction mixture was then filtered 1o and the filtrate was purified by HPLC using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound as a white solid, 5mg.
LRMS (APCI+): m/z [M+H]+ 481 Example 85 (2S)-1-f(2R)-4-Benzoyl-2-methyl-~perazin-1-yll-2-f1- 2H-pyrazol-3-ylamino)-isoquinolin-5-Lrloxy]-propan-1-one O
/ ( CH3 ~N
H
N / O N /
W
N
2o A mixture of the compound of Example 63 (45mg, 0.1 mmol), tetrabutyl ammonium fluoride (27mg, 0.2mmol), triethylamine (0.14mL, 1 mmol) and 3-aminopyrazole (83mg, 1 mmol) in dimethylsulfoxide (1 mL) was heated at 100°C for 24 hours. The reaction mixture was then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/formic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title compound in 39%
yield, l9mg.
LRMS (APCI+): m/z [M+H]+ 485 Example 86 ~2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1- rLl)]-2-(3,6-dimethyl-1 H-indazol-yloxy)-pro~an-1-one / ~ CH3 ~N I \
\ N /
HN ~O
N- O CHs 4M hydrochloric acid in dioxane (1 mL) was added to the compound of Preparation 77 (45mg, 86pmol) in methanol and the solution was stirred for 2 hours. The reaction mixture was evaporated under reduced pressure and the residue was dissolved in dichloromethane and basified with 1 M sodium 1o hydroxide solution to pHl2. The mixture was then passed through a phase separation column and the filtrate was concentrated in vacuo. Purification by column chromatography on silica gel, eluting with dichloromethane:methano1:0.88 ammonia, 96:4:1, afforded the title compound as a pale pin4c foam in 59~/~ yield, 20mg.
~ 5 LRMS (APCI+): m/z [M+H]+ 421 Example 87 l2Sl-1-f(2Rl-2-Methvl-4-lavridine-2-carbonyl)-aiaerazin-1-vll-2-(auinolin-5-~iloxy~propan-1-one O
/ I CH3 ~N \
N/ O N I /
\ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), picolinic acid (49mg, 0.6mmol) O-(1H-benzotriazol-1-yl)-N,N,N',hP-tetramethyluronium hexafluorophosphate (190mg, 0.75mmol) and triethylamine (0.93mL, l0mmol) in dichloromethane (3mL) was stirred for 18 hours at room temperature. The reaction mixture was then diluted with further dichloromethane and washed with sodium hydroxide (lOmL) and water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography-on silica gel, eluting with dichloromethane:methanol, 99:1 to 95:5, afforded the title compound as a white solid in 49% yield, 99mg.
LRMS (APCI+): m/z [M+H]+ 405 Example 88 (2S)-1-f4- 2-Fluoro-benzoyl)~2R)-2-methyl-loiperazin-1-girl]-2~(guinolin-5-ylo~)-propan-1-one / ~ CHs N / ~ w0 \ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), 2-fluorobenzoyl chloride and triethylamine in dichloromethane (3mL) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, afforded the title compound as a white solid in 73% yield, 153mg.
LRMS (APCI+): m/z [M+H]+ 422 2o Example 89 4-f (1 S)-2-f (2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy?-3-methoxy-N-methyl-benzamide O O
Me~H / Me ~N \
\~ N ~/
~O
OMe O Me To a solution of (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med.
Chem. (2000), 43(23), 4499) (22 g, 0.11 mol) and (2S)-2-(2-methoxy-4-methylcarbamoyl-phenoxy)-propionic acid (25 g, 0.1 mol) (Preparation 5) in dry THF (250 ml) were added 1-N hydroxybenzatriazole monohydrate (20 g, 0.13 mol), 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) and diisopropylethylamine (17 ml, 0.1 mol). After stirring for 1 hour a further portion of 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) was added followed by additional diisopropylethylamine (17 ml, 0.1 mol).
After another hour a further portion of 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide.HCl (17 g, 0.09 mol) was added followed by another portion of diisopropylethylamine (17 ml, 0.1 mol). The mixture was then stirred for a further 16 hours. After this time LCMS analysis 1o indicated that all of the propionic acid had been consumed. The reaction mixture was evaporated to give a viscous oil which was treated with water (200 ml) followed by the slow addition of concentrated aqueous hydrochloric acid until the mixture was pH 3. The resulting off-white precipitate was filtered off and washed with water (3 x 100 ml). The solid was twice re-crystallised from ethanol:water (1:1 by volume, 120 ml) to afford the title compound as a white solid (32 g).
'H NMR (400MHz, CDC13): 8 : 7.50-7.30 (6H, m), 7.27 (1 H, m), 6.9 (1 H, m) 6.08 (1 H, br s), 5.1 (11 H, br m), 4.90-2.80 (7H, m), 3.90 (3H, br s), 3.00 (3H, br s), 2.40 (3H, s), 1.70 (3H, br d), 1.40-0.9 (3H, m) ppm.
2o LRMS (ESI+) : m/z [M+H]+ 440 [a]p -26.9° (1 mg/ml in MeOH, 25°C, wavelength 589nM) Example 90 5-((1 S~[(2R)-4-Benzoyl-2-meth~piperazin-1-~]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester ~ O
Me~O N
Me ~N ~ \
\ O N
OMe O Me Di-tert-butyl azodicarboxylate (0.14 g, 0.6 mmol) and polymer supported 3o triphenylphosphine (0.25 g, 0.75 mmol) were added to a stirred solution of (2R)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)-2-hydroxy-propan-1-one (Preparation 76) (0.083 g, 0.3 mmol) and 5-hydroxy-4-methoxy-pyridine-2-carboxylic acid methyl ester (0.083 g, 0.45 mmol) (Tetrahedron Letters, 38, 1297 (1997)) in dichloromethane (3 ml) at 0°C. After one hour the reaction mixture was allowed to warm to room temperature and additional di-tert-butyl azodicarboXylate (0.14 g, 0.6 mmol) and polymer supported triphenylphosphine (0.25 g, 0.75 mmol) were added. After 18 hours at room 5 temperature the reaction mixture was filtered through Arbocel~, washing through with dichloromethane (10 mL). The filtrate was washed with saturated aqueous sodium hydrogencarbonate solution (20 ml), then the organic phase separated, dried (MgS04) and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel, 1o eluting with ethyl acetate:pentane, 80:20, then ethyl acetate and finally ethyl acetate:methanol, 95:5, to afford the title compound as a white solid, 0.1 g.
LRMS (APCI+): m/z [M+H]+ 442 Example 91 15 5-{~1S -2-('(2R -4-BenzoVl-2-methyl-piperazin-1-yll-1-methyl-2-oxo-ethoxY}-methoxy-pyridine-2-carboxylic acid methylamide O
Me Me ~N ~ \
O N
O Me 2o A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.2 g, 0.45 mmol) in a 33% w/w solution of methylamine in ethanol (3 ml) was heated in a Reacti-vialT"" at 50°C for 18 hours. After cooling to room temperature solvent was evaporated under reduced pressure. The residue 25 was purified by column chromatography on silica gel, eluting with dichloromethane:methanoI:NH3, 98:2:0.5 to 95:5:0.5, to afford the title compound as a white solid, 0.18 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.75 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 3.95 (3H, br s), 2.90 (3H, s), 1.60-1.00 (6H, so m) ppm.
Found C, 61.65; H, 6.47; N, 12.41. C23H2gN~O5. 0.1 mol CH2CI2 requires C, 61.80; H, 6.33; N, 12.48%
LRMS (APCI+): m/z [M+H]+ 441 [a]o -15.5° (1 mg/ml in MeOH, 25°C, wavelength 589nM) Example 92 , 5-f ( 1 S)-2-j(2R)-4-Benzo~rl-2-methyl-~iperazi n-1-yl]-1-methyl-2-oxo-ethoxy)-methoxy-pyridine-2-carbox relic acid amide H2N N ~ Me ~N ~ \
\ O N
OMe O Me A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy)-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.2 g, 0.45 mmol) in concentrated aqueous ammonia solution (2 ml) and methanol (1 ml) was heated in a Reacti-vialT"' at 50°C for 18 hours.
After pooling to room temperature solvent was evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanoI:NH3, 98:2:0.5 to 95:5:0.5, to afford the title compound as a white solid, 0.16 g.
'H NMR (400MHz, CD3OD): 8 : 8.05 (1 H, s), 7.75 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (9H, m), 3.95 (3H, br s), 1.60-1.00 (6H, m) ppm.
Found C, 59.67; H, 6.11; N, 12.49. C22H26N4O5. 0.25 mol CH2C12 requires C, 59.78; H, 5.97; N, 12.54%
LRMS (APCI+): m/z [M+H]+ 427 Example 93 5-(~1S)-2-[(2R -4-Benzo~l-2-methyl-loiperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid ethylamide O O
Me~H N ( Me ~N \
\ O N U
I
OMe O Me A solution of 5-f (1 S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2--oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.15 g, 0.34 mmol) in ethylamine (1 ml) was heated in a Reacti-vialT"" at 50°C for 18 hours. After cooling to room temperature solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol 96:4, to afford the title compound as a white solid, 0.14 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.80 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 4.00 (3H, br s), 3.45 (2H, q), 1.60-1.00 (6H, 1o m), 1.20 (3H, t) ppm.
Found C, 60.89; H, 6.72; N, 11.93. C24H3aN4O5. 0.25 mol CH2C12 requires C, 61.22; H, 6.46; N, 11.78%
LRMS (APCI+): m/z [M+H]+ 455 Example 94 5-~(1 S)-2-f (2R)-4-Benzoyl-2-methyl-piperazin-1-~1-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cycloprop 1y amide O
Me ~N \
N ~/
OMe O Me A solution of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methyl ester (Example 90) (0.12 g, 0.27 mmol) in cyclopropylamine (1 ml) was heated in a Reacti-vialT"' at 50°C for 18 hours. After cooling to room temperature solvent was 2s evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol 95:5, to afford the title compound as a white solid, 0.09 g.
'H NMR (400MHz, CD30D): b : 8.05 (1 H, s), 7.70 (1 H, s), 7.50-7.40 (5H, m), 5.40 (1 H, m), 4.60-3.00 (8H, m), 3.95 (3H, br s), 2.85 (1 H, m), 1.60-1.00 (6H, 3o m), 0.8 (2H, m), 0.6 (2H, m) ppm.
Found C, 63.02; H, 6.63; N, 11.83. C25H3pN4O5. 0.13 mol CH2C12 requires C, 63.20; H, 6.39; N, 11.73%
LRMS (APCI+): m/z [M+H]+ 467 Preparation 1 ~2S)-2- Quinolin-5-ylo~)-propionic acid methyl ester Me O OMe Triphenylphosphine (2.17 g, 8.27 mmol) was added to a stirred suspension of di-isopropyl azodicarboxylate (1.47 ml, 7.56 mmol) in THF (25 ml) at -5°C.
5-Hydroxyquinoline (1.0 g, 6.90 mmol) and methyl (R)-lactate (0.66 ml, 6.90 1o mmol) were then added and the solution allowed to stir at room temperature for 14 hours. The reaction mixture was diluted with ethyl acetate (50 ml), washed with water (30 ml), saturated potassium carbonate solution (30 ml) and brine (30 ml). The solution was dried (MgS04) and solvent evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel eluting with a gradient system of pentane : ethyl acetate (4:1 ) changing to pentane : ethyl acetate (3:2). The title compound was obtained as a white solid (1.30 g).
LRMS (APCI+) : mlz [M+H]+ 232.
2o Preparation 2 (2S)-~Quinolin-5-yloxy)-propionic acid sodium salt Me ~ O Na+
\ O
A solution of (S)-2-(quinolin-5-yloxy)-propionic acid methyl ester (Preparation 1 ) (1.30 g, 5.60 mmol) and 1 N sodium hydroxide solution (5.62 ml) in dioxane (40 ml) was heated at 60 °C for two hours. After this time tlc analysis indicated that starting material remained so additional 1 N sodium hydroxide solution (1.4 ml) was added and heating at 60 °C continued for one hour.
so The reaction mixture was then concentrated under reduced pressure to afford the title compound as a yellow solid which was used without further purification.
LRMS (ESI+) : m/z [M+H]+ 218.
PrJoaratiori 3 1-[(2R -4-Benzoyl-2-methyl-~i~erazin-1-yl]-2-bromo-propan-1-one O
Me ~N ~ \
N
Br O Me To a solution of (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med.
1o Chem. (2000), 43(23), 4499) (4.06 g, 19.6 mmol) in dichloromethane (60 ml) and N,N dimethylformamide (2 ml) were added 2-bromopropionic acid (3.0 g, 19.6 mmol), O-(1 H-benzotriazol-1-yl)-N,N,I~P,N'-tetramethyiuronium hexafluorophosphate (8.18 g, 21.6 mmol) and triethylamine (2.74 ml, 19.6 mmol). The reaction mixture was stirred at room temperature for 48 hours and then washed with water (50 ml), 10 % w/v aqueous citric acid solution (50 ml) and saturated aqueous sodium hydrogencarbonate solution (50 ml). The solution was dried (MgS~4) and solvent evaporated under reduced pressure.
The' crude product was purified by column chromatography on silica gel eluting with a gradient system of dichloromethane: methanol (99:1 ) changing 2o to dichloromethane : methanol (95:5). The product was then purified further by column chromatography on silica gel eluting with a gradient system of ethyl acetate: dichloromethane (30:70) changing to ethyl acetate: dichloromethane (45:55) to afford the title compound as a white solid (3.80 g).
LRMS (ESI+) : m/z [M+H]+ 340.
Preparation 4 4-Hydroxy-3-methoxy-N-methyl-benzamide OH
Me To a mechanically stirred suspension of vanillic acid (84 g, 0.5 mol) in dry-THF (300 ml) was added portion-wise carbonyldiimidazole (97 g, 0.6 mol).
Gaseous evolution was observed and the mixture became homogeneous after approx 5 minutes. After further stirring for 30 minutes an off-white 5 precipitate form and stirring was maintained for a further 3 hours under nitrogen. After this time LCMS analysis indicated that the vanillic acid had been consumed and a solution of 2 M methylamine in THF (1000 ml, 2 mol) was added in one portion and the mixture stirred for a further 16 hours to generate a tan precipitate. The precipitate was filtered, washed with THF
o (2 x 250m1) followed by ether (300 ml) and dried under vacuum to afford the N-methylammonium salt of the title compound (87g, 82%).
LRMS (ESI+): m/z [M+H]+ 182.
A portion of the ammonium salt {1.06g, 5 mmol) was refluxed in ethyl acetate under a stream of nitrogen for 2 hours. The reaction was evaporated to give ~5 an oily solid, which was triturated with ethyl acetate to afford the title compound as a tan solid (750 mg) LRMS (ESI+): m/z [M+H]+ 182.
Preparation 5 20 (2S)-~2-Methox~4-methylcarbamoyl-phenoxy)-propionic acid OH
Mew To a stirred mixture of triphenylphosphine (42 g, 0.16 mol), 4-hydroxy-3-25 methoxy-N-methyl-benzamide (Preparation 4) (20 g, 0.11 mol) and methyl (R)-lactate (12 g, 0.12 mol) in dry THF (300 ml) at -5 °C was added dropwise a solution of di-isopropyl azodicarboxylate (32 ml, 0.16 mmol) in dry THF
(100 ml) over 30 minutes. The solution was allowed to warm to room temperature and stirred for 2 hours. After this time tlc analysis indicated that 3o the starting phenol had been consumed. The crude reaction mixture was evaporated under reduced pressure to give a viscous oil. To a stirred solution of this oil in methanol (150 ml) was added lithium hydroxide monohydrate (5.4 g, 0.13 mol) and the mixture stirred for 48 hours. After this time LCMS
analysis indicated that the intermediate methyl ester had been consumed.
The crude reaction mixture was evaporated and partitioned between ether-(500 ml) and water (150 ml). The aqueous phase was separated and washed with ether (2 x 300 ml) and ethyl acetate (2 x 300m1). The aqueous phase was then acidified to pH 2 using concentrated aqueous hydrochloric acid resulting in the formation of a white precipitate. This precipitate was filtered off, washed with water (2 x 100m1) and recrystallised from ethanol water (1:1 by volume, 80 ml per 20 g) to afford the title compound as a white solid (21 g, 75%).
LRMS (ESI+): m/z [M+H]+ 254.
Preparation 6 , 3-Methoxy-4-[(1 S)-1-methoxycarbon I-e~y]-benzoic acid methyl ester H3C~0 CHs O
O ~CH3 ~O O
~iisopropyl azodicarboxylate (4mL, 20mmol) in tetrahydrofuran (l5mL) was added dropwise to an ice-cooled solution of methyl vanillate (3.64g, 20mmol), methyl (R)-lactate (2.08g, 20mmol) and triphenyl phosphine (5.24g, 20mmol) in tetrahydrofuran (30mL) and the reaction mixture was stirred at room temperature for 18 hours. The solvent was then evaporated under reduced pressure and the residue was stirred in a mixture of diethyl ether (50mL) and 2o hexane (50mL). The resulting precipitate was filtered off and the filtrate was concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with hexane:ethyl acetate, 85:15 to 75:25 afforded the title compound in 71 % yield, 3.8g LRMS (ES+): m/z [M+H]+ 269 Preparation 7 4-[s1 S)-1-Carboxy-ethoxy]-3-methoxy-benzoic acid methyl ester H3Cw0 CHs OH
O
,O O
Lithium hydroxide monohydrate (4.2g, 100mmol) was added portionwise to a solution of the compound of Preparation 6 (32g, 120mmol) in methanol (150mL) and the mixture was stirred at room temperature for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed with diethyl ether. The aqueous mixture was acidified with 2M hydrochloric acid to pH4 and was then 1o extracted with ethyl acetate (3x150mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The resulting foam was dried under reduced pressure to afford the title compound in 91 % yield, 23g.
LRMS (ES+): m/z [M+H]+ 255 Preparation 8 4-~~(1 S~-2-[(2R~4-Benzo~rl-2-methyl-piperazin-1-yll-1-methyl-2-oxo-ethoxy~-3-methoxy-benzoic acid methyl ester O
H~C~O CH3 ~N
N /
O
2o Hianig's base (1.BmL, 10.5mmol) was added to a solution of the compound of Preparation 7 (1.8g, 7mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(1.6g, 7.7mmol), J. Med. Chem. 43(23), 4499; 2000], and 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (2.75g, 9.1 mmol) in dichloromethane (l6mL). The mixture was stirred for 4 hours and was then evaporated under reduced pressure. The residue was taken up in ethyl acetate (200mL) and washed with 10% sodium carbonate solution (2x50mL) and brine (2x50mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with hexane:ethyl acetate, 25:75 to 5:95 afforded the title compound in 95% yield, 2.95g.
LRMS (ES+): mlz [M+H]+ 441 Pr~aration 9 4~(1 S)-2-f(2R)-4-Benzoyl-2-methylpiperazin-1 yl1-1-methyl-2-oxo-ethoxy)-3-methoxy-benzamide N
O
O
The compound of Preparation 8 (0.46g, 1.04mmol) and 2M ammonia in methanol (lOmL) were heated in a sealed vessel at 120°C for 18 hours.
The reaction mixture was then concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2 to 92:8, to afford the title compound as a colourless foam in 55% yield, 243mg.
LRMS (ES+): m/z [M+H]+ 426 Preparation 10 4-f (1 S)-2-f (2R)-4-Benzoyl-2-meth r~l-piperazin-1-yll-1-methyl-2-oxo-ethox~r)-N-dimethylaminomethylene-3-methoxy-benzamide H3C\N~CH3 ~N CH
N
O
The compound of Preparation 9 (240mg, 0.56mmol) and N,N-dimethylformamide dimethylacetal (lOmL) were heated under reflux for 7 hours. The reaction mixture was then evaporated under reduced pressure to-give a pale orange solid. The solid was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 97:3, to provide a colourless oil. The oil was then azeotroped with dichloromethane and the resulting foam was dried at 40°C for 3 hours to afford the title compound in 94 yield, 255mg.
LRMS (ES+): m/z [M+Na]+ 503 Preparations 11 to 13 The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 10 using the appropriate ketone and dimethylformamide dimethylacetal.
Rb O
\ ~CH3 Ra N~CH3 No. Ra Rb LRMS ES+ : m/z M+H +
13 H OCH2-Ph 312 Preparation 11 uses 1-(3-methoxy-2-methyl-phenyl)-ethanone, prepared as described in Tetrahedron 25(18), 4249; 1969.
Preparatiori 14 3-(3-Methox~-2-meth rLl-phenyl)-1-methyl-1 H-pyrazole \ OwCHs ~CH3 N
The compound of Preparation 11 (2.05g, 9.35mmol) was added portionwise to a solution of methylhydrazine (547pL, 10.28mmol) in acetic acid (15mL) 1o and the mixture was heated at 90°C for 2.5 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in dichloromethane and washed with 10% sodium carbonate solution and saturated sodium hydrogen carbonate solution. The organic phase was dried over magnesium sulfate and concentrated in vacuo to give an orange oil. The 15 oil was purified firstly by column chromatography on silica gel, eluting with dichloromethane:ethyl acetate, 99:1 to 97:3. This was followed by further purification using an Isolute~ Flash silica column, eluting with dichloromethane:ethyl acetate, 99:1 to 97:3, to afford the title compound as a yellow oil in 31 % yield, 568mg.
2o LRMS (ES+): m/z [M+H]+ 203 Preparations 15 to 16 The following compounds, of the general formula shown below, were 25 prepared by the method described above for Preparation 14 using the appropriate enamine and hydrazine monohydrate.
Rb O
\ ~CH3 / Ra H \
N
No. Ra Rb LRMS ES+ : m/z M+H +
16 H OCH2Ph 281 s Preparation 17 2-Meth~(1-methyl-1 H ~yrazol-3-~~phenol \ OH
~CH3 N ~~
N
Boron tribromide (1 M in dichloromethane, 8.16mL, 8.16mmol) was added 1o dropwise to an ice-cooled solution of the compound of Preparation 14 (550mg, 2.72mmol) in dichloromethane (6mL). The resulting solution was allowed to warm to room temperature and was stirred for 2 hours. The reaction mixture was then poured carefully onto ice and was neutralized with 10% sodium carbonate solution. The mixture was extracted with 1s dichloromethane (2x50mL) and the combined organic phases were dried over magnesium sulfate and concentrated in vacuo. The residue was chromatographed using an Isolute~ Flash silica column, eluting with dichloromethane:methanol, 98:2 to 97:3, to give a brown oil. The oil was azeotroped with dichloromethane to afford the title compound as brown foam in 61 % yield, 31 Omg.
LRMS (ESf): m/z [M+H]+ 189 Preparations 18 to 20 The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 17 using the appropriate methoxybenzene derivative and boron tribromide.
NO. Ra R LRMS ES+ : m/z M+H
18 CH3 ~ 152 HaN
19 CH3 ~N 175 N\
20 H ~N 161 N' Preparation 18: title compound is prepared by dealkylation of 3-methoxy-2-methylbenzamide (J.Chem.Soc.Perkin Trans.l, 2389-2396; 1984) Preparation 21 (2S)-2-[3-(2H-Pyrazol-3-yl~phenoxy]-propionic acid meth 1y ester CHI
O
O ~CH3 O
H\~
N
OH
/
wRa R°
Diisopropyl azodicarboxylate (295pL, 1.50mmol) was added dropwise to an ice-cooled solution of the compound of Preparation 20 (240mg, l.5mmol) methyl (R)-lactate (156mg, 1.50mmol) and triphenyl phosphine (393mg;
l.5mmol) in tetrahydrofuran (5mL). The reaction mixture was stirred at room temperature for 18 hours and was then diluted with diethyl ether (50mL) and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The oil was purified on an Isolute~ flash silica column, eluting with diethyl ether:dichloromethane, 80:20 to 95:5, to afford the title compound as a viscous yellow oil in 54%
yield, 200mg.
LRMS (ES-): m/z [M-H]- 245 Preaaration 22 ~2S~j2-Methy~2H-pyrazol-3-yl)-phenoxyl-propionic acid methyl ester O
O ~CH3 O
~CH3 H \
N
The title compound was prepared by the method described above for Preparation 21 using the compound of Preparation 19 and methyl (R)-lactate:
LRMS (ES-): m/z [M-H]- 259 Preparation 23 (2S)-2-[3-(2H-Pyrazol-3- r1 -phenoxy~-propionic acid OH
O
O
H ~
Lithium hydroxide monohydrate (80.9mg, 1.93mmol) was added portionwise to a solution of the compound of Preparation 21 (190mg, 0.77mmol) in methanol (6mL) and the mixture was stirred at 60°C for 8 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed with diethyl ether. The aqueous mixture was acidified with 2M hydrochloric acid to pH4 and was then extracted with ethyl acetate (3x30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The resulting foam was dried under reduced pressure to afford the title compound in 75% yield, 135mg.
LRMS (ES-): m/z [M-H]- 231 Preparation 24 !2S)-2-[2-Methyl-3- 2H-pyrazol-3-Lrl)-phenoxy]-propionic acid OH
O
O
H\
N
The title compound was prepared by the method described above for Preparation 22 using the compound of Preparation 22 and lithium hydroxide.
LRMS (ES-): m/z [M-H]- 245 Preparation 25 1-[!2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one CH3 ~N ~ \
N
Br 2-Bromopropionic acid (1.53g, l0mmol) was added to a solution of N,N'-dicyclohexylcarbodiimide (2.06g, l0mmol) in dichloromethane (40mL), cooled to -15°C. The reaction mixture was stirred for 20 minutes before (2R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(2.04g, l0mmol), J. Med. Chem.
43(23), 4499; 2000] in dichloromethane (l6mL) was added dropwise. The reaction mixture was stirred at -15°C for 90 minutes and was then diluted with diethyl ether (100mL) and stirred for a further 10 minutes. The mixture was then filtered through Celite, washing through with diethyl ether and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with hexane:ethyl acetate, 40:60 to 20:80 to afford the title compound in 76% yield, 2.5g.
LRMS (ES+): m/z [M+H]+ 340 Preparation 26 3-~2-[(2R)-4-Benzoyl-2-methylpiperazin-1-yll-1-methyl-2-oxo-ethoxy~-2-methyl-benzamide O
/ CHs ~N ~ \
HEN \ N /
~O
O ~ ~ CHs The compounds of Preparation 18 (180mg, 1.19mmol) and Preparation 25 (403.9mg, 1.19mmol) and cesium carbonate (387mg, 1.19mmol) in N,N-dimethylformamide (lOmL) were heated at 80°C for 18 hours. The cooled reaction mixture was then evaporated under reduced pressure and the residue was partitioned between dichloromethane (50mL) and water (lOmL).
The organic phase was separated, dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to give a colourless foam. The foam was azeotroped with dichloromethane and dried 2o under reduced pressure to afford the title compound in 98% yield, 475mg.
LRMS (ES+): m/z [M+H]+ 410 Preparation 27 1-[(2R~4-Benzoyl-2-meth-piperazin-1-~l-~3-methoxy-5-vitro-phenoxy)-propan-1-one Hs O
OzN / O CHs ~N
\I N U
O
O CHs The title compound was prepared by the method described above for -Preparation 26 using the compound of Preparation 25 and 2-methoxy-5-nitrophenol:
LRMS (APCI+): m/z [M+H]+ 428 Preparation 28 3-(2-f (2R)-4-Benzovl-2-methvlpiperazin-1-vll-1-methyl-2-oxoethoxvl-N
(dimethylamino~meth 1y ene]-2-methylbenzamide i Hs i H C N ~ ~ CH3 N \ N
~O
p The title compound was prepared by the method described above for Preparation 10 using the compound of Preparation 26 and N,N-dimethylformamide dimethylacetal.
LRMS (APCI+): m/z [M+H]+ 465 Preparation 29 3-~2-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-1-methyl-2-oxo-ethoxvl-N-hydroxyaminomethylene-2-meth~rl-benzamide H
HO~N~ ~ ~ GH3 IIN \ f O
O CH3 O ,, 2o Sodium hydroxide solution (1 M, 1.06mL, 1.06mmol) was added dropwise to a suspension of hydroxylamine hydrochloride (73.6mg, 1.06mmol) in acetic acid (6mL). The compound of Preparation 28 (410mg, 0.88mmol) was then added portionwise and the resulting solution was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and the oily residue was partitioned between dichloromethane (30mL) and water (6mL), and neutralized with 10% sodium carbonate solution. The organic phase was separated and the aqueous phase was re-extracted with dichloromethane (30mL). The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to afford the title compound as a colourless foam in 78% yield, 310mg.
LRMS (ES-): m/z [M-H]- 451 Preparation 30 ~4-Amino-2-methoxy-phenoxy)-1-[(2R -4-benzoyl-2-methyl-piperazin-1=yll-propan-1-one Hs O
HaN / O CHs ~ N ~ \
\I N
25% Pd/C (150mg) and ammonium formate (443mg, 7mmol) were added to a solution of the compound of Preparation 27 (600mg, l.4mmol) in ethanol (30mL) and the mixture was heated at 70°C for 2 hours. The reaction mixture was then cooled and filtered through Arbocel~, washing through with ethanol (lOmL). The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a pale pink solid in 80% yield, 443mg.
LRMS (APCI+): m/z [M+H]+ 398 Preparation 31 4-Benzylox~r-3-methoxy-benzamidine H
"Butyl lithium (1.6M in hexane, 35.9mL, 57.47mmol) was added dropwise to a solution of hexamethyldisilazane (11.64mL, 55.17mmol) in diethyl ether (60mL), cooled to -5°C, and the reaction mixture was stirred for 30 minutes at a constant temperature of 0°C. 3-Methoxy-4-(phenylmethoxy)-benzonitrile (5.5g, 22.99mmol) was added portionwise and the mixture was stirred at room temperature 4 hours. The reaction mixture was then poured onto ice cold 2M hydrochloric acid (100mL) and was washed with diethyl ether (2x 100mL). The aqueous phase was basified to pHlO with 6M sodium hydroxide solution and was extracted with dichloromethane (3x100mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a white solid in 68% yield, 3.99g.
1o LRMS (ES+): m/z [M+H]+ 257 Preparation 32 2-(4-Benzyloxy-3-methoxy-~ohenyl)-1 H-imidazole H
N
The compound of Preparation 31 (1 g, 3.90mmol) in chloroform (40mL) was added to a solution of chloroacetaldehyde (336mg, 3.90mmol) in chloroform (lOmL) and the mixture was stirred at room temperature for 18 hours. The resulting white precipitate was filtered off and the filtrate was washed with 2o saturated sodium hydrogen carbonate solution (30mL). The aqueous phase was re-extracted with 10% methanol in dichloromethane (2 x 50mL) and the combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 98:2 to 96:4, to give a brown foam. The foam was purified further on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99.5:0.5 to 98:2, to give a beige foam.
The foam was then azeotroped with dichloromethane and dried at 40°C to afford the title compound in 16% yield, 180mg.
LRMS (ES+): m/z [M+H]+ 281 Preparation 33 4J1 H-Imidazol-2-ail)-2-methoXy-phenol OH
N ~ /
-O
~N CH3 To a solution of the compound of Preparation 32 (170mg, 0.61 mmol) in methanol (lOmL) was added portionwise 10% Pd/C (85mg) and ammonium formate (191 mg, 3.03mmol). The mixture was heated under reflux for 2 hours. The reaction mixture was then cooled and filtered through Arbocel~, washing through with a mixture of dichloromethane and methanol (50:50, 250mL). The filtrate was concentrated in vacuo and the residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to afford the title compound as a white solid in 91 % yield, 105mg.
LRMS (ES+): mlz [M+H]+ 191 Preparation 34 2-Methoxy-4-(2H-pyrazol-3-yl~phenol OH
N ~ /
Ni ~ ~ _O
The title compound was prepared by the method described above fior Preparation 33 using the compound of Preparation 16.
LRMS (ES+): m/z [M+H]+ 191 Preparation 35 1-Benzyloxy-4-bromo-2-methoxy-benzene Br \ / O
O
A mixture of 4-bromo-2-methoxyphenol (5g, 24.63mmol), benzyl bromide-(4.21 g, 24.63mmol) and cesium carbonate (8g, 24.63mmol) in acetone (60mL) were heated under reflux for 4 hours. The cooled reaction mixture was then evaporated under reduced pressure and the residue was partitioned 5 between diethyl ether (200mL) and water (80mL). The aqueous phase was separated and re-extracted with diethyl ether (200mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was azeotroped with dichloromethane to afford the title compound as white solid in 100% yield, 7.198.
1 o LRMS (ES+): m/z [M+Na]+ 317 Preparation 36 1-(4-Benzyloxy-3-methoxy-phenyl)-1 H-pyrazole N
~ \
N ~ ~ O
O
15 HsC
A mixture of the compound of Preparation 35 (1.5g, 5.12mmol), pyrazole (697mg, 10.23mmol), copper (I) iodide (195mg, 1.02mmol) and potassium carbonate in N,N-dimethylformamide (lOmL) was heated at 140°C for 18 hours. The cooled reaction mixture was then evaporated under reduced 2o pressure and the residue was partitioned between dichloromethane (50mL) and water (30mL). The aqueous phase was separated and re-extracted with diethyl ether (200mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 25 100:0 to 96:4, to afford the title compound as a white solid in 82% yield, 1.18g.
LRMS (ES+): m/z [M+H]+ 281 Preparation 37 2-Methoxy-4-~yrazol-1-yl-phenol N
N ~ ~ OH
O
The title compound was prepared by the method described above for Preparation 33 using the compound of Preparation 36.
LRMS (ES+): m/z [M+H]+ 191 Preparation 38 (2S)-~Quinolin-5-,~y~-propionic acid metal ester O
N ~ ~ ~O ~CH3 \ O
Triphenylphosphine (2.17g, 8.27mmol) was added to a stirred suspension of diisopropyl azodicarboxylate (1.47mL, 7.56mmol) in tetrahydrofuran (25mL) at -5°C. 5-Hydroxyquinoline (1.0g, 6.90mmol) and methyl-(R)-lactate (0.66mL, 6.90mmol) were added and the solution was allowed to stir at room temperature for 14 hours. The reaction mixture was then diluted with ethyl acetate (50mL), washed with water (30mL), saturated potassium carbonate 2o solution (30mL) and brine (30mL). The solution was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 80:20 to 60:40, to afford the title compound as a white solid in 81 % yield, 1.30g.
LRMS (ES+): m/z [M+H]+ 232 Preparation 39 (2S)-2-(Iso~uinolin-5-yloxy)-propionic acid meth~rl ester / I O OwCHs N\ O
The title compound was prepared by the method described above for Preparation 38 using 5-hydroxyisoquinoline and methyl-(R)-lactate.
LRMS (APCI+): m/z [M+H]+ 232 Preparation 40 ~2S)-2-(Quinolin-5-yloxy~-propionic acid sodium salt O Na+
N / I w0 O
A solution of the compound of Preparation 38 (1.308, 5.60mmol) and 1 M
sodium hydroxide solution (5.62mL) in 1,4-dioxane (40mL) was heated at 60°C for two hours. After this time tlc analysis indicated that starting material remained so additional 1 M sodium hydroxide solution (1.4m1) was added and heating continued at 60°C for one hour. The reaction mixture was then concentrated in vacuo to yield the title compound as a yellow solid in 2o quantitative yield.
LRMS (ES+): m/z [M+H]+ 218 Preparation 41 2S -2-~Isoguinolin-5-vloxv)-propionic acid sodium salt / O Na+
N \ I _O
The title compound was prepared by the method described above for Preparation 40 using the compound of Preparation 39.
LRMS (APCI+): m/z [M+H]+ 218 Preparation 42 (2S)-1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-Lrl]-~quinolin-5-yloxy)-propan-1-one / I CH3 ~N I \
N/ I O N /
\ O CH3 1o A solution of the compound of Preparation 40 (1.0 g, 4.6mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(0.94 g, 4.6mmol) J. Med. Chem., 43(23), 4499; 2000], ~(1H-benzotriazol-1-yl)-N, N,N',N-tetramethyluronium hexafluorophosphate (2.62g, 6.9mmol) and triethylamine (1.93m1, 13.8mmol) in N,N dimethylformamide (30m1) was stirred at room temperature for 14 hours. The reaction mixture was then diluted with dichloromethane (100m1), washed with water (3x50m1), dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol, 98:2, to afford the title compound as a white solid in 49% yield, 0.91 g.
2o LRMS (ES+): m/z [M+H]+ 404 Preparation 43 (2S)-1-f(2R)-4-Benzoyl-2-methyl-piperazin-1-yl -~2-(isoguinolin-5-ylo~)-propan-1-one / ~ CH3 ~N ~ \
O N /
N \ O CH3 The title compound was prepared by the method described above for Preparation 42 using the compound of Preparation 41 and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med. Chem., 43(23), 4499; 2000.
LRMS (APCI+): m/z [M+H]+ 404 Preparation 44 (2S)-1-[~(2R~4-Benz~l-2-methyl-piperazin-1-yl]-2-(8-bromo-quinolin-5-yloxy)-~ropan-1-one Br / ~ CHI
N / ~ w0 J
A mixture of the compound of Preparation 42 (450mg, 1.1 mmol) and N-bromosuccinimide (795mg, 4.4mmol) in acetonitrile (90mL) was stirred at room temperature for 2 hours. The solvent was then evaporated under 1o reduced pressure and the residue was dissolved in ethyl acetate (50mL) and washed with water (2x20mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate:pentane, 33:67 to 100:0 to afford the title compound as a white solid in 98% yield, 526mg.
LFtMS (ES+): m/z [M+H]+ 482/484 Preparation 45 (2S)-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vl1-2-~[2-(2-trimethylsilan etho~methy~-2H-~yrazol-3-yl]-quinolin-5-yloxy}-propan-1-one ~ i\ CHs N~N~O CH3 O
/ /
CH3 ~N ~ \
N/ O N /
Tetrakis(triphenylphosphine)palladium(0) (6mg, cat), 1-[[(2-(trimethylsilyl)ethoxy]methyl]pyrazolyl-5-boronic acid [(50mg, 0.1 mmol), J.
Med. Chem. 41 2019-2028; 1998] and sodium carbonate (175mg, l.6mmol) in water (0.5mL) were added to the compound of Preparation 44 (50mg, 0.1 mmol) in tetrahydrofuran (2mL) and the mixture was heated under reflux for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in dichloromethane and washed with water (5m~) and brine (2x5mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give an orange oil. The oil 5 was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 96:4 to afford the title compound as a yellow solid.
LRMS (APCI+): m/z [M+H]+ 600 1 o Preparation 46 ~2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-oxy-quinolin-5- I~oxy)-prop~an-1-one O~N+i O
\ ~ O
meta-Chloroperbenzoic acid (1.54g, 4.44mmol) was added to an ice-cooled solution of the compound of Preparation 42 (1.5g, 3.7mmol) in dichloromethane (l5mL) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was then diluted with dichloromethane (lOmL) 2o and washed with saturated aqueous potassium carbonate solution (lOmL) and water (2x 10m1). The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a white solid in quantitative yield, 1.~g.
LRMS (APCI+): m/z [M+H]+ 420 Pre~~aration 47 5-f2-f 2R -4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy~-quinoline-2-carboxylic acid meth, 1y ester O
CH3 ~N ~ \
N
N ~ ~ ~O
O \ O CH3 O
H3C~
The chloro compound of Preparation 66 (130mg, 0.3mmol), dichloro-bis(triphenylphosphine)palladium (24mg, 0.03mmol) and triethylamine (83pL, 0.6mmol) were dissolved in a mixture of methanol (3mL) and N,N-dimethylformamide (0.5mL), and transferred to a sealed vessel. The vessel 1o was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in vacu~. Purification of the residue by column chromatography on silica gel, eluting with ethyl acetate:pentane, 75:25 to 100:0, afforded the title compound in 41 % yield, 50mg.
LRMS (APCI+): m/z [M+H]+ 462 Preparation 48 5-~2-f f 2 R)-4-Benzoyl-2-methyl-piperazin-1-y~-1-methyl-2-oxo-ethox~r}-2o quinoline-2-carboxylic acid OH
N
1 M Sodium hydroxide solution (130pL, 0.135mmol) was added to a solution of the compound of Preparation 47 (40mg, 0.09mmol) in dioxane (3mL) and the mixture was heated at 60°C for 3 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in water (20mL) and washed with ethyl acetate. The phases were separated and the organic phase was discarded. The aqueous phase was acidified with glacial acetic acid and re-extracted with ethyl acetate. The retained organic phase (2"d washing) was dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a pale yellow solid in 67% yield, 26mg.
LRMS (APCI+): m/z [M+H]+ 448 Preparation 49 (2Sl-1-f(2Rl-4-Benzovl-2-methyl-aiperazin-1-vl1-2-(2-benzvlamino-auinolin-5-1 o ylox~r -propan-1-one O
CH3 ~N ~ \
N
\ O
N /
NH
/
A mixture of the compound of Example 60 (50mg, 0.11 mmol), tetrabutyl ammonium fluoride (30mg, 0.22mmol), triethylamine (0.16mL, 1.1 mmol) and benzylamine (0.13mL, 1.1 mmol) in dimethylsulfoxide (1 mL) was heated at 120°C for 72 hours. The reaction mixture was then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title comloound in 34% yield.
LRMS (APCI+): m/z [M+H]+ 509 Preparation 50 (3R)-3-Methyl-4-[(2S~2-(quiriolin-5-ylox~i -propionyl]-piperazine-1-carboxylic acid tert-but, 1y ester O CHs / CH N~O CH3 N
N ~ ~ ~O
\ 0 CH3 1-Hydroxybenzotriazole hydrate (249mg, 1.87mmol) was added to a suspension of the compound of Preparation 40 (400mg, l.7mmol) in N,N-dimethylformamide to form a solution. 1-Ethyl-3-(3-dimethyl amino propyl) carbodiimide (351 mg, 1.87mmol) and triethylamine (0.7mL, 5.1 mmol) were 1o added and the solution was stirred for 5 minutes. (3S)-3-Methyl-piperazine-carboxylic acid tent butyl ester (335 mg, 1.7mmol) was added and the mixture was stirred for 18 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in ethyl acetate (30mL) and washed with water (20mL). The organic phase was dried over magnesium sulfate and ~5 concentrated in vacuo to afford the title compound in 48% yield, 332mg.
LRMS (APCI+): m/z [M+H]+ 400 Preparation 51 (2S)-1-[(2R)-2-Methyl-piperazin-1-yll-2-(quinolin-5-yloxy)-propan-1-one;
2o hydrochloride HCI
CH3 ~N.
N
N ~ ~ ~O
\ O CH3 The compound of Preparation 50 (300mg, 0.75mmol) was stirred in 4M
hydrochloric acid in dioxane (3mL) for 2 hours. The reaction mixture was concentrated in vacuo to afford the title compound as a pale yellow solid in 25 quantitative yield, 348 mg.
LRMS (APCI+): mlz [M+H]+ 300 Preparation 52 (2S)-1-[(2R)-4-Benzo~l-2-meth rLl-piperazin-1-yll-2-(2,8-dichloro-auinolin-5-ylox~~-propan-1-one t O
A mixture of the compound of Example 60 (200mg, 0.4mmol) and N-chlorosuccinimide (61 mg, 0.4mmol) in acetonitrile (1 OmL) was heated at 40°C
for 48 hours. The solvent was then evaporated under reduced pressure and o the residue was dissolved in dichloromethane (20mL) and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, to afford the title compound as a white solid in 78% yield, 169mg.
LRMS (APCI+): m/z [M+H]+ 472 Preparation 53 ~2S~ 1-[(2R)-2-MethLrl-4-_(pyridine-2-carbonyl)-piperazin-1-yll-2-(auinolin-5-ylox~r)-propan-1-one O
~ I CH3 ~N \
,0 1 \ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), picolinic acid (49mg, 0.6mmol) O-(1 H-benzotriazol-1-yl)-N,N,I~P,N-tetramethyluronium hexafluorophosphate (190mg, 0.75mmol) and triethylamine (0.93mL, l0mmol) in dichloromethane (3mL) was stirred for 18 hours at room temperature. The reaction mixture was then diluted with further dichloromethane and washed with sodium hydroxide (lOmL) and water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 95:5, afforded the title compound as a white solid in 49% yield, 99mg.
LRMS (APCI+): m/z [M+H]+ 405 5 Preparation 54 j2S)-1-[4-~(2-Fluoro-benzoyl)-(2R)-2-methyl-piperazin-1-yl]-2~quinolin-5-yloxy)-pro~an-1-one N / ~ w0 \ O CH3 1o A mixture of the compound of Preparation 51 (150mg, 0.5mmol), 2-fluorobenzoyl chloride and triethylamine in dichloromethane (3mL) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by 15 column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, afforded the title compound as a white solid in 73% yield, 153mg.
LRMS (APCI+): m/z [M+H]+ 422 Preparation 55 20 4-Bromo-2-trifluoromethoxy-phenol OH
O eF
F F
Br Bromine (449mg, 2.81 mmol) was added to a solution of 2-(trifluoromethoxy)phenol (500mg, 2.81 mmol) and sodium acetate (169mg, 25 2.81 mmol) in acetic acid (5mL) and the solution was stirred for 1 hour.
The reaction mixture was then diluted with water (30mL) and extracted with ethyl acetate (2x50mL). The organic extracts were combined, dried over magnesium sulfate and concentrated in vacuo to give a colourless oil. The oil was purified by column chromatography on silica gel, eluting with -pentane:ethyl acetate, 85:15, to afford the title compound as a white solid in 23% yield.
LRMS (APCI+): m/z [M+H]+ 255/257 Preparation 56 ~2S)-2- 4-Bromo-2-trifluoromethoxy-phenoxy~propionic acid methyl ester O
F
1o Diisopropyl azodicarboxylate (414pL, 2.14mmol) was added dropwise to an ice-cooled solution of the compound of Preparation 55 (500mg, 1.95mmol) methyl (R)-lactate (202mg, 1.95mmol) and triphenyl phosphine (614mg, 2.34mmol) in tetrahydrofuran (20mL). The reaction mixture was stirred at room temperature for 18 hours and was then evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed with 10%
potassium carbonate solution (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a colourless oil in 76% yield, 638mg.
2o LRMS (APCI+): m/z [M+H]+ 305/307 Preparation 57 S)-2-(4-Bromo-2-trifluoromethoxy-phenoxy)-propionic acid g O
A mixture of the compound of Preparation 56 (574mg, 1.67mmol) and 1 M
sodium hydroxide solution (4.2mL, 4.2mmol) in dioxane (lOmL) was stirred at 55°C for 3 hours, The solvent was then evaporated under reduced pressure and the residue was dissolved in water (30mL). The aqueous solution was acidified to pH2 with 2M hydrochloric acid and extracted with ethyl acetate (2x50mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a yellow solid in 80% yield.
LRMS (APCI+): mlz [M+H]+ 327 Preparation 58 (2S~-1-[S2R)-4-Benzoyl-2-methyl-piherazin-1-yl]-2-(4-bromo-2-trifluoromethoxy-phenoxy)-propan-1-one CH3 ~N
N /
F
A solution of the compound of Preparation 57 (150mg, 0.46mmol), (3Fi)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(93mg, 0.46mmol) J. Med. Ghem., 43(23), 4499; 2000], O-(1H-benzotriazol-1-yl)-N,N,N,hP-tetramethyluronium hexafluorophosphate (260mg, 0.69mmol) and triethylamine (0.13m1, 0.92mmol) in dichloromethane (30m1) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane (50m1) 2o and washed with water (50m1). The aqueous phase was re-extracted with dichforomethane (50mL) and the combined organic extracts were dried over magnesium sulfate and concentrated in vacu~. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanof, 99:1, to afford the title compound as a white foam in 90% yield, 213mg.
LRMS (APCI+): m/z [M+H]+ 5371539 Preparation 59 4-,;~1 S)-2-[(2R -4-Benzoyl-2-methyl-piperazin-1-girl]-1-methyl-2-oxo-ethoxy~-3-trifluoromethoxy-benzoic acid methyl ester O
H3Cw0 ~N ~ \
N /
The compound of Preparation 58 (190mg, 0.37mmol), dichloro-bis(triphenylphosphine)palladium (30mg, 0.04mmol) and triethylamine (0.10mL, 0.74mmol) were dissolved in methanol (lOmL) and transferred to a o sealed vessel. The vessel was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in ~acu~. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 97:3 to afford the title compound as an orange solid in 85% yield, 155mg.
LRMS (APCI+): m/z [M+H]+ 495 Preparations 60 to 61 2o The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 26 using the compound of Preparation 25 and the appropriate hydroxyquinoline or hydroxyisoquinoline.
O
CH3 ~N ~ \
R\ N /
O
No. R5 LRMS APCI+ : m/z M+H +
\ \
N
\ \
N / /
The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 46 using the s compounds of Preparations 60 and 61 and meta-chloroperbenzoic acid CH3 ~N ( \
R~ N /
O
No. R5 LRMS APCI+ : m/z M+H +
\ \
N+
(_ O
\ \
- iN / /
O
Preparatiori 64 (2S;I-1-f(2R-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-ox -~~uinolin-5- lyoxy)~
5 propan-1-one N
O
\ ~ J
- O~N / /
The title compound was prepared by the method described above for 1o Preparation 46 using the compound of Preparation 43.
LRMS (APCI+): m/z [M+H]+ 420 Preparation 65 ~2S)-1-[(2R)-4-Benzoyl-2-meth rL1-piperazin-1-yl]-~1-chloro-isoquinolin-5-15 yloxK -propan-1-one o CH3 ~N ~ \
N /
O
\ \ O CH3 N / /
CI
Phosphorus oxychloride (0.20mL, 2.18mmol) was added to a solution of the compound of Preparation 64 (305mg, 0.73mmol) in dichloromethane (l5mL) and the reaction mixture was heated at 100°C for two hours. The mixture was 2o then cooled to room temperature and poured onto water (75mL). The resulting aqueous mixture was basified with concentrated ammonia solution and extracted with dichloromethane (2x75mL). The combined organic extracts were then dried over magnesium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting -with dichloromethane:methanol, 99:1, afforded the title compound as a white foam in 40% yield, 127mg.
LRMS (APCI+): m/z [M+H]+ 438 Preparation 66 1-[f 2R)-4-Benz~l-2-methyl-piperazin-1-yl]-2-(2-chloro-quinolin-5-~y)-propan-1-one O
CH3 ~N
N
O
CI N
1o The title compound was prepared by the method described above for Preparation 65 using the compound of Preparation 62.
LRMS (APCI+): m/z [M+H]+ 438 Preparation 67 2-Methoxy-4-methylsulfanyl-phenol OH
tButyl lithium (1.7M in pentane, 14.5mL, 24.6mmol) was added dropwise to a solution of 4-bromo-2-methoxyphenol (2.00g, 9.85mmol) in tetrahydrofuran (25mL) cooled to -78°C. The mixture was stirred for 15 minutes and was then warmed to -40°C and stirred for a further 30 minutes. Dimethyl disulfide (1.06mL, 11.8mmol) was added and the mixture was stirred at room temperature for 18 hours. Water was then added to the reaction and the resulting mixture was acidified to pH1 with 2M hydrochloric acid. The aqueous phase was separated and re-extracted with ethyl acetate. The combined organic fractions were then dried over magnesium sulfate and concentrated in vacuo to give an orange oil. This oil was purified by column chromatography on silica gel, eluting with pentane:diethyl ether, 95:5 to 80:20, to afford the title compound as a white solid in 48% yield, 800mg.
'HNMR(CDC13, 400MHz) S: 2.40(s, 3H), 3.90(s, 3H), 5.50(brs, 1 H), 6.80-6.90(m, 3H) Prea~aration 68 6-Hydroxy-7-methox -y 3,4-dihydro-2H-isoquinolin-1-one OH
HN ~ ~ OMe O
A mixture of lithium iodide (0.32g, 2.41 mmol) and 6,7-dimethoxy-3,4-dihydro-2H-isoquinolin-1-one (0.5 g, 2.41mmol) in 2,4,6-collidine (10m1) was heated at 130°C for 18 hours. The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 96:4, to afford the title com~aound as a pale yellow solid, 0.19 g LRMS (APCI+): m/z [M+H]+ 194 Preparation 69 2o Acetic acid 3-acetoxv-5-methyl-ahenvl ester O~CH
H C_ 'O
Acetic anhydride (22.6mL, 0.24mo1) was added to an ice-cooled solution of 3,5-dihydroxytoluene (9.93g, 0.08mo1) and triethylamine (56mL, 0.40mo1) in dichloromethane (86mL). The reaction mixture was warmed to room temperature and was stirred for 60 hours. Water (100mL) was then added and the mixture was stirred vigorously for 3 hours. The organic layer was separated and the aqueous layer was re-extracted with dichloromethane (3x80mL). The combined organic extracts were washed with brine (80mL);
dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate:pentane, 66:33, to afford the title compound as a colourless oil in 94% yield, 15.7g.
LRMS (APCI+): m/z [M+NH4]+ 226 Preparation 70 ~2.6-Dihydroxy-4-methyl-phenyl)-ethanone OH O
\ ~CH3 HsC OH
A solution of the compound of Preparation 69 (10.12g, 48.6mmol) in chlorobenzene (lOmL) was added dropwise to a suspension of aluminium chloride (19.44g, 145.8mmol) in chlorobenzene (50mL), warmed to 90°C, and the mixture was stirred for one hour. The reaction mixture was then cooled and was pipetted carefully onto a mixture of ice and 2M hydrochloric acid.
The resulting mixture was extracted with ethyl acetate (3x200mL) and the combined organic layers were washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 84:16, 80:20, 75:25 to afford the title compound as a yellow solid in 66% yield, 5.31 g.
LRMS (APCI+): m/z [M+H]+ 167 Preparation 71 3,8-Dimethyl-1 H-indazol-4-0l ~\
/
HsC H
A solution of the compound of Preparation 70 (4.15g, 25mmol) in ethylene glycol (70mL) was added dropwise to a solution of hydrazine monohydrate so (2.4mL, 50mmol) in ethylene glycol (l5mL) and the mixture was stirred at room temperature for 1 hour and at 150°C for 80 minutes. The cooled reaction mixture was then poured onto water and was acidified to pH6 with acetic acid. The aqueous mixture was extracted with ethyl acetate (4x200mL) and the combined extracts were washed with 5% sodium sulphite (200mL) and brine (200mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with ethyl acetate:pentane, 50:50, afforded the title compound as a yellow solid in 95% yield, 3.84g.
LRMS (APCI+): m/z [M+H]+ 163 Preparation 72 4-~tert-Butyl-dimethyl-silanLrlox~r)-3,6-dimethyl-1 H-indazole ~ Hs CHs H3C- i i CHs CHs N_. CHs tent Butyldimethylchlorosilane (511 mg, 3.39mmol) and imidazole (1.05g, 15.4mmol) were added to a solution of the compound of Preparation 71 (500mg, 3.08mmol) in N,N-dimethylformamide and the reaction mixture was stirred at 0°C for 1 hour and at room temperature for 18 hours.
Additional tent 2o butyldimethylchlorosilane (511 mg, 3.39mmol) was added and the reaction mixture was heated at 80°C for 48 hours. The solvent was then evaporated under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic phase was separated, washed with brine (2x10mL), dried with magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 15:85, to afford the title compound as an orange oil in 23% yield.
LRMS (APCI+ : m/z [M+Hl+ 27 Preparation 73 4- tart-Butyl-dimethyl-silanyloxy)-3,6-dimethyl-indazole-1-carboxylic acid tart butyl ester i ~3 CH3 H3C- I i~CH3 H3C ~ O ~CH3 /~.cH3 N-N
O
H3C ~~~
O
Di-tart-butyl dicarbonate (503mg, 2.3mmol) and 4-dimethylaminopyridine (51 mg, 0.4mmol) were added to the compound of Preparation 72 (580mg, 2mmol) in dichloromethane (5mL) and the reaction mixture was stirred for 18 1o hours. Water was then added to the reaction mixture and the aqueous mixture was extracted with dichloromethane (3x10mL). The combined organic extracts was dried over sodium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting with pentane:ethyl acetate, 95:5, afforded the title compound as a colourless oil in 66% yield, 527mg.
LRMS (APCI+): m/z [M+HJ+ 377 Pr~aration 74 4-Hydroxy-3,6-dimethyl-indazole-1-carboxylic acid tart-but I e,~ster H3C ~ OH
~CH3 N_N
O
H3C \\~
O
HsC CHs Tetrabutylammonium fluoride solution (1 M in tetrahydrofuran, 21 mL, 2.1 mmol) was added dropwise to a solution of the compound of Preparation 73 (527mg, 1.4mmol) in tetrahydrofuran (9mL) and the solution was stirred at 0°C for 30 minutes and at room temperature for 5 minutes. Water was then added to tre mixture and the aqueous mixture was extracted with ethyl acetate (2x10mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on silica gel, eluting with pentane:ethyl acetate, 70:30 to 60:40, afforded the title compound as a white solid in 76% yield, 280mg.
LRMS (APCI-): mlz [M-H]- 261 Preparation 75 (2R)-1-[~,2R)-4-Benzoyl-2-meth r~l-piperazin-1-~]-2-benzyloxy-propan-1-one O
H3C\
N
O ~N \
\ O
1-Hydroxybenzotriazole hydrate (825mg, 5.3mmol), N-methylmorpholine (808pL, 7.3mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.13g, 5.8mmol) and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(1.0g, 4.9mmol), J. Med. Chem. 43(23), 4499; 2000] were added to a solution of (R)-(+)-2-benzyloxypropionic acid (972mg, 5.3mmol) in 2o dichloromethane (lOmL) and the mixture was stirred for 18 hours. Additional (R)-(+)-2-benzyloxypropionic acid (486mg, 2.65mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.65mg, 2.9mmol), 1-hydroxybenzotriazole hydrate (413mg, 2.65mmol) and N-methylmorpholine (808pL, 7.3mmol) were added and the mixture was heated under reflux for 3 2s hours. Water was then added to the reaction mixture and the aqueous solution was extracted with dichloromethane (2x10mL). The combined organic extracts were washed with 2M hydrochloric acid, 1 M sodium hydroxide solution and brine. The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on 3o silica gel, eluting with pentane:ethyl acetate, 50:50, followed by ethyl acetate:methanol, 90:10, afforded the title compound as a white foam in 81 yield, 1.45g LRMS (APCI-): m/z [M-H]- 367 Preparation 76 (2R)-1-[(2R)-4-Benzoyl-2-meth~rl-piperazin-1-yl -2-hydrox~propan-1-one O
- N~ ~
OH ~N
H3C~' ~
O
Pd(OH)2 (300mg, 2.2mmol) and ammonium formate (1.37g, 22mmol) were 1o added to a solution of the compound of Preparation 75 (1.458, 3.9mmol) in ethanol (30mL) and the mixture was heated at 60°C for 2 hours. Tlc analysis then showed that the reaction had not reached completion so additional Pd(OH)2 (300mg, 2.2mmol) was added, followed by ammonium formate (1.37g, 22mmol) added at 45 minute intervals until all of the starting material was consumed. The reaction mixture was then cooled and filtered through Arbocel~, washing through with ethanol (lOmL). The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a white gum in 91 % yield, 1 g.
2o LRMS (APCI+): m/z [M+H]+ 277 Preparation 77 4-[(,1 S~2-[~2R)-4-Benzo~rl-2-methyl-piperazin-1-arl]-1-methyl-2-oxo-ethoxyl-3,6-dimethyl-indazole-1-carboxylic acid terl-butyl ester H3C~O ~ CH3 N \
H3C ~ \ _ N
O N O
N- O CHs The compound of Preparation 76 (70mg, 0.25mmol), di-tert-butyl azodicarboxylate (233mg, 1.01 mmol) and polymer supported triphenyl phosphine (380mg, 1.l3mmol) were added to a solution of the compound of Preparation 74 (70mg, 0.25mmol) in dichloromethane (3mL) and the reaction mixture was stirred 0°C for 30 minutes and at room temperature for 18 hours.
The reaction mixture was then filtered through a filter tube, washing through with dichloromethane. The filtrate was washed with sodium hydroxide solution, dried over magnesium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting 1o with pentane:ethyl acetate, 40:60 to 20:80 afforded the title compound as a white foam in 34% yield, 45mg LRMS (APCI+): m/z [M+H]+ 521 Biological Data The ability of the compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives to modulate gp120 activity, in particular inhibit the interaction of gp120 with CD4, is demonstrated using a gp160 induced cell-cell fusion assay to determine the ICSO values of 2o compounds against HIV-1 fusion. The gp160 induced cell-cell fusion assay uses a HeLa P4 cell line and a CHO-TatlO cell line.
The HeLa P4 cell line expresses CCR5 and CD4 and has been transfected with HIV-1 LTR-(3-Galactosidase. The media for this cell line is Dulbecco modified eagle's medium (D-MEM) (without L-glutamine) containing 10% foetal calf serum (FCS), 2mM L-glutamine penicillin/streptomycin (Pen/Strep; 100U/mL penicillin + l0mg/mL streptomycin), and 1 p.g/ml puromycin.
The CHO cell line is a Tat (transcriptional traps activator)-expressing clone from a CHO JRR17.1 cell line that has been transfected with prat puro so plasmid. The media for this cell line is rich medium for mammalian cell culture originally developed at Roswell Park Memorial Institute RPM11640 (without L-glutamine) containing 10% FCS, 2mM L-glutamine, 0.5 mg/ml Hygromycin B and 12pg/ml puromycin. The CHO JRR17.1 line expresses gp160 (JRFL) and is a clone that has been selected for its ability to fuse with a CCRS/CD4 expressing cell line.
Upon cell fusion, Tat present in the CHO cell is able to transactivate the HIV-1 long terminal repeat (LTR) present in the HeLa cell leading to the expression of the (3-Galactosidase enzyme. This expression is then measured using a Fluor AceT"" ~i-Galactosidase reporter assay kit (Bio-Rad cat no. 170-3150). This kit is a quantitative fluorescent assay that determines the level of expression of ~i-galactosidase using 4-methylumbelliferul-galactopyranoside (MUG) as substrate. (i-Galactosidase hydrolyses the fluorogenic substrate resulting in release of the fluorescent molecule 4-methylumbelliferone (4MU). Fluorescence of 4-methylumbelliferone is then measured on a fluorometer using an excitation wavelength of 360nm and emission wavelength of 460nm.
1o Compounds that inhibit fusion will give rise to a reduced signal and, following solubilisation in an appropriate solvent and dilution in culture medium, a dose-response curve for each compound can be used to calculate ICSO values.
All the Examples of the invention have ICSO values, according to the above method, of less than 1.SpM. ICSO values for the compounds of Examples 12, 29 and 44 are, respectively, l5nM, 134nM and 825nM.
The ability of compounds of formula (I) to inhibit the interaction of gp120 with CD4 is further demonstrated using an enzyme linked immunosorbent assay (ELISA). Maxisorp plates (Nunc) are coated with 2~.g/well of anti-gp120 antibody (D7324). 100p,1 of gp120 (dilution pre-determined by titration) is added to each well and incubated for 90 minutes at room temperature. The sample is removed and the wells are washed with PBS (phosphate buffered saline) + 0.01% TWEEN~ (polyethylene glycol sorbitan monolaurate). 50~1/well of compound is added followed by 50p,1 (0.1 ~.g) of soluble CD4 conjugated to horseradish peroxidase (Autogen Bioclear). The plate is incubated for 90 minutes at room temperature before the wells are washed again. The substrate ~PD (o-phenylenediamine, Sigma) is added at a concentration of 0.5mg/ml and the plate incubated in the dark at room temperature for 3 minutes before 3M HCI is added to stop the 3o reaction. Compounds that inhibit the interaction of gp120 with soluble CD4 will give rise to a reduced absorbance at 492nm.
All the Examples of the invention have ICSO values, according to the above method, of less than 15~.M. ICSO values for the compounds of Examples 1, 11 and 12 are, respectively, 0.92p,M, 1.Op,M and 0.75p,M.
Preparatiori 14 3-(3-Methox~-2-meth rLl-phenyl)-1-methyl-1 H-pyrazole \ OwCHs ~CH3 N
The compound of Preparation 11 (2.05g, 9.35mmol) was added portionwise to a solution of methylhydrazine (547pL, 10.28mmol) in acetic acid (15mL) 1o and the mixture was heated at 90°C for 2.5 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in dichloromethane and washed with 10% sodium carbonate solution and saturated sodium hydrogen carbonate solution. The organic phase was dried over magnesium sulfate and concentrated in vacuo to give an orange oil. The 15 oil was purified firstly by column chromatography on silica gel, eluting with dichloromethane:ethyl acetate, 99:1 to 97:3. This was followed by further purification using an Isolute~ Flash silica column, eluting with dichloromethane:ethyl acetate, 99:1 to 97:3, to afford the title compound as a yellow oil in 31 % yield, 568mg.
2o LRMS (ES+): m/z [M+H]+ 203 Preparations 15 to 16 The following compounds, of the general formula shown below, were 25 prepared by the method described above for Preparation 14 using the appropriate enamine and hydrazine monohydrate.
Rb O
\ ~CH3 / Ra H \
N
No. Ra Rb LRMS ES+ : m/z M+H +
16 H OCH2Ph 281 s Preparation 17 2-Meth~(1-methyl-1 H ~yrazol-3-~~phenol \ OH
~CH3 N ~~
N
Boron tribromide (1 M in dichloromethane, 8.16mL, 8.16mmol) was added 1o dropwise to an ice-cooled solution of the compound of Preparation 14 (550mg, 2.72mmol) in dichloromethane (6mL). The resulting solution was allowed to warm to room temperature and was stirred for 2 hours. The reaction mixture was then poured carefully onto ice and was neutralized with 10% sodium carbonate solution. The mixture was extracted with 1s dichloromethane (2x50mL) and the combined organic phases were dried over magnesium sulfate and concentrated in vacuo. The residue was chromatographed using an Isolute~ Flash silica column, eluting with dichloromethane:methanol, 98:2 to 97:3, to give a brown oil. The oil was azeotroped with dichloromethane to afford the title compound as brown foam in 61 % yield, 31 Omg.
LRMS (ESf): m/z [M+H]+ 189 Preparations 18 to 20 The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 17 using the appropriate methoxybenzene derivative and boron tribromide.
NO. Ra R LRMS ES+ : m/z M+H
18 CH3 ~ 152 HaN
19 CH3 ~N 175 N\
20 H ~N 161 N' Preparation 18: title compound is prepared by dealkylation of 3-methoxy-2-methylbenzamide (J.Chem.Soc.Perkin Trans.l, 2389-2396; 1984) Preparation 21 (2S)-2-[3-(2H-Pyrazol-3-yl~phenoxy]-propionic acid meth 1y ester CHI
O
O ~CH3 O
H\~
N
OH
/
wRa R°
Diisopropyl azodicarboxylate (295pL, 1.50mmol) was added dropwise to an ice-cooled solution of the compound of Preparation 20 (240mg, l.5mmol) methyl (R)-lactate (156mg, 1.50mmol) and triphenyl phosphine (393mg;
l.5mmol) in tetrahydrofuran (5mL). The reaction mixture was stirred at room temperature for 18 hours and was then diluted with diethyl ether (50mL) and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The oil was purified on an Isolute~ flash silica column, eluting with diethyl ether:dichloromethane, 80:20 to 95:5, to afford the title compound as a viscous yellow oil in 54%
yield, 200mg.
LRMS (ES-): m/z [M-H]- 245 Preaaration 22 ~2S~j2-Methy~2H-pyrazol-3-yl)-phenoxyl-propionic acid methyl ester O
O ~CH3 O
~CH3 H \
N
The title compound was prepared by the method described above for Preparation 21 using the compound of Preparation 19 and methyl (R)-lactate:
LRMS (ES-): m/z [M-H]- 259 Preparation 23 (2S)-2-[3-(2H-Pyrazol-3- r1 -phenoxy~-propionic acid OH
O
O
H ~
Lithium hydroxide monohydrate (80.9mg, 1.93mmol) was added portionwise to a solution of the compound of Preparation 21 (190mg, 0.77mmol) in methanol (6mL) and the mixture was stirred at 60°C for 8 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in water and washed with diethyl ether. The aqueous mixture was acidified with 2M hydrochloric acid to pH4 and was then extracted with ethyl acetate (3x30mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The resulting foam was dried under reduced pressure to afford the title compound in 75% yield, 135mg.
LRMS (ES-): m/z [M-H]- 231 Preparation 24 !2S)-2-[2-Methyl-3- 2H-pyrazol-3-Lrl)-phenoxy]-propionic acid OH
O
O
H\
N
The title compound was prepared by the method described above for Preparation 22 using the compound of Preparation 22 and lithium hydroxide.
LRMS (ES-): m/z [M-H]- 245 Preparation 25 1-[!2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one CH3 ~N ~ \
N
Br 2-Bromopropionic acid (1.53g, l0mmol) was added to a solution of N,N'-dicyclohexylcarbodiimide (2.06g, l0mmol) in dichloromethane (40mL), cooled to -15°C. The reaction mixture was stirred for 20 minutes before (2R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(2.04g, l0mmol), J. Med. Chem.
43(23), 4499; 2000] in dichloromethane (l6mL) was added dropwise. The reaction mixture was stirred at -15°C for 90 minutes and was then diluted with diethyl ether (100mL) and stirred for a further 10 minutes. The mixture was then filtered through Celite, washing through with diethyl ether and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with hexane:ethyl acetate, 40:60 to 20:80 to afford the title compound in 76% yield, 2.5g.
LRMS (ES+): m/z [M+H]+ 340 Preparation 26 3-~2-[(2R)-4-Benzoyl-2-methylpiperazin-1-yll-1-methyl-2-oxo-ethoxy~-2-methyl-benzamide O
/ CHs ~N ~ \
HEN \ N /
~O
O ~ ~ CHs The compounds of Preparation 18 (180mg, 1.19mmol) and Preparation 25 (403.9mg, 1.19mmol) and cesium carbonate (387mg, 1.19mmol) in N,N-dimethylformamide (lOmL) were heated at 80°C for 18 hours. The cooled reaction mixture was then evaporated under reduced pressure and the residue was partitioned between dichloromethane (50mL) and water (lOmL).
The organic phase was separated, dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to give a colourless foam. The foam was azeotroped with dichloromethane and dried 2o under reduced pressure to afford the title compound in 98% yield, 475mg.
LRMS (ES+): m/z [M+H]+ 410 Preparation 27 1-[(2R~4-Benzoyl-2-meth-piperazin-1-~l-~3-methoxy-5-vitro-phenoxy)-propan-1-one Hs O
OzN / O CHs ~N
\I N U
O
O CHs The title compound was prepared by the method described above for -Preparation 26 using the compound of Preparation 25 and 2-methoxy-5-nitrophenol:
LRMS (APCI+): m/z [M+H]+ 428 Preparation 28 3-(2-f (2R)-4-Benzovl-2-methvlpiperazin-1-vll-1-methyl-2-oxoethoxvl-N
(dimethylamino~meth 1y ene]-2-methylbenzamide i Hs i H C N ~ ~ CH3 N \ N
~O
p The title compound was prepared by the method described above for Preparation 10 using the compound of Preparation 26 and N,N-dimethylformamide dimethylacetal.
LRMS (APCI+): m/z [M+H]+ 465 Preparation 29 3-~2-f (2R)-4-Benzovl-2-methyl-piperazin-1-vll-1-methyl-2-oxo-ethoxvl-N-hydroxyaminomethylene-2-meth~rl-benzamide H
HO~N~ ~ ~ GH3 IIN \ f O
O CH3 O ,, 2o Sodium hydroxide solution (1 M, 1.06mL, 1.06mmol) was added dropwise to a suspension of hydroxylamine hydrochloride (73.6mg, 1.06mmol) in acetic acid (6mL). The compound of Preparation 28 (410mg, 0.88mmol) was then added portionwise and the resulting solution was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and the oily residue was partitioned between dichloromethane (30mL) and water (6mL), and neutralized with 10% sodium carbonate solution. The organic phase was separated and the aqueous phase was re-extracted with dichloromethane (30mL). The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to afford the title compound as a colourless foam in 78% yield, 310mg.
LRMS (ES-): m/z [M-H]- 451 Preparation 30 ~4-Amino-2-methoxy-phenoxy)-1-[(2R -4-benzoyl-2-methyl-piperazin-1=yll-propan-1-one Hs O
HaN / O CHs ~ N ~ \
\I N
25% Pd/C (150mg) and ammonium formate (443mg, 7mmol) were added to a solution of the compound of Preparation 27 (600mg, l.4mmol) in ethanol (30mL) and the mixture was heated at 70°C for 2 hours. The reaction mixture was then cooled and filtered through Arbocel~, washing through with ethanol (lOmL). The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a pale pink solid in 80% yield, 443mg.
LRMS (APCI+): m/z [M+H]+ 398 Preparation 31 4-Benzylox~r-3-methoxy-benzamidine H
"Butyl lithium (1.6M in hexane, 35.9mL, 57.47mmol) was added dropwise to a solution of hexamethyldisilazane (11.64mL, 55.17mmol) in diethyl ether (60mL), cooled to -5°C, and the reaction mixture was stirred for 30 minutes at a constant temperature of 0°C. 3-Methoxy-4-(phenylmethoxy)-benzonitrile (5.5g, 22.99mmol) was added portionwise and the mixture was stirred at room temperature 4 hours. The reaction mixture was then poured onto ice cold 2M hydrochloric acid (100mL) and was washed with diethyl ether (2x 100mL). The aqueous phase was basified to pHlO with 6M sodium hydroxide solution and was extracted with dichloromethane (3x100mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a white solid in 68% yield, 3.99g.
1o LRMS (ES+): m/z [M+H]+ 257 Preparation 32 2-(4-Benzyloxy-3-methoxy-~ohenyl)-1 H-imidazole H
N
The compound of Preparation 31 (1 g, 3.90mmol) in chloroform (40mL) was added to a solution of chloroacetaldehyde (336mg, 3.90mmol) in chloroform (lOmL) and the mixture was stirred at room temperature for 18 hours. The resulting white precipitate was filtered off and the filtrate was washed with 2o saturated sodium hydrogen carbonate solution (30mL). The aqueous phase was re-extracted with 10% methanol in dichloromethane (2 x 50mL) and the combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 98:2 to 96:4, to give a brown foam. The foam was purified further on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99.5:0.5 to 98:2, to give a beige foam.
The foam was then azeotroped with dichloromethane and dried at 40°C to afford the title compound in 16% yield, 180mg.
LRMS (ES+): m/z [M+H]+ 281 Preparation 33 4J1 H-Imidazol-2-ail)-2-methoXy-phenol OH
N ~ /
-O
~N CH3 To a solution of the compound of Preparation 32 (170mg, 0.61 mmol) in methanol (lOmL) was added portionwise 10% Pd/C (85mg) and ammonium formate (191 mg, 3.03mmol). The mixture was heated under reflux for 2 hours. The reaction mixture was then cooled and filtered through Arbocel~, washing through with a mixture of dichloromethane and methanol (50:50, 250mL). The filtrate was concentrated in vacuo and the residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 99:1 to 96:4, to afford the title compound as a white solid in 91 % yield, 105mg.
LRMS (ES+): mlz [M+H]+ 191 Preparation 34 2-Methoxy-4-(2H-pyrazol-3-yl~phenol OH
N ~ /
Ni ~ ~ _O
The title compound was prepared by the method described above fior Preparation 33 using the compound of Preparation 16.
LRMS (ES+): m/z [M+H]+ 191 Preparation 35 1-Benzyloxy-4-bromo-2-methoxy-benzene Br \ / O
O
A mixture of 4-bromo-2-methoxyphenol (5g, 24.63mmol), benzyl bromide-(4.21 g, 24.63mmol) and cesium carbonate (8g, 24.63mmol) in acetone (60mL) were heated under reflux for 4 hours. The cooled reaction mixture was then evaporated under reduced pressure and the residue was partitioned 5 between diethyl ether (200mL) and water (80mL). The aqueous phase was separated and re-extracted with diethyl ether (200mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was azeotroped with dichloromethane to afford the title compound as white solid in 100% yield, 7.198.
1 o LRMS (ES+): m/z [M+Na]+ 317 Preparation 36 1-(4-Benzyloxy-3-methoxy-phenyl)-1 H-pyrazole N
~ \
N ~ ~ O
O
15 HsC
A mixture of the compound of Preparation 35 (1.5g, 5.12mmol), pyrazole (697mg, 10.23mmol), copper (I) iodide (195mg, 1.02mmol) and potassium carbonate in N,N-dimethylformamide (lOmL) was heated at 140°C for 18 hours. The cooled reaction mixture was then evaporated under reduced 2o pressure and the residue was partitioned between dichloromethane (50mL) and water (30mL). The aqueous phase was separated and re-extracted with diethyl ether (200mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 25 100:0 to 96:4, to afford the title compound as a white solid in 82% yield, 1.18g.
LRMS (ES+): m/z [M+H]+ 281 Preparation 37 2-Methoxy-4-~yrazol-1-yl-phenol N
N ~ ~ OH
O
The title compound was prepared by the method described above for Preparation 33 using the compound of Preparation 36.
LRMS (ES+): m/z [M+H]+ 191 Preparation 38 (2S)-~Quinolin-5-,~y~-propionic acid metal ester O
N ~ ~ ~O ~CH3 \ O
Triphenylphosphine (2.17g, 8.27mmol) was added to a stirred suspension of diisopropyl azodicarboxylate (1.47mL, 7.56mmol) in tetrahydrofuran (25mL) at -5°C. 5-Hydroxyquinoline (1.0g, 6.90mmol) and methyl-(R)-lactate (0.66mL, 6.90mmol) were added and the solution was allowed to stir at room temperature for 14 hours. The reaction mixture was then diluted with ethyl acetate (50mL), washed with water (30mL), saturated potassium carbonate 2o solution (30mL) and brine (30mL). The solution was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 80:20 to 60:40, to afford the title compound as a white solid in 81 % yield, 1.30g.
LRMS (ES+): m/z [M+H]+ 232 Preparation 39 (2S)-2-(Iso~uinolin-5-yloxy)-propionic acid meth~rl ester / I O OwCHs N\ O
The title compound was prepared by the method described above for Preparation 38 using 5-hydroxyisoquinoline and methyl-(R)-lactate.
LRMS (APCI+): m/z [M+H]+ 232 Preparation 40 ~2S)-2-(Quinolin-5-yloxy~-propionic acid sodium salt O Na+
N / I w0 O
A solution of the compound of Preparation 38 (1.308, 5.60mmol) and 1 M
sodium hydroxide solution (5.62mL) in 1,4-dioxane (40mL) was heated at 60°C for two hours. After this time tlc analysis indicated that starting material remained so additional 1 M sodium hydroxide solution (1.4m1) was added and heating continued at 60°C for one hour. The reaction mixture was then concentrated in vacuo to yield the title compound as a yellow solid in 2o quantitative yield.
LRMS (ES+): m/z [M+H]+ 218 Preparation 41 2S -2-~Isoguinolin-5-vloxv)-propionic acid sodium salt / O Na+
N \ I _O
The title compound was prepared by the method described above for Preparation 40 using the compound of Preparation 39.
LRMS (APCI+): m/z [M+H]+ 218 Preparation 42 (2S)-1-f (2R)-4-Benzoyl-2-methyl-piperazin-1-Lrl]-~quinolin-5-yloxy)-propan-1-one / I CH3 ~N I \
N/ I O N /
\ O CH3 1o A solution of the compound of Preparation 40 (1.0 g, 4.6mmol), (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(0.94 g, 4.6mmol) J. Med. Chem., 43(23), 4499; 2000], ~(1H-benzotriazol-1-yl)-N, N,N',N-tetramethyluronium hexafluorophosphate (2.62g, 6.9mmol) and triethylamine (1.93m1, 13.8mmol) in N,N dimethylformamide (30m1) was stirred at room temperature for 14 hours. The reaction mixture was then diluted with dichloromethane (100m1), washed with water (3x50m1), dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol, 98:2, to afford the title compound as a white solid in 49% yield, 0.91 g.
2o LRMS (ES+): m/z [M+H]+ 404 Preparation 43 (2S)-1-f(2R)-4-Benzoyl-2-methyl-piperazin-1-yl -~2-(isoguinolin-5-ylo~)-propan-1-one / ~ CH3 ~N ~ \
O N /
N \ O CH3 The title compound was prepared by the method described above for Preparation 42 using the compound of Preparation 41 and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone (J. Med. Chem., 43(23), 4499; 2000.
LRMS (APCI+): m/z [M+H]+ 404 Preparation 44 (2S)-1-[~(2R~4-Benz~l-2-methyl-piperazin-1-yl]-2-(8-bromo-quinolin-5-yloxy)-~ropan-1-one Br / ~ CHI
N / ~ w0 J
A mixture of the compound of Preparation 42 (450mg, 1.1 mmol) and N-bromosuccinimide (795mg, 4.4mmol) in acetonitrile (90mL) was stirred at room temperature for 2 hours. The solvent was then evaporated under 1o reduced pressure and the residue was dissolved in ethyl acetate (50mL) and washed with water (2x20mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate:pentane, 33:67 to 100:0 to afford the title compound as a white solid in 98% yield, 526mg.
LFtMS (ES+): m/z [M+H]+ 482/484 Preparation 45 (2S)-1-f (2R)-4-Benzovl-2-methyl-piperazin-1-vl1-2-~[2-(2-trimethylsilan etho~methy~-2H-~yrazol-3-yl]-quinolin-5-yloxy}-propan-1-one ~ i\ CHs N~N~O CH3 O
/ /
CH3 ~N ~ \
N/ O N /
Tetrakis(triphenylphosphine)palladium(0) (6mg, cat), 1-[[(2-(trimethylsilyl)ethoxy]methyl]pyrazolyl-5-boronic acid [(50mg, 0.1 mmol), J.
Med. Chem. 41 2019-2028; 1998] and sodium carbonate (175mg, l.6mmol) in water (0.5mL) were added to the compound of Preparation 44 (50mg, 0.1 mmol) in tetrahydrofuran (2mL) and the mixture was heated under reflux for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was dissolved in dichloromethane and washed with water (5m~) and brine (2x5mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give an orange oil. The oil 5 was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 96:4 to afford the title compound as a yellow solid.
LRMS (APCI+): m/z [M+H]+ 600 1 o Preparation 46 ~2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-oxy-quinolin-5- I~oxy)-prop~an-1-one O~N+i O
\ ~ O
meta-Chloroperbenzoic acid (1.54g, 4.44mmol) was added to an ice-cooled solution of the compound of Preparation 42 (1.5g, 3.7mmol) in dichloromethane (l5mL) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was then diluted with dichloromethane (lOmL) 2o and washed with saturated aqueous potassium carbonate solution (lOmL) and water (2x 10m1). The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a white solid in quantitative yield, 1.~g.
LRMS (APCI+): m/z [M+H]+ 420 Pre~~aration 47 5-f2-f 2R -4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy~-quinoline-2-carboxylic acid meth, 1y ester O
CH3 ~N ~ \
N
N ~ ~ ~O
O \ O CH3 O
H3C~
The chloro compound of Preparation 66 (130mg, 0.3mmol), dichloro-bis(triphenylphosphine)palladium (24mg, 0.03mmol) and triethylamine (83pL, 0.6mmol) were dissolved in a mixture of methanol (3mL) and N,N-dimethylformamide (0.5mL), and transferred to a sealed vessel. The vessel 1o was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in vacu~. Purification of the residue by column chromatography on silica gel, eluting with ethyl acetate:pentane, 75:25 to 100:0, afforded the title compound in 41 % yield, 50mg.
LRMS (APCI+): m/z [M+H]+ 462 Preparation 48 5-~2-f f 2 R)-4-Benzoyl-2-methyl-piperazin-1-y~-1-methyl-2-oxo-ethox~r}-2o quinoline-2-carboxylic acid OH
N
1 M Sodium hydroxide solution (130pL, 0.135mmol) was added to a solution of the compound of Preparation 47 (40mg, 0.09mmol) in dioxane (3mL) and the mixture was heated at 60°C for 3 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in water (20mL) and washed with ethyl acetate. The phases were separated and the organic phase was discarded. The aqueous phase was acidified with glacial acetic acid and re-extracted with ethyl acetate. The retained organic phase (2"d washing) was dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a pale yellow solid in 67% yield, 26mg.
LRMS (APCI+): m/z [M+H]+ 448 Preparation 49 (2Sl-1-f(2Rl-4-Benzovl-2-methyl-aiperazin-1-vl1-2-(2-benzvlamino-auinolin-5-1 o ylox~r -propan-1-one O
CH3 ~N ~ \
N
\ O
N /
NH
/
A mixture of the compound of Example 60 (50mg, 0.11 mmol), tetrabutyl ammonium fluoride (30mg, 0.22mmol), triethylamine (0.16mL, 1.1 mmol) and benzylamine (0.13mL, 1.1 mmol) in dimethylsulfoxide (1 mL) was heated at 120°C for 72 hours. The reaction mixture was then purified directly by HPLC
using a Phenomenex Luna C18 system, eluting with water/acetonitrile/trifluoroacetic acid (5:95:0.1 ):acetonitrile, 95:5 to 5:95, to afford the title comloound in 34% yield.
LRMS (APCI+): m/z [M+H]+ 509 Preparation 50 (3R)-3-Methyl-4-[(2S~2-(quiriolin-5-ylox~i -propionyl]-piperazine-1-carboxylic acid tert-but, 1y ester O CHs / CH N~O CH3 N
N ~ ~ ~O
\ 0 CH3 1-Hydroxybenzotriazole hydrate (249mg, 1.87mmol) was added to a suspension of the compound of Preparation 40 (400mg, l.7mmol) in N,N-dimethylformamide to form a solution. 1-Ethyl-3-(3-dimethyl amino propyl) carbodiimide (351 mg, 1.87mmol) and triethylamine (0.7mL, 5.1 mmol) were 1o added and the solution was stirred for 5 minutes. (3S)-3-Methyl-piperazine-carboxylic acid tent butyl ester (335 mg, 1.7mmol) was added and the mixture was stirred for 18 hours. The solvent was then evaporated under reduced pressure and the residue was dissolved in ethyl acetate (30mL) and washed with water (20mL). The organic phase was dried over magnesium sulfate and ~5 concentrated in vacuo to afford the title compound in 48% yield, 332mg.
LRMS (APCI+): m/z [M+H]+ 400 Preparation 51 (2S)-1-[(2R)-2-Methyl-piperazin-1-yll-2-(quinolin-5-yloxy)-propan-1-one;
2o hydrochloride HCI
CH3 ~N.
N
N ~ ~ ~O
\ O CH3 The compound of Preparation 50 (300mg, 0.75mmol) was stirred in 4M
hydrochloric acid in dioxane (3mL) for 2 hours. The reaction mixture was concentrated in vacuo to afford the title compound as a pale yellow solid in 25 quantitative yield, 348 mg.
LRMS (APCI+): mlz [M+H]+ 300 Preparation 52 (2S)-1-[(2R)-4-Benzo~l-2-meth rLl-piperazin-1-yll-2-(2,8-dichloro-auinolin-5-ylox~~-propan-1-one t O
A mixture of the compound of Example 60 (200mg, 0.4mmol) and N-chlorosuccinimide (61 mg, 0.4mmol) in acetonitrile (1 OmL) was heated at 40°C
for 48 hours. The solvent was then evaporated under reduced pressure and o the residue was dissolved in dichloromethane (20mL) and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, to afford the title compound as a white solid in 78% yield, 169mg.
LRMS (APCI+): m/z [M+H]+ 472 Preparation 53 ~2S~ 1-[(2R)-2-MethLrl-4-_(pyridine-2-carbonyl)-piperazin-1-yll-2-(auinolin-5-ylox~r)-propan-1-one O
~ I CH3 ~N \
,0 1 \ O CH3 A mixture of the compound of Preparation 51 (150mg, 0.5mmol), picolinic acid (49mg, 0.6mmol) O-(1 H-benzotriazol-1-yl)-N,N,I~P,N-tetramethyluronium hexafluorophosphate (190mg, 0.75mmol) and triethylamine (0.93mL, l0mmol) in dichloromethane (3mL) was stirred for 18 hours at room temperature. The reaction mixture was then diluted with further dichloromethane and washed with sodium hydroxide (lOmL) and water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with dichloromethane:methanol, 99:1 to 95:5, afforded the title compound as a white solid in 49% yield, 99mg.
LRMS (APCI+): m/z [M+H]+ 405 5 Preparation 54 j2S)-1-[4-~(2-Fluoro-benzoyl)-(2R)-2-methyl-piperazin-1-yl]-2~quinolin-5-yloxy)-pro~an-1-one N / ~ w0 \ O CH3 1o A mixture of the compound of Preparation 51 (150mg, 0.5mmol), 2-fluorobenzoyl chloride and triethylamine in dichloromethane (3mL) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane and washed with water (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by 15 column chromatography on silica gel, eluting with dichloromethane:methanol, 98:2, afforded the title compound as a white solid in 73% yield, 153mg.
LRMS (APCI+): m/z [M+H]+ 422 Preparation 55 20 4-Bromo-2-trifluoromethoxy-phenol OH
O eF
F F
Br Bromine (449mg, 2.81 mmol) was added to a solution of 2-(trifluoromethoxy)phenol (500mg, 2.81 mmol) and sodium acetate (169mg, 25 2.81 mmol) in acetic acid (5mL) and the solution was stirred for 1 hour.
The reaction mixture was then diluted with water (30mL) and extracted with ethyl acetate (2x50mL). The organic extracts were combined, dried over magnesium sulfate and concentrated in vacuo to give a colourless oil. The oil was purified by column chromatography on silica gel, eluting with -pentane:ethyl acetate, 85:15, to afford the title compound as a white solid in 23% yield.
LRMS (APCI+): m/z [M+H]+ 255/257 Preparation 56 ~2S)-2- 4-Bromo-2-trifluoromethoxy-phenoxy~propionic acid methyl ester O
F
1o Diisopropyl azodicarboxylate (414pL, 2.14mmol) was added dropwise to an ice-cooled solution of the compound of Preparation 55 (500mg, 1.95mmol) methyl (R)-lactate (202mg, 1.95mmol) and triphenyl phosphine (614mg, 2.34mmol) in tetrahydrofuran (20mL). The reaction mixture was stirred at room temperature for 18 hours and was then evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed with 10%
potassium carbonate solution (2x10mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a colourless oil in 76% yield, 638mg.
2o LRMS (APCI+): m/z [M+H]+ 305/307 Preparation 57 S)-2-(4-Bromo-2-trifluoromethoxy-phenoxy)-propionic acid g O
A mixture of the compound of Preparation 56 (574mg, 1.67mmol) and 1 M
sodium hydroxide solution (4.2mL, 4.2mmol) in dioxane (lOmL) was stirred at 55°C for 3 hours, The solvent was then evaporated under reduced pressure and the residue was dissolved in water (30mL). The aqueous solution was acidified to pH2 with 2M hydrochloric acid and extracted with ethyl acetate (2x50mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a yellow solid in 80% yield.
LRMS (APCI+): mlz [M+H]+ 327 Preparation 58 (2S~-1-[S2R)-4-Benzoyl-2-methyl-piherazin-1-yl]-2-(4-bromo-2-trifluoromethoxy-phenoxy)-propan-1-one CH3 ~N
N /
F
A solution of the compound of Preparation 57 (150mg, 0.46mmol), (3Fi)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(93mg, 0.46mmol) J. Med. Ghem., 43(23), 4499; 2000], O-(1H-benzotriazol-1-yl)-N,N,N,hP-tetramethyluronium hexafluorophosphate (260mg, 0.69mmol) and triethylamine (0.13m1, 0.92mmol) in dichloromethane (30m1) was stirred at room temperature for 18 hours. The reaction mixture was then diluted with dichloromethane (50m1) 2o and washed with water (50m1). The aqueous phase was re-extracted with dichforomethane (50mL) and the combined organic extracts were dried over magnesium sulfate and concentrated in vacu~. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanof, 99:1, to afford the title compound as a white foam in 90% yield, 213mg.
LRMS (APCI+): m/z [M+H]+ 5371539 Preparation 59 4-,;~1 S)-2-[(2R -4-Benzoyl-2-methyl-piperazin-1-girl]-1-methyl-2-oxo-ethoxy~-3-trifluoromethoxy-benzoic acid methyl ester O
H3Cw0 ~N ~ \
N /
The compound of Preparation 58 (190mg, 0.37mmol), dichloro-bis(triphenylphosphine)palladium (30mg, 0.04mmol) and triethylamine (0.10mL, 0.74mmol) were dissolved in methanol (lOmL) and transferred to a o sealed vessel. The vessel was heated to 100°C and the mixture was stirred under 100psi of carbon monoxide gas for 42 hours. The reaction mixture was then filtered through Arbocel~, washing through with methanol and the filtrate was concentrated in ~acu~. The residue was purified on an Isolute~ flash silica column, eluting with dichloromethane:methanol, 97:3 to afford the title compound as an orange solid in 85% yield, 155mg.
LRMS (APCI+): m/z [M+H]+ 495 Preparations 60 to 61 2o The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 26 using the compound of Preparation 25 and the appropriate hydroxyquinoline or hydroxyisoquinoline.
O
CH3 ~N ~ \
R\ N /
O
No. R5 LRMS APCI+ : m/z M+H +
\ \
N
\ \
N / /
The following compounds, of the general formula shown below, were prepared by the method described above for Preparation 46 using the s compounds of Preparations 60 and 61 and meta-chloroperbenzoic acid CH3 ~N ( \
R~ N /
O
No. R5 LRMS APCI+ : m/z M+H +
\ \
N+
(_ O
\ \
- iN / /
O
Preparatiori 64 (2S;I-1-f(2R-4-Benzoyl-2-methyl-piperazin-1-yl]-~1-ox -~~uinolin-5- lyoxy)~
5 propan-1-one N
O
\ ~ J
- O~N / /
The title compound was prepared by the method described above for 1o Preparation 46 using the compound of Preparation 43.
LRMS (APCI+): m/z [M+H]+ 420 Preparation 65 ~2S)-1-[(2R)-4-Benzoyl-2-meth rL1-piperazin-1-yl]-~1-chloro-isoquinolin-5-15 yloxK -propan-1-one o CH3 ~N ~ \
N /
O
\ \ O CH3 N / /
CI
Phosphorus oxychloride (0.20mL, 2.18mmol) was added to a solution of the compound of Preparation 64 (305mg, 0.73mmol) in dichloromethane (l5mL) and the reaction mixture was heated at 100°C for two hours. The mixture was 2o then cooled to room temperature and poured onto water (75mL). The resulting aqueous mixture was basified with concentrated ammonia solution and extracted with dichloromethane (2x75mL). The combined organic extracts were then dried over magnesium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting -with dichloromethane:methanol, 99:1, afforded the title compound as a white foam in 40% yield, 127mg.
LRMS (APCI+): m/z [M+H]+ 438 Preparation 66 1-[f 2R)-4-Benz~l-2-methyl-piperazin-1-yl]-2-(2-chloro-quinolin-5-~y)-propan-1-one O
CH3 ~N
N
O
CI N
1o The title compound was prepared by the method described above for Preparation 65 using the compound of Preparation 62.
LRMS (APCI+): m/z [M+H]+ 438 Preparation 67 2-Methoxy-4-methylsulfanyl-phenol OH
tButyl lithium (1.7M in pentane, 14.5mL, 24.6mmol) was added dropwise to a solution of 4-bromo-2-methoxyphenol (2.00g, 9.85mmol) in tetrahydrofuran (25mL) cooled to -78°C. The mixture was stirred for 15 minutes and was then warmed to -40°C and stirred for a further 30 minutes. Dimethyl disulfide (1.06mL, 11.8mmol) was added and the mixture was stirred at room temperature for 18 hours. Water was then added to the reaction and the resulting mixture was acidified to pH1 with 2M hydrochloric acid. The aqueous phase was separated and re-extracted with ethyl acetate. The combined organic fractions were then dried over magnesium sulfate and concentrated in vacuo to give an orange oil. This oil was purified by column chromatography on silica gel, eluting with pentane:diethyl ether, 95:5 to 80:20, to afford the title compound as a white solid in 48% yield, 800mg.
'HNMR(CDC13, 400MHz) S: 2.40(s, 3H), 3.90(s, 3H), 5.50(brs, 1 H), 6.80-6.90(m, 3H) Prea~aration 68 6-Hydroxy-7-methox -y 3,4-dihydro-2H-isoquinolin-1-one OH
HN ~ ~ OMe O
A mixture of lithium iodide (0.32g, 2.41 mmol) and 6,7-dimethoxy-3,4-dihydro-2H-isoquinolin-1-one (0.5 g, 2.41mmol) in 2,4,6-collidine (10m1) was heated at 130°C for 18 hours. The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 96:4, to afford the title com~aound as a pale yellow solid, 0.19 g LRMS (APCI+): m/z [M+H]+ 194 Preparation 69 2o Acetic acid 3-acetoxv-5-methyl-ahenvl ester O~CH
H C_ 'O
Acetic anhydride (22.6mL, 0.24mo1) was added to an ice-cooled solution of 3,5-dihydroxytoluene (9.93g, 0.08mo1) and triethylamine (56mL, 0.40mo1) in dichloromethane (86mL). The reaction mixture was warmed to room temperature and was stirred for 60 hours. Water (100mL) was then added and the mixture was stirred vigorously for 3 hours. The organic layer was separated and the aqueous layer was re-extracted with dichloromethane (3x80mL). The combined organic extracts were washed with brine (80mL);
dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate:pentane, 66:33, to afford the title compound as a colourless oil in 94% yield, 15.7g.
LRMS (APCI+): m/z [M+NH4]+ 226 Preparation 70 ~2.6-Dihydroxy-4-methyl-phenyl)-ethanone OH O
\ ~CH3 HsC OH
A solution of the compound of Preparation 69 (10.12g, 48.6mmol) in chlorobenzene (lOmL) was added dropwise to a suspension of aluminium chloride (19.44g, 145.8mmol) in chlorobenzene (50mL), warmed to 90°C, and the mixture was stirred for one hour. The reaction mixture was then cooled and was pipetted carefully onto a mixture of ice and 2M hydrochloric acid.
The resulting mixture was extracted with ethyl acetate (3x200mL) and the combined organic layers were washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 84:16, 80:20, 75:25 to afford the title compound as a yellow solid in 66% yield, 5.31 g.
LRMS (APCI+): m/z [M+H]+ 167 Preparation 71 3,8-Dimethyl-1 H-indazol-4-0l ~\
/
HsC H
A solution of the compound of Preparation 70 (4.15g, 25mmol) in ethylene glycol (70mL) was added dropwise to a solution of hydrazine monohydrate so (2.4mL, 50mmol) in ethylene glycol (l5mL) and the mixture was stirred at room temperature for 1 hour and at 150°C for 80 minutes. The cooled reaction mixture was then poured onto water and was acidified to pH6 with acetic acid. The aqueous mixture was extracted with ethyl acetate (4x200mL) and the combined extracts were washed with 5% sodium sulphite (200mL) and brine (200mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification of the residue by column chromatography on silica gel, eluting with ethyl acetate:pentane, 50:50, afforded the title compound as a yellow solid in 95% yield, 3.84g.
LRMS (APCI+): m/z [M+H]+ 163 Preparation 72 4-~tert-Butyl-dimethyl-silanLrlox~r)-3,6-dimethyl-1 H-indazole ~ Hs CHs H3C- i i CHs CHs N_. CHs tent Butyldimethylchlorosilane (511 mg, 3.39mmol) and imidazole (1.05g, 15.4mmol) were added to a solution of the compound of Preparation 71 (500mg, 3.08mmol) in N,N-dimethylformamide and the reaction mixture was stirred at 0°C for 1 hour and at room temperature for 18 hours.
Additional tent 2o butyldimethylchlorosilane (511 mg, 3.39mmol) was added and the reaction mixture was heated at 80°C for 48 hours. The solvent was then evaporated under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic phase was separated, washed with brine (2x10mL), dried with magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with pentane:ethyl acetate, 15:85, to afford the title compound as an orange oil in 23% yield.
LRMS (APCI+ : m/z [M+Hl+ 27 Preparation 73 4- tart-Butyl-dimethyl-silanyloxy)-3,6-dimethyl-indazole-1-carboxylic acid tart butyl ester i ~3 CH3 H3C- I i~CH3 H3C ~ O ~CH3 /~.cH3 N-N
O
H3C ~~~
O
Di-tart-butyl dicarbonate (503mg, 2.3mmol) and 4-dimethylaminopyridine (51 mg, 0.4mmol) were added to the compound of Preparation 72 (580mg, 2mmol) in dichloromethane (5mL) and the reaction mixture was stirred for 18 1o hours. Water was then added to the reaction mixture and the aqueous mixture was extracted with dichloromethane (3x10mL). The combined organic extracts was dried over sodium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting with pentane:ethyl acetate, 95:5, afforded the title compound as a colourless oil in 66% yield, 527mg.
LRMS (APCI+): m/z [M+HJ+ 377 Pr~aration 74 4-Hydroxy-3,6-dimethyl-indazole-1-carboxylic acid tart-but I e,~ster H3C ~ OH
~CH3 N_N
O
H3C \\~
O
HsC CHs Tetrabutylammonium fluoride solution (1 M in tetrahydrofuran, 21 mL, 2.1 mmol) was added dropwise to a solution of the compound of Preparation 73 (527mg, 1.4mmol) in tetrahydrofuran (9mL) and the solution was stirred at 0°C for 30 minutes and at room temperature for 5 minutes. Water was then added to tre mixture and the aqueous mixture was extracted with ethyl acetate (2x10mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on silica gel, eluting with pentane:ethyl acetate, 70:30 to 60:40, afforded the title compound as a white solid in 76% yield, 280mg.
LRMS (APCI-): mlz [M-H]- 261 Preparation 75 (2R)-1-[~,2R)-4-Benzoyl-2-meth r~l-piperazin-1-~]-2-benzyloxy-propan-1-one O
H3C\
N
O ~N \
\ O
1-Hydroxybenzotriazole hydrate (825mg, 5.3mmol), N-methylmorpholine (808pL, 7.3mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.13g, 5.8mmol) and (3R)-(3-methyl-piperazin-1-yl)-phenyl-methanone [(1.0g, 4.9mmol), J. Med. Chem. 43(23), 4499; 2000] were added to a solution of (R)-(+)-2-benzyloxypropionic acid (972mg, 5.3mmol) in 2o dichloromethane (lOmL) and the mixture was stirred for 18 hours. Additional (R)-(+)-2-benzyloxypropionic acid (486mg, 2.65mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.65mg, 2.9mmol), 1-hydroxybenzotriazole hydrate (413mg, 2.65mmol) and N-methylmorpholine (808pL, 7.3mmol) were added and the mixture was heated under reflux for 3 2s hours. Water was then added to the reaction mixture and the aqueous solution was extracted with dichloromethane (2x10mL). The combined organic extracts were washed with 2M hydrochloric acid, 1 M sodium hydroxide solution and brine. The organic phase was dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on 3o silica gel, eluting with pentane:ethyl acetate, 50:50, followed by ethyl acetate:methanol, 90:10, afforded the title compound as a white foam in 81 yield, 1.45g LRMS (APCI-): m/z [M-H]- 367 Preparation 76 (2R)-1-[(2R)-4-Benzoyl-2-meth~rl-piperazin-1-yl -2-hydrox~propan-1-one O
- N~ ~
OH ~N
H3C~' ~
O
Pd(OH)2 (300mg, 2.2mmol) and ammonium formate (1.37g, 22mmol) were 1o added to a solution of the compound of Preparation 75 (1.458, 3.9mmol) in ethanol (30mL) and the mixture was heated at 60°C for 2 hours. Tlc analysis then showed that the reaction had not reached completion so additional Pd(OH)2 (300mg, 2.2mmol) was added, followed by ammonium formate (1.37g, 22mmol) added at 45 minute intervals until all of the starting material was consumed. The reaction mixture was then cooled and filtered through Arbocel~, washing through with ethanol (lOmL). The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol, 95:5, to afford the title compound as a white gum in 91 % yield, 1 g.
2o LRMS (APCI+): m/z [M+H]+ 277 Preparation 77 4-[(,1 S~2-[~2R)-4-Benzo~rl-2-methyl-piperazin-1-arl]-1-methyl-2-oxo-ethoxyl-3,6-dimethyl-indazole-1-carboxylic acid terl-butyl ester H3C~O ~ CH3 N \
H3C ~ \ _ N
O N O
N- O CHs The compound of Preparation 76 (70mg, 0.25mmol), di-tert-butyl azodicarboxylate (233mg, 1.01 mmol) and polymer supported triphenyl phosphine (380mg, 1.l3mmol) were added to a solution of the compound of Preparation 74 (70mg, 0.25mmol) in dichloromethane (3mL) and the reaction mixture was stirred 0°C for 30 minutes and at room temperature for 18 hours.
The reaction mixture was then filtered through a filter tube, washing through with dichloromethane. The filtrate was washed with sodium hydroxide solution, dried over magnesium sulfate and concentrated in vacuo.
Purification of the residue by column chromatography on silica gel, eluting 1o with pentane:ethyl acetate, 40:60 to 20:80 afforded the title compound as a white foam in 34% yield, 45mg LRMS (APCI+): m/z [M+H]+ 521 Biological Data The ability of the compounds of formula (I) and their pharmaceutically acceptable salts, solvates and derivatives to modulate gp120 activity, in particular inhibit the interaction of gp120 with CD4, is demonstrated using a gp160 induced cell-cell fusion assay to determine the ICSO values of 2o compounds against HIV-1 fusion. The gp160 induced cell-cell fusion assay uses a HeLa P4 cell line and a CHO-TatlO cell line.
The HeLa P4 cell line expresses CCR5 and CD4 and has been transfected with HIV-1 LTR-(3-Galactosidase. The media for this cell line is Dulbecco modified eagle's medium (D-MEM) (without L-glutamine) containing 10% foetal calf serum (FCS), 2mM L-glutamine penicillin/streptomycin (Pen/Strep; 100U/mL penicillin + l0mg/mL streptomycin), and 1 p.g/ml puromycin.
The CHO cell line is a Tat (transcriptional traps activator)-expressing clone from a CHO JRR17.1 cell line that has been transfected with prat puro so plasmid. The media for this cell line is rich medium for mammalian cell culture originally developed at Roswell Park Memorial Institute RPM11640 (without L-glutamine) containing 10% FCS, 2mM L-glutamine, 0.5 mg/ml Hygromycin B and 12pg/ml puromycin. The CHO JRR17.1 line expresses gp160 (JRFL) and is a clone that has been selected for its ability to fuse with a CCRS/CD4 expressing cell line.
Upon cell fusion, Tat present in the CHO cell is able to transactivate the HIV-1 long terminal repeat (LTR) present in the HeLa cell leading to the expression of the (3-Galactosidase enzyme. This expression is then measured using a Fluor AceT"" ~i-Galactosidase reporter assay kit (Bio-Rad cat no. 170-3150). This kit is a quantitative fluorescent assay that determines the level of expression of ~i-galactosidase using 4-methylumbelliferul-galactopyranoside (MUG) as substrate. (i-Galactosidase hydrolyses the fluorogenic substrate resulting in release of the fluorescent molecule 4-methylumbelliferone (4MU). Fluorescence of 4-methylumbelliferone is then measured on a fluorometer using an excitation wavelength of 360nm and emission wavelength of 460nm.
1o Compounds that inhibit fusion will give rise to a reduced signal and, following solubilisation in an appropriate solvent and dilution in culture medium, a dose-response curve for each compound can be used to calculate ICSO values.
All the Examples of the invention have ICSO values, according to the above method, of less than 1.SpM. ICSO values for the compounds of Examples 12, 29 and 44 are, respectively, l5nM, 134nM and 825nM.
The ability of compounds of formula (I) to inhibit the interaction of gp120 with CD4 is further demonstrated using an enzyme linked immunosorbent assay (ELISA). Maxisorp plates (Nunc) are coated with 2~.g/well of anti-gp120 antibody (D7324). 100p,1 of gp120 (dilution pre-determined by titration) is added to each well and incubated for 90 minutes at room temperature. The sample is removed and the wells are washed with PBS (phosphate buffered saline) + 0.01% TWEEN~ (polyethylene glycol sorbitan monolaurate). 50~1/well of compound is added followed by 50p,1 (0.1 ~.g) of soluble CD4 conjugated to horseradish peroxidase (Autogen Bioclear). The plate is incubated for 90 minutes at room temperature before the wells are washed again. The substrate ~PD (o-phenylenediamine, Sigma) is added at a concentration of 0.5mg/ml and the plate incubated in the dark at room temperature for 3 minutes before 3M HCI is added to stop the 3o reaction. Compounds that inhibit the interaction of gp120 with soluble CD4 will give rise to a reduced absorbance at 492nm.
All the Examples of the invention have ICSO values, according to the above method, of less than 15~.M. ICSO values for the compounds of Examples 1, 11 and 12 are, respectively, 0.92p,M, 1.Op,M and 0.75p,M.
Claims (25)
1. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:
R1 is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo, C1-C6 alkoxy, CF3, OCF3, or CN;
R2 and R3 are independently H, or C1-C6alkyl;
R4 is C1-C6 alkyl;
R5 is phenyl; naphthyl; or a C-linked, 6 to 10 membered, mono- or bicyclic, aromatic or partially saturated, heterocycle wherein said heterocycle contains 1 to 4 nitrogen heteroatom(s), 1 or 2 nitrogen and 1 oxygen heteroatoms, or 1 or 2 nitrogen and 1 sulphur heteroatoms; wherein said phenyl, napthyl or heterocycle is optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C7 cycloalkyl, phenyl, OH, C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkyl, OC1-C6fluoroalkyl, C0-C2 alkylene NR6R7, halo, C0-C2 alkylene CN, C0-C2 alkylene CO2R8, C0-C2 alkylene CONR6R7, C0-C2 alkylene SR9, C0-C2 alkylene SOR9, C0-C2 alkylene SO2R9, C0-C2 alkylene SO2NR6R7, C0-C2 alkylene NR8COR9, C0-C2 alkylene NR8CONR6R7, C0-C2 alkylene NR8SO2R9, or C0-C2 alkylene R10, or, where R5 is a heterocycle, oxo;
R6 and R7 are independently H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or R10;
or when taken together with the nitrogen to which they are attached form an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, or thiomorpholine ring; wherein the said substituents are 1 or 2 groups selected from C1-C6 alkyl, or C0-C6 alkylene NH2;
R8 is H, C1-C6 alkyl or phenyl;
R9 is C1-C6 alkyl or phenyl; and R10 is imidazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzimidazolyl, quinazolinyl, phthalazinyl, benzoxazolyl or quinoxalinyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, cyano or halo.
R1 is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo, C1-C6 alkoxy, CF3, OCF3, or CN;
R2 and R3 are independently H, or C1-C6alkyl;
R4 is C1-C6 alkyl;
R5 is phenyl; naphthyl; or a C-linked, 6 to 10 membered, mono- or bicyclic, aromatic or partially saturated, heterocycle wherein said heterocycle contains 1 to 4 nitrogen heteroatom(s), 1 or 2 nitrogen and 1 oxygen heteroatoms, or 1 or 2 nitrogen and 1 sulphur heteroatoms; wherein said phenyl, napthyl or heterocycle is optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C7 cycloalkyl, phenyl, OH, C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkyl, OC1-C6fluoroalkyl, C0-C2 alkylene NR6R7, halo, C0-C2 alkylene CN, C0-C2 alkylene CO2R8, C0-C2 alkylene CONR6R7, C0-C2 alkylene SR9, C0-C2 alkylene SOR9, C0-C2 alkylene SO2R9, C0-C2 alkylene SO2NR6R7, C0-C2 alkylene NR8COR9, C0-C2 alkylene NR8CONR6R7, C0-C2 alkylene NR8SO2R9, or C0-C2 alkylene R10, or, where R5 is a heterocycle, oxo;
R6 and R7 are independently H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or R10;
or when taken together with the nitrogen to which they are attached form an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, or thiomorpholine ring; wherein the said substituents are 1 or 2 groups selected from C1-C6 alkyl, or C0-C6 alkylene NH2;
R8 is H, C1-C6 alkyl or phenyl;
R9 is C1-C6 alkyl or phenyl; and R10 is imidazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzimidazolyl, quinazolinyl, phthalazinyl, benzoxazolyl or quinoxalinyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, cyano or halo.
2. A compound as claimed in claim 1 wherein R1 is phenyl or pyridyl, wherein said phenyl or pyridyl is optionally substituted by 1 or 2 atoms or groups selected from halo.
3. A compound as claimed in claim 1 or 2 wherein R1 is phenyl, fluorophenyl or pyridyl.
4. A compound as claimed in any of claims 1 to 3 wherein R1 is phenyl.
5. A compound as claimed in any preceding claim wherein R2 is C1-C4alkyl.
6. A compound as claimed in any preceding claim wherein R2 is methyl.
7. A compound as claimed in any preceding claim wherein R3 is H.
8. A compound as claimed in any preceding claim wherein R4 is C1-C4alkyl.
9. A compound as claimed in any preceding claim wherein R4 is methyl.
10. A compound as claimed in any preceding claim wherein R5 is an optionally substituted phenyl, naphthyl, pyridyl, indazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzopiperidinyl or benzoxazolyl;
wherein said substituents are 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, halo, CN, CO2R8, CONR6R7, or R10.
wherein said substituents are 1 to 3 atoms or groups selected from C1-C6 alkyl, C1-C6 alkoxy, halo, CN, CO2R8, CONR6R7, or R10.
11. A compound as claimed in any preceding claim wherein R5 is an optionally substituted phenyl or pyridyl, wherein said substituents are 1 to 3 groups selected from C1-C6 alkoxy, CO2R8, or CONR6R7.
12. A compound as claimed in any preceding claim wherein R6 is H or C1-C4 alkyl.
13. A compound as claimed in any preceding claim wherein R7 is H, C1-C4 alkyl or C3-C6 cycloalkyl.
14. A compound as claimed in any preceding claim wherein R8 is C1-C4 alkyl.
15. A compound as claimed in any preceding claim wherein R10 is imidazolyl, pyrazolyl, triazolyl or oxadiazolyl, each optionally substituted by 1 to 3 atoms or groups selected from C1-C4 alkyl, C1-C4 alkoxy, cyano or halo.
16. A compound as claimed in any preceding claim of formula (Ia) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R1, R2, R3, R4 and R5 are as defined in any of claims 1 to 15.
17. A compound as claimed in claim 16 of formula (Ib) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R1, R2, R4 and R5 are as defined in any of claims 1 to 15.
18. A compound as claimed in claim 1 which is selected from:
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)]-2-(3-methyl-1H-indazol-4-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[2-(2H-pyrazol-3-ylamino)-quinolin-5-yloxy]-propan-1-one;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-isoquinoline-1-carboxylic acid methylamide;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(8-chloro-2-methylamino-quinolin-5-yloxy)-propan-1-one;
(2S)-1-((2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[1-(2H-pyrazol-3-ylamino)-isoquinolin-5-yloxy]-propan-1-one;
4-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-3-methoxy-N-methyl-benzamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methylamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid amide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid ethylamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cyclopropylamide;
and pharmaceutically acceptable salts, solvates or derivatives thereof.
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl)]-2-(3-methyl-1H-indazol-4-yloxy)-propan-1-one;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[2-(2H-pyrazol-3-ylamino)-quinolin-5-yloxy]-propan-1-one;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-isoquinoline-1-carboxylic acid methylamide;
(2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(8-chloro-2-methylamino-quinolin-5-yloxy)-propan-1-one;
(2S)-1-((2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-[1-(2H-pyrazol-3-ylamino)-isoquinolin-5-yloxy]-propan-1-one;
4-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-3-methoxy-N-methyl-benzamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methylamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid amide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid ethylamide;
5-{(1S)-2-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid cyclopropylamide;
and pharmaceutically acceptable salts, solvates or derivatives thereof.
19. A pharmaceutical composition including a compound of formula (I)or a pharmaceutically acceptable salt, solvate or derivative thereof, according to any preceding claim, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
20. A pharmaceutical composition according to claim 19 including one or more additional therapeutic agents.
21. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 18 for use as a medicament.
22. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 18 for use in the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
23. The use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof as claimed in any one of claims 1 to 18 for the manufacture of a medicament for the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
24. A method of treatment of a mammal suffering from HIV, a retroviral infection genetically related to HIV, or AIDS which comprises treating said mammal with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 18.
25. A compound of formulae (II), (IV) or (VII).
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0319149A GB0319149D0 (en) | 2003-08-14 | 2003-08-14 | Chemical compounds |
GB0319149.1 | 2003-08-14 | ||
GB0322153.8 | 2003-09-22 | ||
GB0322153A GB0322153D0 (en) | 2003-09-22 | 2003-09-22 | Chemical compounds |
GB0406656A GB0406656D0 (en) | 2004-03-24 | 2004-03-24 | Chemical compounds |
GB0406656.9 | 2004-03-24 | ||
PCT/IB2004/002562 WO2005016344A1 (en) | 2003-08-14 | 2004-08-04 | Piperazine derivatives for the treatment of hiv infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2534866A1 true CA2534866A1 (en) | 2005-02-24 |
Family
ID=34198586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002534866A Abandoned CA2534866A1 (en) | 2003-08-14 | 2004-08-04 | Piperazine derivatives for the treatment of hiv infections |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1663234A1 (en) |
JP (1) | JP2007502266A (en) |
KR (1) | KR20060037442A (en) |
AP (1) | AP2006003514A0 (en) |
AR (1) | AR045931A1 (en) |
AU (1) | AU2004264724A1 (en) |
BR (1) | BRPI0413469A (en) |
CA (1) | CA2534866A1 (en) |
EA (1) | EA200600225A1 (en) |
EC (1) | ECSP066361A (en) |
IL (1) | IL173365A0 (en) |
IS (1) | IS8275A (en) |
MA (1) | MA27990A1 (en) |
MX (1) | MXPA06001762A (en) |
NL (1) | NL1026827C2 (en) |
NO (1) | NO20061170L (en) |
OA (1) | OA13235A (en) |
PA (1) | PA8608901A1 (en) |
PE (1) | PE20050867A1 (en) |
TN (1) | TNSN06051A1 (en) |
TW (1) | TW200512208A (en) |
UY (1) | UY28466A1 (en) |
WO (1) | WO2005016344A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PL1656372T3 (en) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
US20060100432A1 (en) | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
FR2880887B1 (en) * | 2005-01-14 | 2009-01-30 | Merck Sante Soc Par Actions Si | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND THERAPEUTIC APPLICATIONS |
WO2006085199A1 (en) * | 2005-02-14 | 2006-08-17 | Pfizer Limited | Piperazine derivatives |
CN105348203B (en) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | Inhibit the composition and method of JAK approach |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7396830B2 (en) | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
US7851476B2 (en) | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
JP2009528295A (en) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibition of the JAK pathway |
US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
US7501419B2 (en) | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
US7572810B2 (en) | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
US7504399B2 (en) | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
MX2010008926A (en) | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases. |
US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009158396A1 (en) | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Diketopiperidine derivatives as hiv attachment inhibitors |
WO2009158394A1 (en) | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
US8450361B2 (en) | 2010-08-06 | 2013-05-28 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
EP2646439B1 (en) | 2010-12-02 | 2016-05-25 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
WO2012142080A1 (en) | 2011-04-12 | 2012-10-18 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
ES2616268T3 (en) | 2011-08-29 | 2017-06-12 | VIIV Healthcare UK (No.5) Limited | Condensed bicyclic diamine derivatives as inhibitors of HIV binding |
US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
ES2616432T3 (en) | 2012-08-09 | 2017-06-13 | VIIV Healthcare UK (No.5) Limited | Derivatives of tricyclic alkenes as inhibitors of HIV binding |
EP2895471B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Piperidine amide derivatives as hiv attachment inhibitors |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
DK2968316T3 (en) | 2013-03-13 | 2019-10-07 | Forma Therapeutics Inc | 2-HYDROXY-1- {4 - [(4-PHENYLPHENYL) CARBONYL] PIPERAZIN-1-YL} ETHAN-1-ON DERIVATIVES AND RELATED COMPOUNDS LIKE FATHERIC ACID SYNTHASE (PHASN) INHIBITORS FOR TREATMENT |
JP6858712B2 (en) | 2015-01-30 | 2021-04-14 | リーバー インスティテュート フォー ブレイン ディベロップメントLieber Institute For Brain Development | COMT inhibition method and composition |
ES2893613T3 (en) | 2015-11-25 | 2022-02-09 | Lieber Inst Inc Dba Lieber Inst For Brain Development | Tetrahydro-8H-pyrido[1,2-a]pyrazin-8-ones as COMT inhibitors for the treatment of neurodegenerative disorders |
TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
CN113382633A (en) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1397193A (en) * | 1963-12-06 | 1965-04-30 | Lepetit Spa | Process for the preparation of new piperazine derivatives |
US3865828A (en) * | 1972-03-22 | 1975-02-11 | Egyt Gyogyszervegyeszeti Gyar | Pyridine derivatives having antidepressant activity |
JPS5139039A (en) * | 1974-09-28 | 1976-04-01 | Mitsubishi Paper Mills Ltd | KARAAYOKANKOZAIRYO |
KR20020084273A (en) * | 2000-03-31 | 2002-11-04 | 화이자 프로덕츠 인코포레이티드 | Novel piperazine derivatives |
US6573262B2 (en) * | 2000-07-10 | 2003-06-03 | Bristol-Myers Sqibb Company | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
-
2004
- 2004-08-04 BR BRPI0413469-9A patent/BRPI0413469A/en not_active IP Right Cessation
- 2004-08-04 EP EP04744202A patent/EP1663234A1/en not_active Withdrawn
- 2004-08-04 EA EA200600225A patent/EA200600225A1/en unknown
- 2004-08-04 AU AU2004264724A patent/AU2004264724A1/en not_active Abandoned
- 2004-08-04 KR KR1020067003015A patent/KR20060037442A/en not_active Application Discontinuation
- 2004-08-04 OA OA1200600049A patent/OA13235A/en unknown
- 2004-08-04 CA CA002534866A patent/CA2534866A1/en not_active Abandoned
- 2004-08-04 WO PCT/IB2004/002562 patent/WO2005016344A1/en not_active Application Discontinuation
- 2004-08-04 MX MXPA06001762A patent/MXPA06001762A/en not_active Application Discontinuation
- 2004-08-04 JP JP2006523071A patent/JP2007502266A/en active Pending
- 2004-08-04 AP AP2006003514A patent/AP2006003514A0/en unknown
- 2004-08-10 PE PE2004000779A patent/PE20050867A1/en not_active Application Discontinuation
- 2004-08-11 TW TW093124083A patent/TW200512208A/en unknown
- 2004-08-12 NL NL1026827A patent/NL1026827C2/en not_active IP Right Cessation
- 2004-08-12 PA PA20048608901A patent/PA8608901A1/en unknown
- 2004-08-12 AR ARP040102888A patent/AR045931A1/en unknown
- 2004-08-12 UY UY28466A patent/UY28466A1/en not_active Application Discontinuation
-
2006
- 2006-01-25 IL IL173365A patent/IL173365A0/en unknown
- 2006-01-31 IS IS8275A patent/IS8275A/en unknown
- 2006-02-13 EC EC2006006361A patent/ECSP066361A/en unknown
- 2006-02-14 TN TNP2006000051A patent/TNSN06051A1/en unknown
- 2006-02-14 MA MA28803A patent/MA27990A1/en unknown
- 2006-03-13 NO NO20061170A patent/NO20061170L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20061170L (en) | 2006-05-15 |
EA200600225A1 (en) | 2006-08-25 |
IL173365A0 (en) | 2006-06-11 |
ECSP066361A (en) | 2006-08-30 |
PE20050867A1 (en) | 2005-11-10 |
UY28466A1 (en) | 2005-03-31 |
TNSN06051A1 (en) | 2007-10-03 |
NL1026827C2 (en) | 2005-11-23 |
NL1026827A1 (en) | 2005-03-09 |
TW200512208A (en) | 2005-04-01 |
EP1663234A1 (en) | 2006-06-07 |
KR20060037442A (en) | 2006-05-03 |
AR045931A1 (en) | 2005-11-16 |
AU2004264724A1 (en) | 2005-02-24 |
IS8275A (en) | 2006-01-31 |
JP2007502266A (en) | 2007-02-08 |
BRPI0413469A (en) | 2006-10-17 |
OA13235A (en) | 2006-12-13 |
WO2005016344A1 (en) | 2005-02-24 |
MA27990A1 (en) | 2006-07-03 |
MXPA06001762A (en) | 2006-05-12 |
AP2006003514A0 (en) | 2006-02-28 |
PA8608901A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2534866A1 (en) | Piperazine derivatives for the treatment of hiv infections | |
JP7317028B2 (en) | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | |
US20050043300A1 (en) | Piperazine derivatives | |
CN109988109B (en) | Amine compound for inhibiting SSAO/VAP-1 and application thereof | |
US20240190844A1 (en) | Pyridazinones as parp7 inhibitors | |
US7449477B2 (en) | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | |
WO2005121094A1 (en) | Piperazine and piperidine derivatives as anti-hiv-agents | |
US20090264425A1 (en) | Chemical compounds | |
US10344026B2 (en) | Compositions and methods of targeting mutant K-ras | |
WO2012095781A1 (en) | Indazole derivatives as sodium channel inhibitors | |
MXPA02003533A (en) | Pyrimidine derivatives. | |
NZ580237A (en) | Compounds with anti-cancer activity | |
WO2006109846A1 (en) | Triazole derivative and the use thereof | |
US20210269440A1 (en) | Immunomodulators, compositions and methods thereof | |
WO2020221006A1 (en) | Bet inhibitor, and preparation method and use thereof | |
JP2007505888A (en) | Substituted triazole derivatives as oxytocin antagonists | |
WO2016170009A1 (en) | Amino-substituted heterocyclic derivatives as sodium channel inhibitors | |
US20080132549A1 (en) | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | |
US20210380558A1 (en) | Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors | |
US20080176919A1 (en) | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | |
ZA200600636B (en) | Piperazine derivatives for the treatment of HIV infections | |
ZA200602096B (en) | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | |
MXPA05003641A (en) | Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |